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Abstract
The functional characterization of H-PRUNE  was performed using different 
approaches, in order to elucidate first the biochemical function o f the protein, and 
then the correlation with other genes and the role in different tumour types.
First, we identified and characterized H-PRUNE phosphodiesterase activity, 
which is suppressed by dipyridamole. Interestingly, H-PRUNE interacts with NM23- 
H l, an anti-metastatic protein involved in different processes as proliferation, 
differentiation and motility, suggesting us to investigate H-PRUNE possible 
correlation to tumour development and progression with respect to NM23-H1. Our 
study has consisted in elucidating H-PRUNE function in three different tumour 
types, as sarcoma, neuroblastoma, and breast cancer.
Both sarcoma and breast cancer analyses revealed that H-PRUNE, localized 
into the cytoplasm, acts as a negative regulator of NM23-H1. In fact, both aggressive 
sarcoma subtypes and metastatic breast cancer showed high protein levels o f H- 
PRUNE and low levels of NM23-H1, indicating its involvement in advanced stages 
of cancer. Moreover, we demonstrated that both the H-PRUNE phosphodiesterase 
activity and the H-PRUNE and NM23-H1 complex increase cell motility in the 
MDA-MB-435 breast cancer cell line. The overview o f genes and pathways 
influenced by H-PRUNE overexpression in the MDA-MB-435 breast cancer cellular 
model has been performed in order to understand the molecular changes in tumour 
cells.
Ill
Interestingly, we found high levels of H-PRUNE, localized into the nuclear 
compartment, correlated to high levels of both NM23-H1 and NM23-H2 (an isoform 
of the NM23 family) in advanced stages of neuroblastoma.
We identified a new function of H-PRUNE as a transcriptional regulator of 
NM23-H2 and we postulated a transcriptional mechanism of regulation, including 
activation of NM23-H1 by NM23-H2 and of NM23-H2 by H-PRUNE.
This study evidences H-PRUNE function, as a regulator of NM23-H1 anti­
metastatic function by two different mechanisms of action, correlated to the different 
compartmentalization of H-PRUNE protein.
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Introduction
The human prune
The P R U N E  gene was first identified in Drosophila melanogaster. T he  
Drosophila prune gene was characterized based on its mutant phenotype that showed 
a brownish-purple eye colour due to the reduction of drosopterins, in contrast to the 
bright red eye of the wild-type fly (Timmons and Sheam, 1996). Homozygous prune 
mutants are viable and fertile. In the presence o f even a single copy of the gain-of- 
function mutation in the abnormal wing disc gene (awd/K-pn; also named Killer-of- 
Prune) prune mutants are synthetically lethal, developing pseudo-melanotic tumors. 
The flies die at the third larval instar stage (Biggs et al., 1988; Orevi and Falk, 1975), 
suggesting a synergism between the prune and awd genes. Mutations in awd result in 
developmental abnormalities of imaginai disc structures (Rosengard et al., 1989).
The human PRUNE  gene (H-PRUNE) homologue o f the Drosophila prune 
gene was identified through dbEST searches and cloned in Dr. Zollo’s laboratory 
(Reymond et al., 1999). The gene is composed of eight exons and is located in the 
lq21.3 chromosomal region; a pseudogene has been sequenced and mapped to 
chromosomal region 13ql2.
Reymond et al. (1999) and recent results (Zollo, personal comunication) 
indicate that Prune mRNA pattern of expression is predominant in the development 
of central nervous system (CNS), and specifically in the regions derived from neural 
crest cells (dorsal root ganglia, V and VIII cranial nerves), in which neuroblastoma 
tumour cells originated. H-PRUNE is ubiquitously expressed in adult human tissues 
(Reymond et al., 1999).
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The H-PRUNE protein belongs to the DHH superfamily, which includes 
several phosphoesterases, such as the RecJ nuclease from bacteria and the 
pyrophosphatases from yeast and bacteria (Aravind and Koonin, 1998b). The DHH 
superfamily can be divided into two main groups on the basis o f a C-terminal motif 
that is very well conserved within each group, but not across the groups. The first 
group is represented only in the Archaea and the bacteria, while the second group is 
also found in eukaryotes (Figure 1). All the members o f the superfamily possess the 
shared N-terminal domain containing the motifs with the absolutely conserved 
signatures of the form DXD (Motif-1), D (Motif-2), DHH (Motif-3) and D/E (Motif- 
4). These residues are all on the same face o f this domain and together form the 
catalytic site that chelates at least two divalent cations. The DHH family is so named 
due to the third motif DHH. The first group of the DHH family includes the RecJ 
protein, a DNA repair protein, and other nucleases and poorly characterized bacterial 
proteins; the second group include the exo-polyphosphatases from yeast. The 
recently availability o f the structures o f the RecJ protein (Yamagata et al., 2002) and 
the bacterial pyrophosphatases (PPASEs) (Ahn et al., 2001) reveal that these two 
major classes of DHH proteins share an N-terminal a /p  domain with a five-stranded 
parallel sheet, but have somewhat different C-terminal domains. The first four motifs 
are the most conserved portions of the N-terminal domain and define the active site 
of these enzymes, whereas the group-specific fifth m otif maps to the divergent C- 
terminal domains. In both DHH families, the C-terminal domain contains a core 
sheet of five strands, four of which form two P-strand hairpins. However, differences 
in the C-terminal domains between the first and the second families of DHH proteins 
may contribute prominently to substrate specificities o f the two superfamilies.
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Introduction
A  clustering analysis o f the DHH proteins shows that PRUNE proteins 
(human and Drosophila) belong to the second group of the DHH family, along with 
the inorganic pyrophosphatases and exopolyphosphatases (Figure 1). Evolutionary 
studies on DHH family have shown that phosphoesterases derived from a number of 
protein folds that encode diverse phosphoesterases and hydrolases. These include: 
the HD fold, from which the classic signalling cyclic nucleotide phosphodiesterases 
(PDEs) are recognized (PDEl-11) (Aravind and Koonin, 1998a, Aravind and 
Koonin, 1998b, Galperin et al., 1999); the metallo-P-lactamase fold (Aravind, 1999; 
Galperin et al., 1999), from which the PdsA-like PDEs are derived; and the 
calcineurin-like phosphoesterase fold (Aravind and Koonin, 1998b), from which Icc- 
like PDEs are derived.
The cyclic nucleotide phosphodiesterases catalyze the hydrolysis o f 3’:5’- 
cyclic nucleotides to their corresponding nucleoside 5’-monophosphates. Cyclic 
nucleotides cAMP and cGMP are well known as second messengers and regulate 
many functions in various tissues; to date, phosphodiesterases are divided into eleven 
distinct fam ilies on the basis o f  substrate specificity and sensitivity to 
endogenous/exogenous regulators and genetically on the basis o f sequence homology 
(Beavo et al., 2002).
Structural analysis of H-PRUNE showed similarities to RecJ (Figure 2) and 
pyrophosphatase proteins (Ahn et al., 2001; Yamagata et al., 2002), thus suggesting 
potentially similar activities to those proteins. Additionally, C-terminal to the DHH 
motif, mammalian PRUNE contains a non-globular extension within which there are 
some conserved serines that could be phosphorylated to modulate H-PRUNE 
function.
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Introduction
H-PRUNE and Drosophila PRUNE proteins belong to DHH family and 
contain the DHR form, which is conserved in the catalytic sites o f some known 
PDEs, as PDE5 and PDE8, PDEIOA and PDEl 1 A. The presence of the DHR form in 
the PRUNE proteins could result in different structural properties correlated to the 
different charges of the amminoacids with respect to the other proteins o f the DHH 
family. In fact, the optimum of pH for the phosphodiesterase activity is pH 7.5-8.0, a 
value at which the arginine is positively charged and the histidine is not charged, 
since the isoelectric points o f the histidine and o f the arginine are 7.6 and 10.8, 
respectively.
Hence, since evolutionary studies on DHH family have shown that 
phosphoesterases derived from protein folds hallmarks of the classic signalling cyclic 
nucleotide phosphodiesterases (PDEs) are recognized (PDEl-11) (Aravind and 
Koonin, 1998a, Aravind and Koonin, 1998b, Galperin et al., 1999) and the 
Drosophila and human PRUNE proteins contain the DHR form, the two proteins 
could define a new class of PDEs, characterized by different putative activities as 
phosphodiesterase, pyrophospatase and/or exonuclease.
Moreover, an interesting example of a family protein characterized by both 
phosphodiesterase and pyrophospatase activities is the type I phosphodiesterase / 
nucleotide pyrophosphatase family (N PPl) consisting o f phosphodiesterases, 
including hum an plasm a-cell m em brane glycoprotein  PC-1 / alkaline 
phosphodiesterase / nucleotide pyrophosphatase (NPPase). These enzymes catalyse 
the cleavage of phosphodiester and phosphosulfate bonds in NAD, deoxynucleotides 
and nucleotide sugars (Cimpean et al., 2004).
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Furthermore, a ScanProsite analysis rhttp://www.expasv.com) revealed the 
presence o f a leucine zipper domain (positions from 157 to 185) in H-PRUNE 
primary sequence (Figure 3), thus suggesting a possible DNA binding capability or 
transcriptional activation activity o f H-PRUNE associated with a nuclear 
localization.
Hence, the sequence alignments indicate that the H-PRUNE could potentially 
have exonuclease, pyrophosphatase, polyphosphatase and/or phosphodiesterase 
activities. Additionally, the m otif scan analysis indicates also a potential DNA 
binding and/or transcriptional activation activity.
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Introduction
The NM23s: the protein partners o f  H-PRUNE,
N m 2 3 -H f  the human homologue o f awd Drosphila gene, is a tumour 
metastasis suppressor that was originally identified by subtraction cloning in murine 
melanomas of differing metastatic potential (Steeg et ah, 1988). N m 23-H l encodes 
for the nucleoside diphosphate kinase (NDPK-A or NM23-H1), which shares almost 
70% similarity at amino acid level to the AWD protein by Drosophila. Reymond et 
al. (1999) demonstrated the physical interaction between H-PRUNE and NM23-H1. 
Humans encode up to eight orthologs (-HI to -H8) of awd, at least four of which are 
active nucleoside diphosphate kinases (NDPKs). The NDPKs are 17-20 kDa proteins 
that are distributed ubiquitously and catalyze the phosphorylation o f nucleoside 
diphosphate to the corresponding nucleoside triphosphate, mainly at the expense o f 
the ATP synthesised through oxidative phosphorylation (Lombardi et al., 2000).
The NM23 family divides into two distinct groups (Table 1): the group I 
encode proteins that generally have highly homologous counte^arts in other 
vertebrate species and possess the classic enzymatic activity o f a NDP kinase. This 
group includes NDP kinase A-D {NM23-H1 to -H4), which share 58 to 88% identity 
with each other.
The protein products of the group II genes {NM23-H5 to -H8) are more 
divergent as the sequences share only 25 to 45% identity with the first group proteins 
and between each other (Lacombe et al., 2000). NM23-H1 and -H2 can form in vitro 
and in vivo homohexamers as well as heterohexamers possessing different ratios o f 
the respective subunits.
10
II
u
i f
i
% !
I
1
I B
IÎ
I
II
III
O  w  CL
§-
1
n
g
SI
Ï
f i ­
l l
ti
ll
1
n
f H
;
a
sI
0> I
i i | j  
1 1
o '3
l l
t |
II li
I
i
5§
£
I
§
li
II
1
I
00
U
C3 RS
S in 
.S %
ll
1
i
•|
a
llna
o \ VO f S
W) m r t
o TT f 4
(N
(S
TT VOa a a
m m
( S n r 4
B B s
s s c
t i
% 0 
§ &
eS
1
4-H r t
M <N
CL CL CT1/3 fTi
VO
00
g
Ia  a  
Q Z,
§
§
i l l
I
ft
a a
fj m
s
s GG
s .=
II
es -d
11Z  b
£
1
I
i
oo
I§
i
I
1B
m
\o
•  im  1-4
l l
I 
§
ct
as
I.
I I
■III
n
IfÎÎ
11
Introduction
The NM23-H1 and NM23-H2 proteins share 88% identity (Figure 4A) and 
are about 95% and 98% identical to the murine Nm23-Ml and Nm23-M2 proteins, 
respectively. The NM23-H1 and NM 23-H2  genes both localize on chromosome 
17q21.3 (Backer et al., 1993).
The well characterized biochem ical activities o f NM23-H1 include 
nucleoside diphosphate kinase, serine autophosphorylation (MacDonald et al., 1993) 
and protein histidine kinase (Engel et al., 1995; Hartsough et al., 2002; Wagner et al., 
1997; Wagner and Vu, 2000). The nucleoside diphosphate kinase activity functions 
via a high-energy nm23-phosphohistidine intermediate; in fact, the NM23-H1 and - 
H2 mutants in HI 18 lack NDPK activity (MacDonald et al., 1993). For NM23-H1, 
two proteolytic fragments containing serines 44 and 120, 122 and 125 exhibited 
serine autophosphorylation (Figure 4A) (MacDonald et al., 1993). Furthermore, 
NM23-H1 is able to phosphorylate in vitro KSR (kinase suppressor o f Ras), a 
scaffold protein for the mitogen activated protein kinase (MAPK cascade), 
suggesting that the histidine protein kinase activity could be correlated to metastasis- 
suppressor activity (Hartsough et al., 2002); this observation, coupled to observations 
that NM23 transfected MDA-MB-435 breast cancer cells had lower levels o f 
phosphorylated MAPK led to the conclusion that NM23 signals through the ERK- 
MAPK pathway (Steeg, 2003).
NM23-H1 associates with the cytoskeleton through an interaction with 13- 
tubulin (Lombardi et al., 1995) and the centrosomal kinase Aurora-A/STK15 (Du et 
al., 2002). Physical interaction with NM23-H1 has also been demonstrated for the 
Epstein-Barr virus nuclear protein EBNA-3C (Subramanian et al., 2001), for small 
and heterotrimeric G-proteins (Kikkawa et al., 1990; Kimura et al., 2003; Randazzo 
et al., 1991), and the ir exchange factors (O tsuki et a l., 2001).
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A  new role of NM23-H1, alternatively named GzmA-activated Dnase, is of note in 
the nucleus, by creating single-stranded DNA nicks, in a caspase-independent 
apoptosis pathway (Fan et ah, 2003). The NM23-H1 role, correlated to apoptotic 
pathways, may offer an alternative mechanism for metastasis suppression. Recently, 
Ma et al. (2004) have demonstrated that NM23-H1 has a 3’-5’ exonuclease activity.
While NM23-H1 is a predominantly cytoplasmatic protein, NM23-H2 is 
found mainly in the nucleus (Kraeft et al., 1996) and has been implicated in 
transcription regulation of CMYC “via” its specific binding to a single strand DNA, a 
nuclease-hypersensitive polypurine/polypyrimidine element (NHE-PuF) (Berberich 
and Postel, 1995; Postel et al., 1993; Postel, 1996; Postel et al., 1996). NM23-H2 
binding to the CMYC NHE sequence can result in double-stranded DNA breaks and 
in the formation o f a covalent protein-DNA complex (Grand et al., 2004; Postel et 
al., 1999), suggesting that NM23-H2 is involved in DNA structural transactions 
necessary for the activity of CMYC regulation of expression.
Several mutations o f NM23 that affect folding, oligomerization, DNA 
binding and NDPK activity have been described in NM23-H1 and NM23-H2 
(Ouatas et al., 2003) (Figure 4B). In particular, the NM23H1-P96S mutation, a 
Drosophila developmental mutation homolog (awd/K-pn), is able to interact with H- 
PRUNE and exhibits autophosphorylation and NDPK normal function, while it is 
deficient for protein histidine kinase activity (Reymond et al., 1999; Freije et al., 
1997a). The NM23-H1P96S shows failure in folding properties associated to 
oligomeric NM23-H1 protein complexes and it is not able to reduce motility with 
respect to the NM23-H1 wild-type protein (Lascu et al., 1992; Freije et al., 1997a).
13
Introduction
A  second mutation, NM23H1-S120G, associated with advanced stages of 
neuroblastoma (Chang et al., 1994) retains NDPK activity and exhibits deficient 
downstream serine autophosphorylation and histidine protein kinase activity (Freije 
et ah, 1997a). The NM23H1-S120G mutant is able to increase cell motility in a 
breast cancer cellular model (MacDonald et al., 1996), and it is impaired in its 
interaction with H-PRUNE (Reymond et al., 1999). The NM23H2-S122P mutation, 
found in melanoma cell lines of high metastatic potential, shows reduced NDPK 
activity of the protein and promotes cell motility (Hamby et al., 1995; Schaertl et al.,
199?X
Thus, NM23s represent a protein family implicated in different physiological 
processes, as motility, proliferation and differentiation.
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r>m23-H1
nm23-H2
Y E
Y E
0  * *  *
» S44
❖ H118
* S120
» 8122
* 8125
B
Isoform NDPK
activity
Auto
phosphorylation
Histidine
protein
kinase
DNA
cleavage
MDA-MB- 
435 Motility
nm23-Hl +++ 1 1 1 +++ +4+ —
nm23-Hl
P968
+++ +-H- + ND +++
nm23-Hl
8120G
1 1 1 ++ ++ +++ +++
nm23-Hl
H118F
— — — +++ ND
nm23-H2 1 1 1 ND ND +++ ND
nm23-H2
8122P
++ ND ND ND +++
Note - ND: not determined
Figure 4. The nm23s partners of h-prune.
A) Clustal alignment of nm23-Hl and nm23-H2 isoforms. The asterisks indicate 
the serines involved in autophorylation and the histidine of the catalytic site.
B) Effect os site direct mutagenesis on nm23-Hl and nm23-H2 biochemical 
characteristics and biological function in motility (Outas et., 2003).
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H-PRUNE andNM23: correlations with cancer.
Tumorigenesis in human is a multistep process; the steps reflect genetic 
alterations that drive the progressive transformation of normal human cells into 
highly malignant derivatives. Many types of cancers are diagnosed in the human 
population with an age-dependent incidence implicating four to seven rate-limiting, 
stochastic events. Pathological analyses o f a number of organ sites reveal lesions that 
appear to represent the intermediate steps in a process through which cells evolve 
progressively from normal status via a series of pre-malignant states into invasive 
cancers. The genomes of tumour cells are invariably altered at multiple sites, having 
suffered disruptions through lesions as subtle as point mutations and as obvious as 
changes in chromosomal complement (Hanahan et al., 2000). Amplification 
represents one o f the major molecular pathways through which the oncogenic 
potential o f proto-oncogenes is activated during tumorigenesis (Schwab, 1998; 
Savalyeva and Schwab, 2001).
Various authors suggested that the vast catalog of cancer cell genotypes is a 
manifestation of six essential alterations in cell-physiology that collectively dictate 
malignant growth: self-sufficiency in growth signals, insensitivity to growth- 
inhibitory (anti-growth) signals, evasion o f programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis.
To date, the main cause o f treatment failure and death for cancer patients is 
metastasis. Metastatic processes require a complex set of ordered cellular functions, 
many of which can be initiated by multiple, redundant stimuli (Steeg, 2003).
Examples are acquisition o f invasive ability, changes in adhesion, initiation 
of motility and extra-cellular matrix proteolysis (Figure 5).
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In breast cancer, metastatic spread is responsible for virtually all cancer 
deaths. To become invasive, tumour cells need to change their adhesive properties, to 
lose contact with other cells in the primary tumour and make new contacts with the 
extracellular matrix o f host cells they encounter as they invade. They also need to be 
able to penetrate into the surrounding host tissue and here the modulation of protease 
activity in the vicinity of the tumour cells plays a critical role. To migrate away from 
the primary tumour, tumour cells also need to gain motility functions. These same 
properties are also thought to be important when circulating tumour cells exit the 
circulatory system and start metastatic colonization in secondary organs (Sleeman, 
2000).
Tumorigenicity and metastasis are distinct, but interrelated phenotypes. 
Tumorigenicity is necessary, but not sufficient, for metastasis. Tumour progression 
results from genetic instability coupled with selection o f subpopulations o f cells. 
Eventually some cells accumulate sufficient capacity to dissociate and spread. 
Depending on whether the mutations occur early or late in tumour progression 
determines proportions of metastatic cells within tumours o f a given size. In part, 
metastasis is also determined, to a great extent, by tumour-host interactions (Liotta et 
al., 2001).
By screening cDNA libraries o f matched metastatic/non-metastatic K1735 
murine melanoma cell lines by differential hybridization, “non-metastatic clone 23” 
gene, was identified as the first metastasis suppressor gene (Steeg et al., 1988).
18
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To date, eight metastasis suppressor genes (NM23-HI, KAIl, KiSSl, BrMSl, 
MKK4, RHOGDI2, CRSP3 and VDUPl) have been isolated and characterized.
Within this group, NM23-H1 plays a major role for its ability to reduce 
cellular motility if  overexpressed in aggressive breast cancer cells, influencing 
anchorage-independent colonization and induction to differentiation (Freije et al., 
1997a; Freije et al., 1997b; Hartsough et al., 2001). The NM 23-HI gene has proved 
to have a clear role as metastasis suppressor gene in breast cancer (Hartsough and 
Steeg, 1998; Hewlett et al., 1994; Kantor et al., 1993; Leone et al., 1993a; Lombardi 
et al., 2000). Moreover, overexpression o f NM23-H1 in rat PC 12 cells promotes 
neuronal differentiation upon nerve growth factor (NGF) induction (Gervasi et al., 
1996).
Numerous tumours and highly proliferative cells overexpress nm23-Hl both 
at mRNA and protein levels, and in most cases this overexpression is linked to early 
stages o f cancer, with a loss of expression in more advanced and aggressive stages. 
In breast, colon, gastric and ovarian carcinomas and in melanomas, high expression 
o f human NM23-H1 is associated with a decreased metastatic potential (Florenes et 
al., 1992; Hermessy et al., 1991; Schneider et al., 2000; Muller et al., 1998; Srivatsa 
et al., 1996). The relation between the expression o f NM23 and the control o f 
metastatic potential is somehow controversial. In fact, in other cancers such as non- 
Hodgkin lymphomas and neuroblastomas, high NM23-H1 expression is associated 
with an adverse outcome (Hartsough and Steeg, 2000; Niitsu et al., 2001).
Furthermore, in neuroblastoma a mutated nm 23-H l mRNA, the «w 23H l- 
S120G, was often found associated with advanced stages of disease and poor patient 
survival (Chang et al., 1994).
19
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In sarcomas, NM23-H1 expression was found to increase with the metastatic 
potential for some tumours, but some aggressive cases also showed loss o f 
expression (Royds et ah, 1997).
Clinical studies assessing NM23 as a marker for metastasis were recently 
reviewed (Salerno et ah, 2003). Briefly, decreased expression (as would be expected 
for a metastasis suppressor) correlated in many, but not in all cancers. Thus, NM23 
has shown promise for some cancer types, but is not yet considered an independent 
prognostic factor.
The synergism between the awd  (the orthologue of N M 23-H I)  and prune  
genes observed in Drosophila, the amplification of the lq21 chromosomal region 
within which H -PRU N E  maps (Muleris et ah, 1994; Nilsson et ah, 2004), the 
interaction between H-PRUNE and NM23-H1, which is impaired with the NM23H1- 
S120G mutation suggest us a possible involvement of H-PRUNE in tumorigenesis 
and/or metastatic processes. Since the opposite correlation o f nm23-HI to cancer 
(high levels of nm23-HI correlate with low metastatic potential in breast cancer but 
low levels of nm23-Hl correlate with low metastatic potential in neuroblastoma), we 
decided to investigate H-PRUNE function in association to NM23-H1 in three 
different types of tumours:
sarcomas, which do not show a unique correlation between nm 23-H l levels 
and aggressiveness of the tumour and present the amplification of the chromosomal 
region lq 2 1 ;
neuroblastoma, where advanced stages o f the tumour present high levels of 
nm23-Hl and are frequently associated to a gain of function mutation, the ww23Hl- 
S120G;
20
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breast cancer, in which low levels o f nm 23-H l are associated with poor 
prognosis and amplification of the chromosomal region lq 21 is reported.
H-PRUNE, NM23-H1 and sarcoma
Sarcomas, tumours o f mesenchymal origin (Enzinger and Weiss, 1995) are 
rare tumours occurring at different sites o f the body and varying greatly in their 
degree of aggressiveness. Approximately 60% o f sarcomas are high grade and 
approximately half o f these will metastasize, predominately to the lung. Bone and 
soft tissue tumours (BSTT) belong to a heterogeneous group of tumours that involve 
a large number of histological subtypes and affect persons o f all ages (Fletcher et al., 
2002). The pattern o f chromosome changes, including numerical and structural 
aberrations, is diverse. Some tumour types exhibit highly specific translocations, 
occurring in 90-95% of a particular tumour type, such as t(12;16)(ql3;pl 1) in 
myxoid liposarcoma and t(X;18)(pl l;q l 1) in synovial sarcoma. These translocations 
result into the formation of fused genes encoding chimeric proteins. Other tumours 
exhibit characteristic, but not tumour-specific, aberrations such as supernumerary 
ring chromosomes and giant marker chromosomes in atypical lipomatous tumours 
(ALT), low-grade m alignant fibrous histiocytom as (MFH) and parosteal 
osteosarcomas. Finally, some BSTTs, such as highly malignant osteosarcomas, low- 
grade malignant fibrous histiocytomas (MFH) and leiomyosarcomas display an 
extensive cytogenetic heterogeneity with numerous structural and numerical 
aberrations.
21
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Sarcomas have been widely studied at the molecular level, and this has 
provided insight into mechanisms of importance for tumour development in general. 
Notably, amplification and overexpression o f M D M 2  and CDK4, representing 
alternative pathways for inactivation of the tumour suppressors p53  and pRb, were 
first described in this group of tumours (Khatib et al., 1993; Oliner et al., 1992). 
Chromosome bands 12ql3-15 are frequently altered in different types o f sarcomas 
(Schwab, 1998). The gene GLI, which encodes a nuclear zinc finger phosphoprotein, 
presumably a transcription factor, maps to 12ql3-15 chromosomal region. In 
malignant fibrous histiocytoma amplified sequences derived from chromosome 
12ql3-14 and encoding a gene designated SAS {sarcoma amplified sequence) were 
reported (Smith et al., 1992). Comparative genomic hybridisation (Kallioniemi et al., 
1992) revealed novel amplified regions that seem to be important for the 
development of sarcomas, in particular Iq21-q22 (Forus et al., 1995a,b; Szymanska 
et al., 1996). Recently, Nilsson et al. (2004) demonstrated the presence o f an 
amplicon originating from lq21-23, containing the candidate oncogenes C O ASl, 
C0AS2  and C0AS3 (Chromosome One Amplified Sequence) in lipomatous tumours.
In sarcomas, the nm 23-H l expression increase in line with metastatic 
potential in many cases analysed but has no value as a prognostic factor for these 
mesenchymal tumours. Metastatic sarcomas with low expression o f nm23-HI have 
also been reported (Royds et al., 1997). Because of the different correlation of nm23- 
H1 to sarcomas progression and of the amplification of the lq21 region, the study of 
H-PRUNE in association with NM23 will be interesting to elucidate H-PRUNE 
function related to NM23-H1.
22
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H-PRUNE, NM23s and neuroblastoma
Neuroblastoma (NB) is a malignant tumour consisting o f undifferentiated 
neuroectodermal cells derived from the neural crest. Neuroblastoma is one of the 
most common malignant disease in children with 7-5 cases in every 100.000 infants 
(Bown, 2001; Schwab et al., 2003). In addition, an interesting phenomenon is 
observed o f spontaneous neuroblastoma regression, with a significant frequency, 
most often observed in infants younger than 1 year (Guin et al., 1969). Finally, at 
low frequency, estimated 1% - 2% of all neuroblastoma world wide reported 
tumours, has been also observed as a familial complex hereditary NB disease (Tonini 
et al., 2003). NB tumours are heterogeneous in their biological, genetic, and 
morphological characteristics and demonstrate diverse clinical phenotype. To date 
three clinical patterns o f NB have been identified: i) spontaneously regressing 
widespread disease; ii) non-metastatic local-regional disease, and iii) metastatic 
disease (stage 4 ,4S).
The study o f the molecular genetics o f NB in the last two decades has 
elucidated several non-random genetic events: allelic losses on chromosomes Ip, 2q, 
3p, 7q, l lq ,  14q and 19q, implicating putative tumour-suppressor gene (Ejeskar et 
al., 1998; Fong et al., 1992; Guo et al., 1999; Maris and Matthay, 1999; Maris et al., 
2002; Marshall et al., 1997), allelic gains on chromosomes Iq, 5q, 7q, 17q, 18q and 
probably affecting growth control genes (Bown et al., 1999; Janoueix-Lerosey et al., 
2000; Meltzer et al., 1996; Mora et al., 2002; Takita et al., 2000); amplification o f 
the oncogene MYCN  (Schwab, 1991; Seeger et al., 1985) and, changes in the normal 
diploid chromosomal content (Kaneko et al., 2000). M YCN  amplification, found to 
be relatively specific for tumours o f neural origin is an important prognostic marker 
and it is well known to correlate with advanced stage disease and in general with an
23
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increased risk of fatal outcome. MYCN  maps to 2p23-24 chromosomal region and it 
is retained in single copy at its normal position during amplification in human 
neuroblastoma cells (Corvi et al., 1994). Because MYCN  amplification occurs only in 
approximately half the cases o f advanced neuroblastoma, it has been suggested that 
MYCN  independent pathways exist in neuroblastoma progression (Brodeur et al., 
1997; Schwab et al., 1997).
High expression of the neurotrophin receptor TRKA is a favourable indicator 
-  perhaps mediating either apoptosis or differentiation in NB tumours. TRKA 
expression levels are inversely correlated to MYCN  amplification, indicating that this 
gene is not prognostic factor independent of M YCN  amplification (Brodeur et al., 
1984; Nakagawara et al., 1993; Tanaka et al., 1998). Conversely, high expression o f 
TRKB with its ligand might provide an autocrine survival pathway in unfavourable 
tumours, particularly those with MYCN  amplification (Brodeur, 2003).
Recently, Takita et al. (2004) performed DNA microarray analysis on early- 
and advanced-stage neuroblastoma in order to identify candidate genes involved in 
neuroblastoma progression. In the early stage group BIRC3 (Baculoviral lAP repeat- 
containing 3, API2) and CDKN2D (Cyclin-dependent kinase inhibitor 2D) genes 
were found significantly increased in their expression levels while SM ARC D 3  
(SWI/SNF related, subfamily d, member 3) expression resulted reduced, indicating 
that these genes are possible candidates for being novel prognostic markers for 
neuroblastoma.
Another prognostic example is measured on Ip NB deletion, which correlates 
with unresectable and metastatic disease, whereas localised and clinically favourable 
tumours showed an intact chromosome 1.
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Among genetic alterations in neuroblastoma, amplifications on Ip at bands 
lp34.2 and lp36.3 were also found (Fix et aL, 2004). Between the most occurring 
neuroblastoma chromosome abnormalities, chromosome 17 is often found as gain 
and the hot region of constant gain has been defined between 17q23.1 and 17qter. 
About 41% of tumours show 17q22 gain. Alternatively, gain o f whole chromosome 
17 is more likely to be seen in tumours showing favourable clinical outcome, while 
unbalanced partial 17q gain is significantly associated with a clinical risk in 
neuroblastoma. In chromosome 17q21 region there are several genes implicated in 
apoptosis, cell cycle control and neuroblastoma cell differentiation. This region 
includes NM23 genes {-HI and -H2) located at 17q21-22 (Backer et al., 1993). A 
striking correlation between MYCN  amplification and mRNA and protein expression 
of both NM23-H1 and NM23-H2 genes was reported for neuroblastoma (Godfried et 
al., 2002). The gain of function mutation (nm23Hl-S120G) has been identified in a 
high proportion of advanced neuroblastomas (Chang et al., 1994), as an indicator of 
poor prognosis and unfavourable outcome.
Because of the mRNA pattern of prune expression predominant in the mouse 
central nervous system, and of the interaction of H-PRUNE, impaired into the gain 
o f function mutation, nm23Hl-S120G, frequently encountered in NB (Chang et al., 
1994; Hailat et al., 1991; Lascu et al., 1997) we decided to investigate the role o f H- 
PRUNE in neuroblastoma tumour.
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H-PRUNE, NM23-H1 and breast cancer.
Breast cancer is the most common malignancy and the second most common 
cause o f cancer-related death in Western European and North American women. 
Mutations in B R C A l  and BRC A2  genes, as well as p5 3 , H er2/neu  and some 
regulatory proteins of the cell cycle, such as cyclinDl and p27 K ipl are used as 
molecular markers to predict breast cancer prognosis. In particular, mutations in 
BRCAl ?inàBRCA2 are found in hereditary breast cancer; the BRCAl and BRCA2 
proteins are implicated in DNA repair and recombination, checkpoint control of cell 
cycle, and transcription. However, only about 10% of breast cancer cases cluster in 
families. The majority of cases (“sporadic”) exhibit no clear-cut familial clustering 
and probably result from the collective effect of multiple, poorly penetrant variations 
in a much larger group of genes, modified by environmental factors (Venkitaraman, 
2002).
Several genes, such as ERBB2 (at 17ql2), MYC  (8q24), and CCNDl (1 lq l3 ) 
are amplified in 10-25% of tumours, and their amplification is associated with 
advanced stages o f the disease (Ross et al., 1999; Cuny et al., 2000). The 17q23 
amplification is associated with poor prognosis of breast cancer patients (Barlund et 
al., 2000); several genes as R P S6K B I, a mediator involved in G l- to S-phase 
progression of the cell cycle (Chou and Blenis, 1995) and APPBP2, a cytoplasmatic 
protein that is involved in cellular trafficking of amyloid precursor protein (Zheng et 
al., 1998) have been proposed as targets for the 17q23 amplification.
26
Introduction
About chromosomal abnormalities the gain o f the whole long arm (Iq) is 
most frequent in breast cancers; local amplification affecting Iq21 -q22 has been 
observed (Tirkkonen et aL, 1998).
A significant association between reduced NM23-H1 expression, at the 
mRNA and protein levels, and aggressive breast cancer behaviour was observed. The 
NM23-H1 is able to induce “low motility cellular processes” if  overexpressed in 
aggressive breast cancer cells (Freije et al., 1997a; Freije et al., 1997b). Transfection 
studies, in which human nm23-Hl cDNA was expressed in the metastatic human 
MDA-MB-435 breast carcinoma cell line, indicate that NM23-H1 suppresses in vivo 
metastatic potential by the means o f 50-90% (Leone et al., 1993a).
The anti-motility effect of NM23-H1 demonstrated in breast cancer and the 
amplification of the chromosomal region lq21 in which H-PRUNE maps, suggest us 
that breast cancer could be an interesting model for studying H-PRUNE function 
correlated to NM23-H1.
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Aim o f the project
The aim of this project is to investigate the functional role of H-PRUNE, 
focusing the attention on the biochemical characterization o f the protein and its 
possible correlation to tumour development and progression with respect to NM23- 
H l. The starting point o f the work was the interaction between H-PRUNE and 
NM23-H1, an anti-metastatic protein involved in different processes as proliferation, 
differentiation and motility.
Confirmed sequencing analysis has associated both Drosophila and human 
PRUNE proteins to a new family o f proteins named DHH phosphoesterases, 
including RecJ (exonuclease) and exopolyphosphatases (Aravind and Koonin, 
1998b). Among the different putative H-PRUNE activities, we decided to investigate 
first the phosphodiesterase (PDE) activity, which could be inversely correlated to the 
cAMP levels in the cell. In order to identify H-PRUNE catalytic activity, we plan to 
purify eukaryotic H-PRUNE to get a functionally active protein, using the 
Baculovirus expression system. After the identification of the enzymatic activity, the 
characterization of H-PRUNE could be performed defining the kinetic properties and 
the sensitivity to PDE inhibitors.
Since interaction between H-PRUNE and wild-type NM23-H1 and some 
mutants has already been demonstrated (Reymond et al., 1999), it would be 
interesting to demonstrate the interaction of H-PRUNE with NM23-H2, which shows 
high homology to NM23-H1.
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By using a variety of known mutations in NM23-H2 already characterized, in 
vivo co-immunoprecipitations will be performed in order to define the role of H- 
PRUNE in the binding capability, which can elucidate the role o f H-PRUNE with 
respect to NM23s proteins.
In order to clarify the role o f H-PRUNE and NM23-H1 in oncogenesis, we 
want to verify the expression level of both genes in sarcoma, neuroblastoma and 
breast cancer using specimens from early and advanced stages o f tumours, to study 
also the correlation with the tumour progression.
Furthermore, NM23-H1 shows a clear role o f in breast cancer (Leone et al., 
1993a). To study the role of H-PRUNE correlated to NM23-H1 in motility, we will 
produce stable clones transfecting h-prune and NM23-H1, alone or in combination, in 
human MDA-MB-435 breast carcinoma cell line and we will perform motility assays.
Reymond et al. (1999) showed a Prune  mRNA pattern o f expression 
specifically in central nervous system (CNS) during mouse development. It would be 
interesting to create a conditional FLIP/FRT prune KO mouse. We plan to prepare the 
construct to generate “null” prune mice by directing the complete disruption of the 
Prune gene using the FLIP recombinase system and, on the basis of the peculiar 
expression pattern of prune in mouse embryo, to verify a conditional FLIP/FRT KO 
mice in brain tissues.
Thus, this thesis represents an approach, both biochemical and functional, to 
elucidate H-PRUNE role in tumour development and progression.
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Cell culture
COS-7, HeLa, MDA-MB-435 breast cancer cell line and IMR-32 and SH- 
SY5Y neuroblastoma cell lines were cultured in Dulbecco’s modified Eagles’ 
medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 
jxg/ml streptomycin at 37°C with 5% CO2. Human neuroblastoma SK-N-BE and SK- 
N-SH cell lines were cultured in RPMI medium supplemented with 10% fetal bovine 
serum, 100 units/ml penicillin, 100 jxg/ml o f streptomycin, 1% non-essential 
aminoacids and 2% HEPES buffer at 37°C with 5% CO2.
Antibodies purification
The A59 polyclonal antibody was produced against a synthetic peptide 
designed on the basis o f the primary aminoacidic sequence, containing the DHR 
motif (conserved in some PDEs as PDE5, PDE 10A, PDEl 1 A). The peptide sequence 
is: NH2-ALEEAVAEVLDHRPIEPK-COOH (PRIMM).
The purification of rabbit IgG was performed on ProteinA Sepharose column 
(Amersham-Pharmacia) using 20 mM Na-phosphate pH 7.4 buffer. Column elution 
was performed with 100 mM glycine, pH 2.5. Buffer 1 M Tris-HCl, pH 9.0 was 
immediately added to each fraction ( 1/10 o f the fraction volume) in order to avoid 
antibody dénaturation. The fractions were further dialysed against 20 mM Na- 
phosphate pH 7.4. The antibody concentration was determined considering A280: 1,33 
O.D. corresponding to an IgG concentration of 1 mg/ml.
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Transient transfection and lysate preparation
Transient COS-7 cell co-transfection of prune-FLAG-pcDNA (previously 
prepared in Dr. Zollo’s laboratory) was performed by LipofectAMINE (Life 
Technologies, Inc.) according to the manufacturer’s instructions. COS-7 cells were 
seeded in 100-mm dishes at 75% confluence. Forty-eight hours after transfection, the 
cells were washed twice with ice-cold phosphate-buffered saline and scraped in ice- 
cold homogenization buffer (20 mM Tris-HCl, pH 7.4, 2 mM magnesium acetate, 
0.3 mM calcium chloride, 1 mM dithiothreitol, 2 pg/ml leupeptin, 2 [ig/ml aprotinin, 
2 pg/ml pepstatin A, 0.2 mM PMSF). The cell suspension was disrupted with a 
sonicator for 10 s (twice, with a 30 s interval) and the homogenates were centrifuged 
at 10,000xg for 20 min. The resulting whole extracts were assayed for total protein 
concentration.
Quantification o f  protein
Protein concentrations were determined using Bradford’s method (Bradford, 
1976). Protein samples were mixed with Bradford reagent (Bio-Rad) and the 
absorbance at 595 nm was measured on a spectrophotometer. Protein absorbances 
were converted to mg/ml concentrations using a standard curve constructed by 
measuring the absorbance of a range of bovine serum albumin (BSA) concentrations.
SDS/PAGE and Western blot analysis
Protein samples were resuspended in disruption buffer (Ix: 20 mM Tris-HCl
pH 6.8, 2% SDS, 5% p-mercaptoethanol, 2.5% glycerol and 2.5% bromophenol
blue) and denatured at 100°C for 5 min. Fifteen p,g of protein were analyzed by SDS-
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PAGE on a 10% (w/v) polyacrylamide gel, using a Bio-Rad mini gel equipment in 
accordance with the manufacturers instructions. New England Biolabs protein 
molecular weight markers were used (175-6.5 kDA range) to establish the apparent 
molecular weight of proteins resolved on SDS-polyacrilamide gels. All gels were run 
at 150V for an appropriate length of time, using SDS running buffer (25 mM Tris, 
192 mM glycine, 0.1% SDS). Proteins were electroblotted onto a PVDF membrane 
(Immobilon-P, Millipore) using a wet blotter (Bio-Rad) at lOOV for Ih  in blotting 
buffer (25 mM Tris, 192 mM glycine, 20% methanol). The membranes were blocked 
against non-specific binding o f antibodies with blocking buffer (PBS containing 5% 
skimmed milk powder and 0.1% Tween 20). H-PRUNE protein overexpressed was 
immuno-detected with polyclonal anti-A59 used at 1:500 dilution and anti-FLAG 
M2 (Sigma) used at 1:3000 dilution, incubated for 2 hrs at room temperature. After 
primary antibody incubation, membranes were washed (3x, 5 min) in a large excess 
of blocking buffer and then incubated with horseradish peroxidase-labeled anti-rabbit 
IgG and anti-mouse IgG for anti-A59 and anti-FLAG respectively, for Ih  at room 
temperature. Membranes were again washed (3x, 5 min) in a large excess o f 
blocking buffer and the v isualiza tion  was perform ed by enhanced 
chemiluminescence system (Amersham-Pharmacia), according to the manufacturer’s 
protocol.
In vitro site directed mutagenesis fo r h-prune mutants
In order to produce the h-prune mutant cDNAs, site-directed mutagenesis of 
the h-prune construct (prune-FLAGpcDNA, available in Dr. Zollo’s laboratory) was 
performed using the QuikChange III Kit (Stratagene) according to the manufacturer 
instruction. The following oligonucleotides were used to generate h-prune mutants:
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h-pruneA (DHRP126-129AAAA): 5’ -  GTA GCA GAG GTG CTA GCC G CT 
GCA GCC ATC GAG CCG AAA CAC -  3’.
D28A: 5’ -  GAA GCC TGT GCT TTG GAC TCC -  3’.
D106A: 5’ -  ACC CTC ATC CTT GTC GCT CAT CAT ATC TTA TCC -  3’. 
D179A: 5’ -  GAA CCA TCA TCC TGG CAT GTG TCA ACA TGG -  3’.
Mutated nucleotides are noted in boldface type and the altered codon is underlined. 
All mutations were confirmed by DNA sequencing.
Constructs fo r  expression studies
The cDNAs coding for nm23-Hl, nm23Hl-S120G, nm23Hl-P96S, h-prune, 
and h-prune mutants: h-pruneA, D28A, D106A, D179A, D28A-D106A, D28A- 
D106A-D126A, D28A-A, 4DA (D28A-D106A-A-D179A) (for the m utants 
preparation see “/«  vitro site directed mutagenesis fo r  h-prune mutants'" paragraph) 
were subcloned into the EcoRI/XhoI digested pFastBac-Hta vector (Invitrogen). The 
full-length h-prune, nm 23-Hl, nm23Hl-S120G and nm23Hl-P96S cDNAs were 
EcoRIiXhoI digQsXQd and isolated from the pcDNA vectors, available in Dr. Zollo’s 
laboratory.
Restriction enzyme digestion o f  DNA
DNA was digested in a final volume o f 20 p,l at 37°C for 1 h. All the 
restriction enzymes were New England Biolabs, and digestions were performed in 
appropriate buffers, supplied by the manufacturer with the enzyme. All digestions 
were analysed by agarose gel electrophoresis.
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Agarose gel electrophoresis
Agarose gels (1% w/v in TAB; 40 mM Tris-Acetate pH 7.5, 2 mM EDTA) 
were prepared and supplemented with ethidium bromide (lp,g /ml). The percentage 
of the agarose in gels was determined depending on the size o f the DNA fragments 
to be solved. Gels were generally run at 120V in Ix TAE buffer, and DNA was 
visualized on a UV transilluminator.
Isolation o f DNA from  agarose gel
Following agarose gel electrophoresis, DNA gel slices were excised under 
UV light. DNA was extracted from these gel slices using QiaexII Gel Extraction Kit 
(QIAGEN) following the protocol supplied by the manufacturer. Purified DNA was 
eluted from the resin using 20 pil dHiO.
DNA sequence analysis
For DNA sequence analysis, plasmids or PGR were processed by the DNA 
sequencing core at TIGEM.
Quantification o f plasmidic DNA
DNA concentration was determined for 1:100 dilutions o f stocks according to 
the following formula: absorbance of one A260 unit indicates a DNA concentration o f 
approximately 50 pg/ml.
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Ligation reaction
The ligation reactions were generally set up as follows:
X ng vector DNA : Y ng insert DNA = 1 : 2  
1 pi 1 Ox ligation
0,5 pi T4 DNA Ligase (400U/pl) (New England Biolabs) 
dHiO to lOpl
Ligation was carried out 16°C over night; the whole reaction was used for 
transformation of chemical competent DH5a E.coli cells. The resulting clones were 
analysed by restriction digestion and sequencing.
Transformation o f E.coli with plasmidic DNA
E.coli DH5a cells were prepared for transformation as follows: cells were 
grown to mid-log phase (A6oo=0.6) in Luria Broth (LB: 1% bactotryptone, 1% NaCl 
and 0.5% Bacto-yeast extract) at 37°C with shaking. Cells were collected by 
centrifugation at 2000xg at 4°C, resuspended into 30 ml (for each 100 ml of culture) 
o f RFl and kept on ice for 90 min. This suspension was then centrifuged at 2000xg 
for 15 min. The resulting pellet was resuspended in 4 ml (for each 100 ml o f culture) 
o f ice cold RF2 and kept on ice for 30 min. At this point cells were aliquoted and 
stored at -80°C. For each transformation, DNA was added to 50 pi o f competent 
cells and incubated on ice for 20 min; then, cells were subjected to heat shock at 
42°C for 2 min and successively incubated on ice for 10 min. Cells were recovered 
in 1ml of LB and incubated for 40 min at 37°C, before plating on LB-agar containing 
appropriate antibiotics and incubation at 37°C overnight.
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Solutions:
RFl (V=250ml)
1.86g KCl
2.47g MnCL 4H2O
0.74g CH3COOK
0.367g CaCl2 2 H2O
37.5ml glycerol
pH 5.8 (with CH3COOH)
RF2 (V=250ml):
0.52g MOPS 
0.187g KCl 
2.75g CaCl2 2 H2O 
37.5ml glycerol 
pH 7.0 (with HCl)
Isolation o f  plasmid DNA from  E.coli
Large-scale (midi-preps) and mini-preps plasmidic DNA preparations were 
carried out using the QIAGEN MIDI and MINI prep kits, respectively. Both 
procedures are based on the alkaline lyses method (Sambrook et al., 1989), but use a 
support column to purify isolated plasmid DNA. Purified DNA was always checked 
by enzymatic digestion with appropriate enzymes.
Protein expression and purification in Baculovirus
Protein expression o f H-PRUNE, H-PRUNE mutants (H-PRUNEA, D28A, 
D106A, D179A, D28A-D106A, D28A-D106A-D126A, D28A-A, 4DA), NM23-H1, 
NM23H1-S120G and NM23H1-P96S, was performed using Baculovirus Expression 
System (Invitrogen). Virus infection and purification conditions were set up in the
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Dr. Zollo’s laboratory and described in (Garzia et al., 2003). Histidine-tagged H- 
PRUNE and H-PRUNEA were further purified on a MonoQ HR 5/5 column 
(Amersham-Pharmacia) using 10 mM Tris-HCl pH 8.0 buffer. Column elution was 
performed with a linear gradient from 0 to 0.8 M NaCl, over 20 min and at a flow 
rate of 1 ml/min. The fractions were further dialysed against 10 mM Tris-HCl pH 8.0 
buffer, and tested for activity. The purity o f isolated proteins was measured by 
electrophoresis SDS page analysis.
Identification o f the H-PRUNE phosphodiesterase activity
Phosphodiesterase (PDE) activity was measured by a cAMP/cGMP 
scintillation proximity assay (Amersham-Pharmacia). Samples were diluted as 
required and incubated at 30°C in 100 pi assay buffer (50 mM Tris-HCl pH 7.4, 8.3 
mM MgCli, 1.7 mM EGTA) containing the desired concentrations o f cAMP or 
cGMP as substrate (3:1 ratio unlabeled to ^H-labeled). All reactions, including 
buffer-only blanks, were conducted in triplicate and allowed to proceed for an 
incubation time giving <25% substrate turnover (empirically determined). Reactions 
were terminated by adding 50 p i Yttrium silicate SPA beads (Amersham- 
Pharmacia). Enzyme activities were calculated for the amount o f radiolabeled 
product detected according to the manufacturer protocol. We performed the assay on 
H-PRUNE, H-PRUNEA mutant and H-PRUNE pre-incubated with the A59 
polyclonal antibody. As positive control we used the PDE2 (Sigma). In particular, 
for H-PRUNE and H-PRUNE mutants PDE activity, 200 ng o f purified enzymes 
were incubated for 10 min at 30 °C.
Lineweaver-Burk plots with Km and Vmax values were determined by 
measuring hydrolysis with a range o f substrate concentrations (0.05-10.0 pM) and a
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fixed amount of diluted enzyme over a time course of 5-40 min. Initial rates were 
calculated at each substrate concentration and plotted against substrate concentration, 
from which the kinetic parameters were determined.
Characterization o f the H-PRUNE phosphodiesterase activity
To study the influence o f different buffers on H-PRUNE PDE activity we 
modified PDE assays, using 50 mM Tris-HCl pH 7.4 or 50 mM HEPES buffer pH 
7.5 with increasing concentrations (0, 1 , 2 , 4 , 8 , 1 6  and 32 mM) o f MgCb. To study 
the ion influence we performed the PDE assays in 50 mM HEPES buffer pH 7.5 (in 
order to avoid oxido-reduction reactions) at increasing concentrations ( 1 ,2 ,4 ,  8, 16, 
32 and 64 mM) of MgCb or MnCb salt. As a negative control, we used H-PRUNEA 
in the same conditions used for H-PRUNE. H-PRUNE activity in the absence of ions 
was tested after extensive dialysis o f the protein against 50 mM Tris-HCl pH 7.4, 1.7 
mM EGTA or 50 HEPES buffer pH 7.5, 1.7 mM EGTA.
The influence of NM23 (NDPK) activity on H-PRUNE PDE activity was 
investigated performing the assays with a pre-incubation of purified H-PRUNE with 
NM23s (yield of purification 70%, -HI,  -H1-S120G or -H1-P96S). We tested the 
possible influence of NM23-H1 on H-PRUNEA pre-incubating the mutant purified 
protein with NM23-H1 and performing the PDE assay.
For the inhibitor studies, eight different potential inhibitors were tested: 
cilostamide, dipyridamole, 3-isobutyl-1-m ethylxanthine (IBMX), m ilrinone, 
rolipram, vinpocetine, sulindac and zaprinast (Sigma). A low concentration o f cAMP 
(0.01 fxM) was employed in order to approximate the IC50 to the Kj. All inhibitor 
studies were carried out in triplicates and were repeated three times.
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Immunohistochemical analysis in sarcomas
All immunohistochemical analyses were done on paraffin sections from 
individual samples or the tissue array. Thirty cases comprising leiomyosarcomas, 
liposarcomas, malignant fibrous histiocytomas, malignant Schwannomas (malignant 
peripheral nerve Sheath tumour), and well-differentiated liposarcomas were 
analyzed. Also, six mammary carcinomas were analysed by immunohistochemical 
analysis.
The ABC procedure was used for immunohistochemistry (VECTASTAIN 
from Vector, Vector Laboratories, Inc). Colorimetric reaction was performed by 
using DAB (Vector, Vector Laboratories, Inc). Microwave pre-treatment was used 
for NM23-H1 detection for 15' at 90°C in 10 mM NaCitrate pH 6 . The monoclonal 
antibody anti-NDP kinase nm23-Hl, clone NM301 (Santa Cruz, USA) was used at 
1:25 dilution; the prune A59 polyclonal antibody was used at 1:300 dilution. The 
primary antibody was omitted for negative controls. Positive controls included 
sections from tissues known to be positive. The controls gave satisfactory results.
Evaluation o f results
Tumours were considered positive if  at least 10% of the tumour cells were 
stained. Signal intensity was grouped as follows: negative (0, expression in <10% of 
the cells), weakly positive (1, expression in 10-30% of the cells), moderately positive 
(2, expression in 30-50% of the cells) and strong (3, expression in >50% o f the 
cells).
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Transient transfection in NIH3T3 cells
1x10^ NIH3T3 cells were transfected by Lipofectamine reagent (Gibco-BRL) 
with 10 ng of pcDNA vector containing h-prune cDNA-FLAG gene under a CMV 
promoter. Forty-eight hours after transfection, cells were plated for proliferation 
assay.
pBABE vector modification
pBABE puro-PC3 vector was modified to include a FLAG epitope at the 
carboxy-terminal region o f the protein and an SP6 promoter and primer site at the 3' 
terminus in the poly-linker sequence at the EcoRI site (modification performed in Dr. 
Zollo’s laboratory). The vector was used to subclone, into the EcoRI/XhoI sites, the 
entire h-prune full-length cDNA, digested from the HA-prune-pcDNA.
The pBABE-pruneFLAG construct was further modified in order to include 
a His-tag at the NHi-terminal region. The His-tag was amplified from the pFastBac- 
Hta vector (Invitrogen) by using the Polymerase Chain Reaction (PCR). The 
following oligonucleotides were used to amplify the His-tag with BamHI and EcoRI 
ends:
His Forward: 5’-CCG GGA TCC ACC ATG TCG TAG TAC-3’
His Reverse: 5’-CGC GAA TTC GGC GCC CTG AAA ATA CAG-3’
We used Pfu Polymerase as follows:
40 ng DNA template 
5 ^1 Pfu buffer 
20  pmol forward primer 
20 pmol reverse primer
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1 \x\ Pfu polymerase (SU/^il)
0.2 mM of each dNTP 
dPLO to 50^1
The PCR reaction was performed with the following cycling parameters:
1 cycle: 1 min at 95°C 
20 cycles: 30 sec at 95°C
30 sec at the annealing temperature
30 sec at 72°C (Imin per each Kb of DNA to amplify)
1 cycle: 10 min at 72°C.
The resulting purified PCR product was analysed by agarose gel electrophoresis, and 
extracted from the gel using Qiaquick columns (QIAGEN), according to the 
manufacturer’s protocol. The purified DNA was then digested with BamHI and 
E coR I restriction enzymes and the fragment was subcloned in frame into the 
BamHI/EcoRI digested pBABE-pruneFLAG eukaryotic vector, in order to obtain the 
pBABE-HispruneFLAG vector (pBABE-h-prune).
H-prune retrovirus production
The pBABE-h-prune vector was used in transient transfection o f BOSC 23 
ecotropic retroviruses cells as described (Pear et al., 1993). High titer retrovirus 
supernatant was collected and used to infect NIH3T3 cells lines. After 4 days on 
puromycin (2 mg/ml) selection, the cells were tested by a cellular proliferation assay.
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Cellular proliferation assay
To test cellular proliferation we used the viability assay MTS protocol (Cell- 
Titer 96TM AQueous proliferation assay-Promega), which is based on the cellular 
conversion o f a tétrazolium salt into a formazan product. The assay measures 
dehydrogenase enzyme activity found in metabolic active cells. Cells, both 
transfecetd and infected, were plated in a 96 well plate and measured by MTS 
protocol (48, 72 and 96 h later). The cell concentrations were ranging from 2.5, 5 and 
10x10^ cells per well. A colorimetric reaction was performed after incubation o f the
cells for 2 h at 37°C measuring the absorbance (O.D.) at 490 nm using a Packard 96- 
well reader spectrophotometer.
Immunofluorescence analysis on neuroblastoma cell lines
Neuroblastoma SH-SY5Y, IMR-32, SK-N-BE and SK-N-SH cell lines were 
attached to slides (Lab-Tek II Chamber Slide, Nalge Nunc International). Twenty- 
four h after coating, the cells were washed twice with ice-cold phosphate-buffered 
saline (PBS) and treated by immunofluorescence analyses following standard 
techniques. Fixed cells were incubated for 3 h at room temperature with primary 
antibody diluted (1:100) in PBS/porcine serum. Slides were then washed three times 
in PBS and incubated in PBS/porcine serum containing directly conjugated 
secondary antibodies (1/100). Secondary antibodies were FITC-conjugated goat anti­
mouse IgG and Texas red-conjugated pig anti-rabbit IgG. After labelling, slides were 
washed three times in PBS and mounted in 10% glycerol. For immunostaining, the 
following antibodies were used: rabbit polyclonal anti-h-prune (A59), monoclonal
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antibody anti-NDP kinase nm 23-H l, clone NM301 (Santa Cruz, USA) and 
monoclonal anti-human nm23-H2, clone H2-206 (Seikagaku Corporation). We 
performed immunofluorescence analysis on transiently trasfected COS-7 cells using 
anti-FLAG M2 (Sigma) or anti-HA clone 12CA5 (Roche) antibodies. Nuclei were 
counterstained with 4 ’,6-diamidino-2-phenyl-indole (DAPI).
In vitro site directed mutagenesis fo r nm23-H2 mutants
To produce the human nm23-H2, -H2-H118F, -H2-N69H, -H2-S122P 
mutants, site directed mutagenesis o f nm23-H2 construct (HA-nm23-H2pcDNA 
available in Dr. Zollo’s laboratory) was performed using QuikChange III Kit 
(Stratagene) according to the m anufacturer’s directions. The follow ing 
oligonucleotides were used to generate the asparagine to histidine mutant (N69H): 
5’-G G G  CTG GTG AAG TAG ATG CAC TCA GGG CCG GTT G TG -3’. To 
create the histidine to phenylalanine (H118F) mutant we used the oligonucleotide 
5’-CAG GTT GGC AGG AAC ATC ATT TTT GGC ACT GAT TCA GTA AAA 
A G -3’ and for the serine to proline (S122P) mutant we used the oligonucleotide: 
5’-GGC AGT GAT CCA GTA AAA AGT G C -3’. Mutated nucleotides are noted in 
boldface type, and the altered codon is underlined. All mutations were confirmed by 
DNA sequencing.
Co-immunoprecipitation and immunoblotting
The co-immunoprecipitation assays were performed on both SH-SY5Y 
neuroblastoma cells and transiently transfected COS-7 cells. Transient COS-7 cells 
were co-transfected with prune-FLAG-pcDNA and HA-nm23-pcDNAs by
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LipofectAMINE (Life Technologies, Inc.) according to the m anufacturer’s 
instructions. The resulting whole extracts o f both SH-SY5Y and transiently 
transfected COS-7 cells (see ^Transient transfection and lysate preparation” 
paragraph for lysate preparation) were assayed for total protein concentration. Each 
lysate of SH-SY5Y neuroblastoma cells was divided into two aliquots and incubated 
with rabbit polyclonal anti-h-prune (A59) and monoclonal anti-human nm23-H2, 
clone H2-206 (Seikagaku Corporation) overnight at 4°C. Each lysate of transiently 
transfected COS-7 cells was divided into two aliquots and incubated with anti-FLAG 
M2 (Sigma) or with anti-HA clone 12CA5 (Roche) overnight at 4°C. Twenty p,g of 
Protein-A beads (Amersham-Pharmacia) were added, and the mixtures were 
incubated for 1 h at 4 °C. The immunoprecipitates were washed three times in 
extraction buffer and the pellets were resuspended in electrophoresis sample buffer. 
Samples were boiled for 5 min and proteins were analyzed by SDS-PAGE on a 10% 
(w/v) or 12.5% (w/v) polyacrylamide gel. Proteins were electroblotted onto a PVDF 
membrane (Immobilon-P, Millipore). For the SH-SY5Y neuroblastoma cells, H- 
PRUNE and NM23-H2 proteins were immuno-detected with rabbit polyclonal anti- 
h-prune (A59) and monoclonal anti-human nm23-H2, clone H2-206 (Seikagaku 
Corporation), respectively. For the transiently transfected COS-7 cells, NM23 and H- 
PRUNE proteins were immuno-detected with monoclonal anti-HA and anti-FLAG 
antibodies, respectively. After incubation with horseradish peroxidase-labeled anti­
mouse IgG, visualization was perform ed by enhanced chem ilum inescence 
(Amersham-Pharmacia).
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Stable clone analysis in neuroblastoma SH-SY5Y cell line
The neuroblastoma SH-SY5Y cell line was transfected with the pBABE-h- 
prune expression vector. The transfections were performed using LipofectAMINE 
(Invitrogen), according to the manufacturer instructions. Transfectants were selected 
in Dulbecco’s modified Eagles’ medium (DMEM) containing 10% fetal bovine 
serum, 100 Units/ml penicillin, 100 jxg/ml streptomycin and 2 jig/ml puromycin 
(Sigma). For the bulk transfected lines, plates containing forty puromycin-resistant 
colonies were trypsinized, and cell lines were established. Two pBABE-h-prune-SH- 
SY5Y puromycin-resistant clones (SH-5YSY-prune #2 and #3) were isolated and 
characterized both by western blot analyses.
For western blot analysis, 15 |ig o f protein lysate in sample buffer were 
analyzed by SDS-PAGE on 10% (w/v) or 12.5% (w/v) polyacrylamide gels and were 
electroblotted onto a PVDF membrane (Immobilon-P, Millipore). The lysates were 
immuno-detected with the A59 polyclonal antibody for H-PRUNE, with the nm23- 
H1 antibody (clone NM301; Santa Cruz, USA) for NM23-H1 and with the 
monoclonal anti-human nm23-H2, clone H2-206 (Seikagaku Corporation), as 
described in ^'SDS/PAGE and Western blot analysis” paragraph. For normalization 
the lysates were immuno-detected with the polyclonal anti-histone H3 for histone H3 
used at 1:1000 dilution (Upstate Biotechnology).
Immunofluorescence analysis on neuroblastoma stable clones
An immunofluorescence analysis was performed on the SH-5YSY-prune #2 
and #3 stable clones following the protocol reported in ^Im m unofluorescence  
analysis on neuroblastoma cell lines ” paragraph. For immunostaining, the following
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antibodies diluted (1:100) were used: rabbit polyclonal anti-prune (A59), monoclonal 
anti-NDP kinase nm23-Hl antibody, clone NM301 (Santa Cruz, USA), monoclonal 
anti-human nm23-H2, clone H2-206 (Seikagaku Corporation) and the monoclonal 
Penta-His antibody against the His-tag (QIAGEN).
Expression analysis in neuroblastoma cohorts
An immunohistochemical analysis of H-PRUNE, NM23-H1 and NM23-H2 
in 47 cases of neuroblastoma (4 from San Raffaele Scientific Institute, 14 from Bari, 
2 from Children Hospital Vittore Buzzi and the remaining from Associazione 
Italiana lotta al Neuroblastoma databank) was performed using the following 
antibodies: the rabbit polyclonal anti-prune (A59) used at 1:100 dilution, the 
monoclonal antibody anti-NDP kinase nm23-Hl, clone NM301 (Santa Cruz, USA) 
at 1:25 dilution and the monoclonal anti-human nm23-H2, clone H2-206 (Seikagaku 
Corporation) at 1:150 dilution. The ABC procedure was performed as described as in 
'Immunohistochemical analysis in sarcomas'' paragraph.
Chromatin immunoprécipitation o f h-prune, nm23-H2, and nm23-Hl 
promoter sequences
The chromatin immunoprécipitation assay (ChIP) was performed on SH-
5
SY5Y neuroblastoma cell lines. Cells, plated 7-9x10 in 100mm Petri dish, were 
cultured in 8ml DMEM supplemented with 10% FBS. The experiment was divided 
in different steps as described below.
CRO SS-LINKING : Cells were fixed by adding 800pl (1/lOvol) o f cross-linking 
solution (11% formaldehyde, 0.1 M NaCl, 1 mM Na-EDTA pH 8 , 0.5 mM Na-
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EGTA pH 8 , 50 mM Hepes pH 8), and by leaving cells in the incubator for an 
additional 20 min. Cross-linking reaction was stopped by addition o f 10ml o f 
quenching solution (0.125 M Glycine in Phosphate-Buffered Saline (PBS)) and 2-3 
minutes incubation at room temperature. Plates were put on ice and washed once 
with ice-cold 0.5 mM PMSF in PBS. All o f the passages reported below were 
performed on ice. One ml buffer A (0.25% Triton X-100, 10 mM Na-EDTA pH 8 , 
0.5 mM Na-EGTA pH 8 , 10 mM Tris-HCl pH 8 , 0.5 mM PMSF, 10 pg/ml aprotinin, 
10 ng/ml leupeptin, 5 mg/ml pepstatin, 0.1 mM sodium orthovanadate, 1 mM tetra- 
sodium pyrophosphate, 1 mM NaF) was added, cells were scraped and collected in 
final 10 ml buffer A/dish in a 15 ml tube. After 10 min incubation at 4°C on a 
rotating wheel, cells were centrifuged for 5 min at lOOOxg, and the pellet was 
resuspended in 10ml o f buffer B (0.2 M NaCl, 10 mM Na-EDTA pH 8, 0.5 mM Na- 
EGTA pH 8 , 10 mM Tris-HCl pH 8 , 0.5 mM PMSF, 10 |ig/ml aprotinin, 10 pig/ml 
leupeptin, 5 mg/ml pepstatin, 0.1 mM sodium orthovanadate, 1 mM tetra-sodium 
pyrophosphate, 1 mM NaF). Incubation and centrifugation steps were then repeated, 
and the pellet was resuspended in 440 \i\ o f sonication buffer (0.2 M NaCl, 10 mM 
Na-EDTA pH 8, 0.5 mM Na-EGTA pH 8 , 10 mM Tris-Cl pH 8, 0.5 mM PMSF, 10 
p,g/ml aprotinin, 10 jxg/ml leupeptin, 5 mg/ml pepstatin, 1 mM sodium 
ortho vanadate, 10 mM tetra-Sodium pyrophosphate, 10 mM NaF). Samples were 
sonicated for 3x30 sec, yielding genomic DNA fragments with a bulk size o f 500- 
2000 base pairs, and the sonication buffer was adjusted to a RIPA buffer (IP buffer) 
by adding to the sonication buffer 1% Triton X-100, 0.1% SDS, and 0.1% Sodium 
Deoxycholate (DOC) final concentration. Samples were incubated for 10 min on a 
rotating wheel at 4°C and then centrifuged for 10 min at lOOOOxg. Fifty fxl/sample
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were kept to recover total DNA input, and the lysates were subjected to 
immunoprécipitation.
PRE-CLEARING: Twenty p,g o f Protein A-sepharose (Amersham-Pharmacia) in 
PBS was incubated in IP buffer without anti-proteases and anti-phosphatases, with 1 
mg/ml BSA and 0.25 mg/ml sheared Salmon sperm final concentration, at 4°C over 
night on a wheel. Eighty \i\ o f blocked protein A beads were then added to the 
lysates and incubated for 30 min-1 hr at 4°C on a wheel and centrifuged for 2 min at 
5000xg at 4°C.
IM M U N O PREC IPITATIO N: Supernatants were transferred to new tubes and 
incubated over night, either with 2 pig o f antibody (anti-human MYCN clone 2 - 
Santa Cruz - for h-prune promoter; anti-h-prune A59 for NM23-H2 promoter; anti­
human nm23-H2 clone H2-206 - Seikagaku Corporation - for NM23-H1 promoter) 
or without antibody, at 4°C on a wheel. Immune complexes were recovered by 
adding 80 ^1 o f blocked protein A-beads and incubated Ih at 4°C on a wheel. Beads 
were washed for 5 times in RIPA buffer, once with LiCl buffer (0.25 M LiCl, 0.5% 
NP-40, 0.5% DOC, 10 mM Tris-HCl pH 8 , 1 mM Na-EDTA pH 8 , 0.1 mM PMSF, 
10 fxg/ml aprotinin, 10 ^ig/ml leupeptin, 5 jxg/ml pepstatin, 0.1 mM sodium 
ortho vanadate, 1 mM tetra-sodium pyrophosphate, 1 mM NaF) and twice with TE 
buffer. DNA-protein complexes were eluted by adding 250 \i\ o f elution buffer (1% 
SDS, 0.1% NaHCOs) and incubated for 15 min on a wheel at RT. After 1 min 
centrifugation at 5000xg at RT, supernatant was transferred to a new tube and elution 
was repeated.
REVERSAL o f  CROSS-LINKING: In order to revert cross-linking, NaCl 0.2 M final 
concentration was added to ChIP samples and DNA input, and incubated over night 
at 65°C. Proteins were then digested by incubating for Ih at 45°C after adding 20
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jxM Tris-HCl pH 6.5 and 0.8 mg/ml proteinase K final concentration, and extracted 
once with phenol chloroform and once with chloroform. DNA was precipitated in 2.5 
volumes ethanol 100%, 1/10 volume 3M Na-Acetate pH 4.8, and 20 [ig glycogen, 
washed with ethanol 70%, centrifuged for 2 min at lOOOOxg and resuspended in TE 
buffer (10 mM Tris-HCl pH 8 and 1 mM Na-EDTA pH 8) 50pd for input DNA 
samples and lOOpl for ChIP DNA.
PC R \ For total chromatin immunoprecipitated both with anti-Nmyc (Santa Cruz, 
USA) and the monoclonal antibody anti-NDP kinase nm23-Hl, clone NM301 (Santa 
Cruz, USA) as negative control, PCR reactions were performed using the following 
oligonucleotides:
E l- Forward: 5’- ACC TTA AAG GGG GTG C -  3’
E l- Reverse: 5’ -  CTC CAG TGC CGC CAG TAG T -  3’
E2- Forward: 5’-  GTT GTG GCC ACT TCC GGA CT -  3’
E2- Reverse: 5’ -  TTT CTT CGT CCT GAT GAG AAC -  3’
For total chromatin immunoprecipitated both with anti-human prune A59 
and the monoclonal antibody anti-NDP kinase nm23-Hl, clone NM301 (Santa Cruz, 
USA) as negative control, PCR reactions were performed using the following 
oligonucleotides:
H2-A Forward: 5’- TCAGAGTCCTGAGGGGAAGCAAG -  3’
H2-A Reverse: 5’ -  GGAAAGTCTAGACCCTGTCATAGAGA -  3’
H2-B Forward: 5’-  CACTGCAAGTAGGAAGTGTCTAC -  3’
H2-B Reverse: 5’ -  GCCTCCCCACCTACATTTCC -  3’
H2-C Forward: 5’ -  AAAACTCGACCGCACTTTAGTGC - 3 ’
H2-C Reverse: 5’ -  CTTTGCTCAGCACCTCAAACG - 3 ’
H2-D Forward: 5’ -  TCATCAAGGCAGGGCAGAGG -  3’
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H2-D Reverse: 5’ -  CCGGCATTAACCTTGACTTGG -  3’
H2-E Forward: 5’ -  GGATAAGGACCGTGGGTGCAC -  3’
H2-E Reverse: 5’ -  CCTATGAGTTCAACTACGCACGT - 3’
H2-F Forward: 5’- A C TG A G A G G TG A G G A G TG G G  -  3’
H2-F Reverse: 5’ -  GCGGCCGGAGAACAGTGT -  3’
H2-G Forward: 5’ -  GTCTCGATCTCTGCCTGGC -  3’
H2-G Reverse: 5’ -  GAGAGCAGAGAGCTGGTGCG -  3’
H2-H Forward: 5’ -  TGTGGTGGTCGCACCAGCTC -  3’
H2-H Reverse: 5’ -  GGGACCTGCGGGAAATC -  3’
H2-I Forward: 5’ -  GATTTCCCGCAGGTCCC -  3’
H2-I Reverse: 5’ -  CCCTCTGCGGAGCCCGAA -  3’
For total chromatin immunoprecipitated both with the anti-human nm23-H2, 
clone H2-206 (Seikagaku Corporations) and the anti-human prune A59 as negative 
control, PCR reactions were performed using the following oligonucleotides:
H l-A  Forward: 5’- TTTCCAGCGTGCTGGGATTAC -  3’
HI-A Reverse: 5’ -  CAAAATGAATCATAGATTTAAATG -  3’
H l-B Forward: 5’ -  CCCCATAAGTGATTTATTG -  3’
H l-B  Reverse: 5’ -  AACATTCCCACTGCTCTAAGG -  3’
H l-C  Forward: 5’ -  TATTAGCATCTCACAACATAAG -  3’
H l-C  Reverse: 5’ -  GCAAATTAATATGTAATAGATCGC -  3’
H l-D  Forward: 5’ -  CCTTTTCTTCACAGCACTTAC -  3’
H l-D  Reverse: 5’ -  GACTTTTCGCTCCCGCTTTGT -  3’
H l-E  Forward: 5’ -  CTTGACAGGCTAGAAAAGG -  3’
H l-E  Reverse: 5’ -  GGCGCTAGCTTTTTCAGACC -  3’
H l-F Forward: 5’ -  AAGAAAGCAAGCAGCTAACC -  3’
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H l-F Reverse: 5’ -  GCACGCACGGAACGCTTC -  3’
For all the PCR reactions, we used AmpHTaq Polymerase (Perkin Elmer) as 
follows:
2 pi DNA immunoprecipitate or 2 pi of a 1:100 dilution of the total sample
5 pi Taq buffer
20 pmol forward primer
20 pmol reverse primer
1 pi Taq polymerase (2.5U/pl)
2.5 mM MgCb 
0.2 mM of each dNTP 
dEbO to 50pl
The PCR reactions were performed with the following cycling parameters:
1 cycle 10 min at 95°C
20 cycles 30 sec at 95 °C
30 sec at the annealing temperature
30 sec at 12°C (Imin per each Kb of DNA to amplify)
1 cycle 10 min at 72°C
The resulting purified PCR products were analysed on agarose gels.
pBABE constructs fo r expression studies
H-pruneA and h-prune4DA cDNAs were subcloned into the E coR I/X hoI  
digested pBABE-His-FLAG vector, in order to obtain pBABE-pruneA and pBABE- 
h-prune4DA constructs.
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The human PDE5A cDNA was PCR amplified from PDE5A-pSVL construct 
(a gift from Dr. Keni Omori), adding EcoRI and X h o l restriction ends, in order to 
clone it into the same His-tagged vector. The following oligonucleotides were used: 
PDE5 Forward: 5’-A TA  GAA TTC ATG GAG CGG GCC GGC CCC A G C-3’ 
PDE5 Reverse: 5’-ATA CTC GAG GTT CCG CTT GGC CTG GCC GCT-3’
For the PCR reaction, we used Pfu Polymerase as follows:
40 ng DNA template 
5 pi Pfu buffer 
20 pmol forward primer 
20  pmol reverse primer 
1 pi Pfu polymerase (3U/pl)
0.2 mM of each dNTP 
dHiO to 50pl
The PCR reaction was performed with the following cycling parameters:
1 cycle 1 min at 95 °C
30 cycles 30 sec at 95°C
30 sec at the annealing temperature
2 min 30 sec at 72°C (Imin per each Kb of DNA to amplify)
1 cycle 10 min at 72°C
The resulting purified PCR product was cloned into the pBABE-His-FLAG vector in 
order to obtain the pBABE-His-PDE5-FLAG construct (pBABE-PDE5A).
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Stable clones analysis in MDA-MB-435 breast cancer cell line
The MDA-ClOO, MDA-Hl-177, MDA-nm23Hl-S120G and MDA-nm23Hl- 
P96S clones (produced by Dr. P.S. Steeg) were transfected with the pBABE-h-prune 
expression vector. The MDA-ClOO clone was transfected with the pBABE-h- 
pruneA, pBABE-h-prune4DA, and pBABE-PDE5A expression vector. The 
transfections were performed using LipofectAMINE (Invitrogen), according to the 
manufacturer instructions. Transfectants were selected in Dulbecco’s modified 
Eagles’ medium (DMEM) containing 10% fetal bovine serum, 100 Units/ml 
penicillin, 100 pg/ml streptomycin and 2 pg/ml puromycin (Sigma). For the bulk 
transfected lines, plates containing one hundred puromycin-resistant colonies were 
trypsinized, and cell lines were established. Several pBABE-h-prune, pBABE-h- 
pruneA, pBABE-h-prune4DA and pBABE-PDE5A puromycin-resistant clones were 
isolated for every MDA clone transfected and characterized by western blot analyses. 
For western blot analysis, 15 pg of protein lysate in sample buffer were analyzed by 
SDS-PAGE on 10% (w/v) or 12.5% (w/v) polyacrylam ide gels and were 
electroblotted onto a PVDF membrane (Immobilon-P, Millipore). The lysates were 
immuno-detected with the specific h-prune A59 polyclonal antibody for H-PRUNE, 
with the nm23-Hl antibody (clone NM301, Santa Cruz, USA) for NM23-H1 and 
with the Penta-His antibody against a His-tag (QIAGEN) for PDE5A. After 
incubation with horseradish peroxidase-labeled anti-IgG, visualization was 
performed by enhanced chemiluminescence (Amersham-Pharmacia). Eleven cell 
lines, MDA-prune (clone #3 and #4), MDA-H1-177-prune (clone #7 and # 8), MDA- 
nm23Hl -S120G-prune (clone #2 and #3), MDA-nm23Hl-P96S-prune (clone #4 and
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#5) and MDA-prune A (clone #11), MD A-prune4D A (clone #19), MDA-PDE5A 
(clone #14), were selected and proteins were normalized on Western blots.
In vitro cell motility assay
Stable MDA clones overexpressing h-prune, h-pruneA, h-prune4DA and 
human PDE5A were analyzed by motility assay, using the trans-well technology (6- 
well - Corning-Costar). In the lower wells, we incubated 2.5 ml o f “motility” 
medium (DMEM containing 0.1% BSA, 100 Units/ml penicillin, 100 pg /m l 
streptomycin, 5 mM HEPES buffer) and the diluted chemo-attractant; in the upper 
wells, we incubated 1x10^ cells in 1.5 ml o f motility medium. The trans-wells were 
incubated for 3 h at 37 °C with 5% CO2. After the attraction procedure, the cells 
were fixed and stained with Hematoxylin solution Gill n°l following manufacturer 
protocol (Coming-Costar); the cells were finally counted under the microscope. The 
control MDA-ClOO breast cancer cell line was used in the cell motility assay, as 
described (Leone et al., 1993a, Leone et al., 1993b), with the cell line overexpressing 
NM23-H1 (MDA-Hl-177), which shows an inhibition o f metastasis processes in 
vivo. Cellular motility was determined using the trans-well technology (6 -well - 
Corning-Costar) using 0.25%, 0.5% PCS, and 2.5, 5.0 ng/ml fibronectin (Sigma) 
final concentrations as chemo-attractants. The in vitro h-prune inhibition motility 
assay was performed as follow. The MDA-prune (clone #3 and #4) and MDA- 
pruneA (clone #10 and #11) were incubated with dipyridamole (8 pM, a 10-fold 
higher concentration with respect to its IC 50) for 24 h to obtain the complete enzyme 
inactivation, and then the motility assay was repeated as described above.
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cAMP content in MDA stable clones
cAMP levels were determined by an immunoassay (R&D systems). For the 
quantitative determination o f cAMP in MDA-ClOO and MDA-prune #3 and #4 
stable clones, 0.1 M HCl was added to a pellet o f 1x10^ cells to prepare the lysates. 
Each experiment was repeated three times in duplicate.
Statistical analyses
All the assays including PDE activity and cellular motility were validated 
using  the unpaired  T -test m ethod using  the too l av a ilab le  at 
http://www.graphpad.com/quickcalcs/index.cfm.
Immunohistochemical analysis on breast cancer samples
Multiple Tissue Array (MTA) breast were immunodetected with the specific 
A59 h-prune polyclonal antibody at 1:300 dilution and the nm23-Hl antibody clone 
K73 at 1:25 dilution (specific for the -HI and H2 isoforms; Apotech Corporation, 
CH). The ABC procedure was performed as described as in "Immunohistochemical 
analysis in sarcomas" paragraph. Intensity o f immunohistochemical staining was 
used to classify the tumor samples as positive if  present in at least 2 0 % of cells 
analyzed under the microscope (strong +++, moderate ++, diffusely weak staining + 
or negative 0 (absent or focally weak staining) for H-PRUNE and NM23-H1 proteins 
expression.
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Tumour case collection and TNM selection
Tumour cases have been collected by AUSLl of Sassari (Italy), including 
patients with a minimum of five years follow-up. The TNM system classification 
applied to this study and since described by Sobin et al. 1997 was used for describing 
the anatomical extent of disease and is based on the assessment of three components: 
T corresponds to the extent o f the primary tumour (from TO to T4), N corresponds to 
absence or presence and extent of regional lymph node metastasis (from NO to N4), 
and M stands for the absence or presence o f distant metastasis (MO or M l). Our 
collection o f fifty-nine tumour breast cases has been categorized as TxNxM l 
positive.
Bioinformatic analysis o f  differentially expressed genes in breast 
cancer stable clones
A gene expression profiling was performed in Dr. Zollo’s laboratory 
(D’Angelo et al., 2004). We selected the genes differentially expressed (P value ^ 
0.05) in MD A-H 1-177 -prune #8 clone with respect to MDA-Hl-177 clone. To study 
the possible pathways altered upon H-PRUNE overexpression, we performed a 
literature search using PubMed annotation thttp://www.ncbi.nlm.nih.gov/entrezA.
Construct fo r  conditional Knock Out mouse model
In order to prepare the construct for conditional KO mouse model, we
planned to isolate two Prune genomic regions (named Intron Arm and Right Arm),
which are required to recombine with the entire Prune genomic region in order to
insert a cassette into the region containing cxon2-intron2. The removal o f exon2 will
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disrupt the Prune open reading frame, creating a truncated protein. The Intron Arm 
(SOOObp) contains a fragment o f intron 1. The Right Arm is a genomic region of 
4350bp, containing exon3-intron3-exon4-intron4-exon5-intron5. The two arms will 
be cloned into the KO conditional vector, the pUC19FRT5, which is a pUC19 vector 
modified by Dr. Cobellis (at TIGEM). The pUC19FRT5 contains a cassette with the 
hygromicine gene to confer resistance and the GreenFluorescent Protein (GFP) as a 
reporter gene. At the ends o f the cassette, two Frt sites (Frt5 at 5’ and Frtl at the 3’ 
end) are present and necessary for recombination.
At the stage of the preparation of this PhD thesis work, we subloned the two 
arms into the pBLUESCRIPT SK(+). Hence, the RPCI-21 PAG library (YAC 
Screening Center, DIBIT, Milan) was screened in Dr. Zollo’s laboratory and the 
PAG containing the Prune genomic region was then used as template in Polymerase 
Chain Reactions (PGRs), in order to amplify and isolate the two arms.
The following oligonucleotides were used to amplify the Intron Arm: 
ArmintronlF: 5’-GAT GTT GGA GAA TGT TTG GAG TGT-3’
ArmintronlR: 5’-GGG AGA AGT GAT AAA GGA TGT GTG-3’
We used Taq Polymerase as follows:
400 ng DNA template
5 pi Taq buffer
50 pmol forward primer
50 pmol reverse primer
1.25 pi Taq polymerase (2.5U/pl)
3.0 mM MgGb 
0.2 mM of each dNTP 
dEbO to 50 pi
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The PCR reaction was performed with the following cycling parameters:
1 cycle 10 min at 95°C
30 cycles 1 min at 95°C
1 min at the annealing temperature (61 °C)
6 min at 72°C (1 min per each Kb of DNA to amplify)
1 cycle 10 min at 72°C
The resulting purified PCR product was analysed by agarose gel electrophoresis, and 
extracted from the gel using Qiaquick columns (QIAGEN), according to the 
manufacturer’s protocol. The purified DNA was then phosphorylated with the T4 
Polynucleotide Kinase (New England Biolabs) as follows:
10 pi Intron Arm
1 pi T4 Polynucleotide Kinase (2.5U/pl)
ImM ATP (final concentration)
5 pi T4 Polynucleotide Kinase buffer 
dH]0 to 50pl
The reaction was incubated for 30 min at 37°C. Then, the DNA was extracted with 
phenol chloroform and precipitated in 2.5 volumes ethanol 100% with 1/10 volume 
3M Na-Acetate pH 4.8. The DNA was resuspended in lOpl dHiO. The Intron Arm 
was therefore cloned into S M A l  digested pBLUESCRIPT SK(+), which was 
previously incubated with the Alkaline Phosphatese, Calf intestinal enzyme (New 
England Biolabs) in order to remove the phosphate at the 5’ end. Thus, we obtained 
the IntronArm pBLUESCRIPT SK(+) vector, which was confirmed by DNA 
sequencing.
59
Experimental procedures
The following oligonucleotides were used to amplify the Right Arm, adding 
Not I  restriction ends:
RightarmF:
5’-ATG CGG CCG CAG TGG GTG TGT AAG TAT GTA GGA TG A -3’ 
RightarmR:
5’-ATG CGG CCG CTC TTG CAT TTT CCT AAG CCT TAT TA T-3’
For the PCR reaction, we used Pfu Polymerase as follows:
400 ng DNA template 
5 pi Pfu buffer 
50 pmol forward primer 
50 pmol reverse primer 
2 pi Pfu polymerase (3U/pl)
0.2 mM of each dNTP 
dFLO to 50pl
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The PCR reaction was performed with the following cycling parameters:
1 cycle 1 min at 95°C
30 cycles 1 min at 95°C
30 sec at the annealing temperature (60°C)
10 min at 72°C (2 min per each Kb of DNA to amplify)
1 cycle 5 min at 72°C
The resulting purified PCR product was analysed by agarose gel electrophoresis, and 
extracted from the gel using Qiaquick columns (QIAGEN), according to the
manufacturer’s protocol. The purified DNA was then digested with N otl and
sublconed into the N o tl  digested pBLUESCRIPT SK(+) in order to generate 
RightArmpBLUESCRIPT SK(+) vector, which was confirmed by DNA sequencing.
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The scheme of the final pUC19FRT5 vector containing the two arms required 
for homologous recombination is represented below. Frtl and Frt5 are the sites for 
the FLIP recombination; the red boxes indicate the Prune exons and the SA-Ires 
HyGFP/A+ indicate the cassette, which will be exchanged with genomic DNA in 
order to remove the exon 2 .
Prune genomic DNA
FrtlFrt5IntronArm RightArmSA-Ires HyGFP/A+
SOOObp 
pUC19FRT5 vector
4350bp
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H-PRUNE biochemical characterization
Expression and purification of H-PRUNE protein
To test the specificity of h-prune A-59 polyclonal antibody, we performed 
transient transfection using a prune-FLAGpcDNA in COS-7 cells. The lysates, both 
transfected and untransfected (control), were analysed by western blot analysis using 
both anti-FLAG and A59 antibodies. The A59 polyclonal antibody reveals with high 
specificity the 60 kDa H-PRUNE protein (Figure 6A). To perform biochemical 
studies, we cloned and expressed H-PRUNE and H-PRUNEA, a mutation created in 
the motif 3 region (DHRP126-129AAAA) using the Baculovirus expression system 
(Figure 7A and B). His-tagged H-PRUNE and H-PRUNEA, were purified by affinity 
chromatography (Figure 9).
Identification of the H-PRUNE phosphodiesterase activity
To determine the ability o f H-PRUNE to disrupt the phosphoester bonds in
cyclic nucleotides (cAMP and cGMP) and to determine the specific substrate, we
used the PDE scintillation proximity assay. H-PRUNE possesses significant PDE
activity that is higher for cAMP than for cGMP as substrate, while H-PRUNEA
shows a 40% reduction of this activity. In fact, the H-PRUNEA has a 60% of cAMP
PDE activity with respect to the H-PRUNE (2.1 pmolxmin'^xpg'^ versus 3.5
pmolxmin ^xp,g'^) indicating a reduction of 40% compared to the wild type protein.
As positive control we used PDE2. In addition, we performed the assay on both H-
PRUNE pre-incubated with the A59 specific polyclonal antibody and H-PRUNEA
(Figure 6B). These results indicate that H-PRUNE protein shows PDE activity.
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Results
Characterization o f the H-PRUNE phosphodiesterase activity
Mutational analysis
Homology modelling o f H-PRUNE structure was performed by Dr. L. 
Aravind (in collaboration with Dr. Zollo) on the basis of the crystal structure o f 
PFASE and RecJ proteins. The structural model (Figure 2), together with the 
sequence alignment o f the DHH superfamily (Figure 1) allowed us to identify the 
aminoacids to mutagenesize in order to define the catalytic site. Thus, a mutation 
analysis at single and multiple sites affecting H-PRUNE PDE activity was 
conducted. We expressed the mutants using the Baculovirus expression system 
(Figure 7B, C and D; Figure 8) and purified them by affinity chromatography to 
homogeneity (with a 80% yield of purification, Figure 9 and Table 2). We tested the 
proteins for cAMP-PDE activity; all the aspartic acids of the DHH characteristic 
motifs were mutated alone and in combination (Figure lOA). We observed an 80% 
decrease in the H-PRUNE4DA (D28A, D106A, A, D179A) mutant (Figure lOB). In 
summary, D28, D126, H127, R128, P129 and D179 aminoacids were found essential 
for H-PRUNE PDE activity, thus indicating that most likely they are part o f the 
catalytic site. Instead, D106A mutation in motif 2 did not influence H-PRUNE PDE 
activity.
H-PRUNE: Km and Vmax
To further characterize H-PRUNE activity, we purified to homogeneity the 
His-tagged H-PRUNE protein by another step o f purification using an ion-exchange 
chromatography (Mono-Q column) with a high yield of purification (90%) (Table 2).
66
B62kDa-
#  r
}K) IW
62kDa
î
3
t / l
3 3rt o 3 3r> n
O O O O
3 3 3 3On -J 00 VO
I I
ï î
O  H-
D
62kDa-
62kDa
1
2
*>
v: By V3 n
re
O O n
w
00
> >
!
I
I
i
I
I
i
I
?
I
Iw
a
i I
i
5-
3W
O
g
I
I
?" 3*3 Sns3re
Figure 7. Purification by affinity chromatography (Ni-NTA resin) of 
h-prune and h-prune mutants. Coomassie staining of the purified h-prune 
and h-prune mutants. In panel A the lysate, flow-throw and the eluted fractions 
of the h-prune were loaded. In panel B the lysate, flow-throw and the eluted 
fractions of the h-prune A mutant were loaded. In panel C the lysates and flow- 
throws of the D106A, D179A and D28A mutants were loaded. In panel D the 
eluted fractions (fractions 1 and 2) for the D106A, D179A and D28A mutants and 
the purified h-prune as positive control were loaded.
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Figure 8. Purification by affinity chromatography (Ni- 
NTA resin) of h-prune mutants. Coomassie staining of the 
purified h-prune mutants. In panel A, C and D the lysate, flow- 
throw and the eluted fractions of the D28A-D106A, D28A-A and 
4DA mutant were loaded respectively. In panel B the lysates and 
and eluted fractions of the D28A-D106A-D179A mutant were 
loaded.
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specific activity of the fraction Yield
of
purification
specific activity of the lysate
h-prune
purified by affinity 
chromatography
3.5 pmolxmin^ x pg"^  
4.4 pmolxmin^ x pg^
80%
h-prune
purified by
ion-exchange
chromatography
3.2 pmolxmin^ x pg-  ^
3.5 pmolxmin^ x pg ^
90%
Table 2. Table of purification for h-prune protein.
For h-prune two steps of purification were performed and the ratio between the 
specific activity of the purified fraction and the specific activity of the lysate loaded 
onto the column was calculated.
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____________________________________________________________________Results
The Km and Vmax values were determined by measuring nucleotides 
hydrolysis with a fixed amount of H-PRUNE purified enzyme in a range of substrate 
concentrations (0.05-10.0 pM) and taking those data points in the linear part of the 
reaction. Both cAMP and cGMP are substrates for H-PRUNE, with Km values of 
0.9±0.03 pM and 2.3±0.11 pM, respectively. The maximal rates o f turnover o f 
substrate ( V m a x )  were found to be 12.8±0.5 pmolxmin'^xpg'^ and 16.1±0.8 
pmolxmin'^xpg'^ purified enzyme for cAMP and cGMP, respectively (Figure l lA  
and B). The affinity o f H-PRUNE is 2.5-fold higher for cAMP as compared with 
cGMP and the maximal rate of turnover substrate is approximately equal for both 
these cyclic nucleotides. Unlike other PDEs with dual-substrate specificity, H- 
PRUNE exhibits very similar Km and Vmax suggesting that the protein could define a 
new class of PDEs, which could exhibit also other more specific putative activities 
(i.e. pyrophospatase and/or exonulcease).
Thus, we present evidence o f a cyclic nucleotide phosphodiesterase activity 
for a protein of the DHH superfamily.
Buffer influence and ion dependence of H-PRUNE PDE activity
To study the buffer influence on H-PRUNE PDE activity, we tested Tris-HCl 
and HEPES buffers in the presence of the same salt and we observed a higher PDE 
activity in the presence o f Tris-HCl buffer (Figure 12A). Considering the ion 
dependence of DHH proteins, we investigated the Mg^^ and Mn^^ ion dependency of 
H-PRUNE in the PDE cAMP assay. Although the higher activity found o f H- 
PRUNE in Tris-HCl buffer, we performed PDE assays in the presence o f HEPES 
buffer to avoid oxido-reduction reactions of the Mn^^ and Mg^^ divalent ions in Tris 
buffer.
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____________________________________________________________________ Results
We used increasing concentrations of two different divalent ions. Although 
some PDE activity was measured in the no-ion buffer, Mg^^ stimulated H-PRUNE 
PDE activity; in contrast, in the presence of MnCb this activity is inhibited (Figure 
12B). The in vitro characterization of H-PRUNE activity indicates that the protein 
does prefer Mn^^ as cofactor at 1 mM of concentration but it is inhibited by the ion at 
higher concentrations. Since the Mn^^ ion is present only in traces in the cell, the in 
vitro analysis could not be correlated to the in vivo H-PRUNE PDE activity. Thus, 
we demonstrated that H-PRUNE PDE activity is influenced by two different ions in 
vitro.
In addition, the Mg^^ ions, as well as the wild-type protein do not activate the 
H-PRUNEA mutant thus, indicating that the m otif 3, modified in H-PRUNEA 
mutant, is necessary for phosphodiesterase activity. In conclusion, we show here that 
H-PRUNE cAMP-PDE activity is influenced by both the Mg^ '*’ and Mn^^ ions.
Influence of NM23-H1 on H-PRUNE PDE activity
Considering that H-PRUNE and NM23-H1 physically interact (Reymond et 
ah, 1999), we investigated whether NM23s may influence the PDE activity o f H- 
PRUNE and the biochemical significance of the NM23-H-PRUNE interaction. This 
was achieved by pre-incubating NM23-H1 with H-PRUNE purified protein and 
measuring the cAMP-PDE activity in vitro. H-PRUNE PDE activity showed up to a 
2-fold increase over the control in the presence of NM23-H1 (Figure 13 A).
In addition, to verify that this increased activity is due to a physical 
interaction, we tested different NM23 mutants.
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cAMP PDE activity
□  h-prune
D h-prune/nm23-Hl
□  h-prune/nm23-Hl-P96S 
D h-prune/nm23-Hl-S120G 
D nm23-Hl
0 h-pruneA 
D h-pruneA/nm23-H 1
B Inh ib itor Selective for  
PD E type
ICj^pM h-prune
ICgQpM
Cilostamide PDE3 0.05 >100
Dipyridamole PDE5/6/9/10/11 0.9/0.38/4.5/1.1/0.37 0.78±0.05
IBMX nonselective 2-59 40.2±0.8
Milrinone PDE3 1.3 >100
Rolipram PDE4 2.0 >100
Vinpocetine PDEIC 8.1 22.3±1.1
Zaprinast PDEl/5/6 6.9/0.76/0.15 >100
Sulindac cGMP PDEs n.a. >100
Figure 13. Influence of nm23-HI on h-prune activity and PDE inhibitor 
studies.
A) H-prune and h-pruneA cAMP-PDE activity in the presence of nm23 proteins (p<0.03). 
Negative control: nm23-Hl and h-pruneA purified proteins. Positive control: h-prune 
purified protein. The activities values are arithmetical means±SD for five independent 
assays each conducted in triplicate.
B) Eight inhibitors were tested for h-prune PDE activity. In second and third columns are 
listed for each inhibitor the specific or selective PDEs and their respective IC5 0  values. On 
the latest column h-prune IC5 0  is reported for the most sensitive compounds: 
dipyridamole, IBMX, and vinpocetine. The activities values presented are arithmetical 
means±SD for three independent assays each conducted in triplicate.
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The non-interacting mutant NM23H1-S120G was not able to increase H- 
PRUNE PDE activity; in contrast, the interacting mutant NM23H1-P96S increased 
H-PRUNE PDE activity almost as the wild-type NM23-H1, although to a lesser 
extent (Figure 13A). This is possible because of the lower binding affinity to H- 
PRUNE, previously reported (Reymond et ah, 1999).
The NM23-H1 wild-type, the NM23H1-S120G and the NM23H1-P96S 
mutants were expressed in Lepidottera cells by Baculo virus infection and purified by 
affinity chromatography in Dr. Zollo’s laboratory. As a further control experiment, 
we tested H-PRUNEA PDE activity in the presence o f NM23-H1 protein. These two 
proteins do not interact by coimmuno-precipitation assays (data not shown). Indeed, 
there is no increase in H-PRUNEA PDE activity measured (Figure 13A). Altogether 
these results demonstrate a correlation between the direct physical interaction o f H- 
PRUNE and NM23-H1 and the increase of H-PRUNE PDE activity.
PDE inhibitor studies of H-PRUNE
To identify the physiological role(s) o f H-PRUNE cAMP PDE activity in the 
cell we tested a panel o f selective PDE inhibitors (Figure 13B) and verified if  any 
were affecting H-PRUNE protein activity. The ability of H-PRUNE to hydrolyze 
cAMP was inhibited selectively by dipyridamole (already known to act against 
PDE5, PDE6, PDE9, PDE 10 and P D E ll). The IC50 measured for dipyridamole 
inhibition of H-PRUNE PDE activity was 0.78±0.05 piM and this value is lower 
(higher specificity) if  compared to the other dipyridamole selective PDEs (PDE5, 
PDE9, PDE 10). Only PDE6 and P D E ll have a lower IC50 compared to H-PRUNE 
IC50 value (Figure 13B).
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The effect o f dipyridamole was determined only at a fixed concentration of 
substrate (0.01 pM cAMP). Therefore, we cannot exclude that the kinetic properties 
o f H-PRUNE PDE activity could be influenced by dipyridamole.
H-PRUNE was also moderately sensitive to IBMX (IC50: 40.2±0.8 pM), a 
non-selective specific PDE inhibitor, and to vinpocetine (IC50: 22.3±1.1 pM), a 
PDEIC specific inhibitor.
Several other inhibitors used in this study did not affect H-PRUNE hydrolysis 
of cAMP, even when applied at 100-fold higher concentrations than those defined as 
their IC50 values against the other PDEs. The results o f the inhibitor studies are 
summarized in Figure 13B.
H-PRUNE and sarcoma tumours
Immunohistochemical analysis of H-PRUNE and NM23-H1 in sarcomas
In order to clarify the role of H-PRUNE in sarcoma tumours, we performed 
immunohistochemical analysis. Expression o f H-PRUNE and NM23-H1 proteins 
was examined on paraffin embedded tissues from 14 o f the samples analysed by 
FISH (Forus et al., 2001), and in 16 additional LS and MFH cases. In sarcomas, 
samples with increased copy numbers o f H-PRUNE in more than 40% o f the nuclei 
generally showed moderate to high expression of the protein (Figure 14), with some 
exceptions: in MS8x, LMS2x and LMS15, no protein could be detected, and in 
LS3x, only very low levels. The absence o f protein signal was probably due to 
improper fixation of the tissues.
Generally, most of the LS and MFH cases examined showed moderate to 
high levels o f H-PRUNE, and more variable expression levels o f NM23-H1
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(examples are shown in Figure 14A and B). Within the study o f H-PRUNE 
expression, also five breast cancer samples with amplification o f H-PR UNE were 
analysed. The mammary carcinoma cases had low or moderate expression of the 
protein, although mRNA levels were generally high. Expression o f NM23-H1 
protein was moderate to high in most o f the breast carcinoma samples, except for 
Ma215, where no expression could be detected (examples are shown in Figure 14A 
and B). The amplification of H-PRUNE reported for sarcoma and breast carcinoma 
tumours is frequently associated to H-PRUNE overexpression (Forus et ah, 2001); in 
our hypothesis, H-PRUNE is involved in a mechanism of negative regulation on 
NM23-H1 activity. In fact, high levels of H-PRUNE correlate with low levels o f 
NM23-H1, suggesting that H-PRUNE could subtract free NM23-H1 forms, 
inhibiting the anti-metastatic function.
Cellular proliferation assay
To further understand the role of H-PRUNE overexpression we tested its cell 
proliferation activity in transient transfection experiments. We observed a 1.2-fold 
increase in proliferation (measured after 48, 72 and 96 h) in transient transfection 
experiments (48 h post transfection) (Figure 15A and B). In retro-viruses infected 
N1H3T3 cells H-PRUNE increased cellular proliferation 2-fold compared to the 
control (Figure 16A). Western blot analysis of both transfected and infected clones 
was performed as a control of H-PRUNE overexpression (Figure 15C and 16B).
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Figure 15. MTS cellular proliferation assay and prune protein content in 
NIH3T3 transfected cells. A) 5.000 cells/well were analysed. Time points have 
been scored for 12 independent wells corresponding to two independent replica clones 
(#1, #2). B) 10.000 cells/well were analyzed. Time points have been scored for 12 
independent wells corresponding to two independent replica clones (#1, #2). C) 
Western blot analysis of transfected clones by using a-prune (A59) and a-FLAG Abs 
respectively.
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Figure 16. MTS cellular proliferation assay and prune protein 
content in infected NIH3T3 cells.
A) NIH3T3 cells infected with both h-prune cDNA retrovirus and empty virus. 
Each column correspond to the average absorbance value (O.D.) obtained in 12 
independent wells with the corresponding standard deviation. B) Western blot 
analysis of infected clones by using a-prune (A59).
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Results
H-PRUNE and neuroblastoma tumors
H-PRUNE protein cellular localization in Neuroblastoma cell lines
As a first step towards the identification o f the function o f H-PRUNE in 
Neuroblastoma development we investigated its cellular localization in four 
neuroblastoma cell lines by immunofluorescence analysis. We previously reported 
that H-PRUNE has mostly a cytoplasmatic localization in breast cancer cells 
(Reymond et al., 1999). We performed immunofluorescence analysis on IMR-32, 
SH-SY5Y, SK-N-BE, SK-N-SH neuroblastom a cell lines, using polyclonal 
antibodies anti-h-prune, monoclonal antibodies anti-nm23-Hl and anti-nm23-H2 to 
visualize the endogenous proteins localization. The three proteins, H-PRUNE, 
NM23-H1 and NM23-H2 are distributed both into the cytoplasm and into the nucleus 
but the nuclear localization in all neuroblastoma cell lines tested is predominant 
(Figure 17A).
The same localization is observed when both H-PRUNE and NM23-H2 
proteins were transfected in COS-7 cells and the transfected proteins were revealed 
using antibodies against tags (-FLAG and -HA) (Figure ISA). These data indicate 
the presence of H-PRUNE, NM23-H1 and NM23-H2 in the nuclear compartment o f 
NB cell lines.
NM23-H2 and H-PRUNEprotein-protein interactions
Reymond et al. (1999) have previously shown the ability o f NM23-H1 to 
interact with H-PRUNE by yeast interaction mating experiments and co- 
immunoprecipitation assay.
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Figure 17. Immunofluorescence analysis and h-prune nm23-H2 co- 
immunoprecipitation.
A) Immunofluorescence analysis on four neuroblastoma cell lines using a polyclonal 
prune Ab (A59), a specific Ab for nm23-Hl and a specific Ab for the nm23-H2 protein. 
H-prune is predominantly nuclear and it co-localizes in the nucleus with both nm23-Hl 
and nm23-H2. B-C) Co-immunoprecipitations of h-prune and nm23-H2 endogenous 
proteins performed in SH-SY5Y cells with anti-prune A59 and anti-nm23-H2 
antibodies. Interaction between the two proteins is observed.
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Because o f the 98% similarity at the aminoacidic level between NM23-H1 
and NM23-H2 and the peculiar nuclear localization of both H-PRUNE and NM23- 
H2 proteins, we verified if H-PRUNE is able to bind to NM23-H2. We performed 
co-immunoprecipitation experiments on endogenous H-PRUNE and NM23-H2 
proteins in SH-SY5Y neuroblastoma cells (Figure 17B and C). In addition, we 
performed co-immunoprecipitation experiments using wild-type H-PRUNE and 
wild-type or mutated forms of NM23-H2, over-expressing transiently them in COS-7 
cells (Figure 18B and Figure 19).
To investigate how H-PRUNE might bind to NM23-H2 (NDPK-B), we 
constructed three NM23-H2 mutants: N69H, which disrupts the DNA binding 
domain (Postel et al., 1996); HI 18F, complete loss of NDPK activity (Hamby et al., 
2000) and S122P, similar to the mutation described in melanomas where the 
suppressor o f metastasis function o f the protein is negatively affected (Schaertl et al., 
1999). Moreover, the mutated residues are conserved between different members o f 
the NDPK family (Lombardi et al. 2000). By co-immunoprecipitations experiments 
H-PRUNE binds to the wild-type NM23-H2 (Figure 18B) and NM23-H2-N69H 
(Figure 19A); conversely it does not bind to NM23-H2-H118F (Figure 19B and D) 
nor NM23-H2-S122P (Figure 19C and E), known to influence, respectively, the 
catalytic NDPK activity and the autophosphorylation NDPK function, under the 
same conditions.
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Figure 18. Co-localization and co-immunoprecipitation 
experiments in COS-7 cells.
A) Immunofluorescence analysis on transiently transfected COS-7 
performed with anti- HA and anti- FLAG antibodies used respectively for 
nm23-H2 and h-prune proteins.
B) Co-immunoprecipitations of h-prune and nm23-H2 performed with 
anti-FLAG and anti-HA antibodies. Interaction between the two proteins is 
observed.
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Figure 19. Co-immunoprecipitations assays.
A) Co-immunoprecipitations of h-prune and nm23-H2-N69F performed 
with anti-FLAG and anti-HA antibodies. Interaction between the two 
proteins is observed.
B-D) Co-immunoprecipitations of h-prune and nm23-H2-H118F performed 
with anti-FLAG and anti-HA antibodies. No interaction between the two 
proteins is observed.
C-F) Co-immunoprecipitations of h-prune and nm23-H2-S122P performed 
with anti-FLAG and anti-HA antibodies. No interaction between the two 
proteins is observed.
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Results
H-PRUNE, NM23-H1 and NM23-H2 expression in SH -SY5Ystable clone
To study H-PRUNE role in a neuroblastoma cell line, we overexpressed 
stably h-prune in SH-SY5Y, a well-characterized cell line with no amplification of 
MYCN. We performed expression analysis at protein level o f the SH-SY5Y wild- 
type and SH-SY5Y-h-prune clones #2 and #3. To investigate the protein level o f H- 
PRUNE, NM23-H1 and NM23-H2, we performed a western blot analysis. The 
lysates were immuno-detected with the polyclonal antibody for H-PRUNE (A59), 
with the nm23-Hl antibody for NM23-H1 (clone NM301), with the monoelonal anti- 
nm23-H2 (clone H2-206) and the polyclonal anti-histone H3 for normalization.
The overexpression of H-PRUNE in SH-SY5Y cells induces the expression 
of NM23-H1 and NM23-H2 at protein levels (Figure 20A), indicating a direct or 
indirect influence of H-PRUNE on the two NM23 isoforms
Immunofluorescence analysis on neuroblastoma stable clones
An immunofluorescence analysis was performed on the SH-SY5Y-prune #2 
and #3 stable clones using the rabbit polyclonal anti-prune (A59), the monoclonal 
anti-NDP kinase nm23-Hl antibody (clone NM301), the monoclonal anti-human 
nm23-H2 (clone H2-206) and the monoclonal Penta-His antibody against the His-tag 
to detect the overexpressed protein. The overexpressed H-PRUNE has the same 
predominant nuclear localization of the endogenous protein. No mis-loealization o f 
both nm 23-H l and nm23-H2 was observed in consequence o f H-PRUNE 
overexpression (Figure 20B).
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Figure 20. Analysis of SH-SY5Y cells overexpressing h-prune .
A) Western blot analyses on endogenous proteins from wild type and SH-SY5Y- 
prune cells. Proteins were detected by anti-h-prune, anti-nm23-Hl, anti-nm23- 
H2 and anti-histone H3 Abs.
B) Immunofluorescence analysis on SH-SY5Y-prune-3 clone. Anti h-prune and 
anti-Histidine Abs were used to detect endogenous and overexpressed proteins. 
Anti-nm23-Hl and anti-nm23-H2 Abs were used to detect endogenous proteins 
after overexpression of h-prune. Co-localization of h-prune, nm23-Hl and nm23- 
H2 in the nucleus is still observed upon h-prune over-expression.
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Results
Immunohîstochemical analyses o f H-PRUNE, nm23-Hl and nm23-H2 in NB 
cohorts
An inverse correlation of nm23-Hl and nm23-H2 expression levels to tumour 
progression has been observed in neuroblastoma; in fact, both NM23-H1 and NM23- 
H2 are expressed at high levels in NB cohorts and in NB cell lines (Godfried et ah,
d
2002). We decided to study the in vivo H-PRUNE expression correlated to the two 
nm23s isoform expression levels. We performed immunobistocbemical analysis on 
47 NB cohorts (classified from stage 1 to stage 4), using Abs directed against the 
human NM23-H1, NM23-H2 and H-PRUNE proteins.
High expression levels o f H-PRUNE, NM23-H1 and NM23-H2 at protein 
levels, were found in the NB stage 4 eases analyzed (examples are shown in Figure 
21).
These data confirm ed our in vitro  analysis on SH-SY5Y-h-prune 
overexpressing clones correlated to NM23-H1 and NM23-H2 increase o f expression, 
thus suggesting a correlation between NM23-H1, NM23-H2 and H-PRUNE 
expression  in neurob lastom a, both  in vivo  and in vitro  analy ses.
90
I
» .'its-
fcs." s i ’ S i
i*
0>I
7
% % w
0)
c
3
P
t e s
CM
X
I
CO
CN
E
c
o*
# '>  .•- #
.V
» " » V," «V
g & m ? .
XI
CO
CN
E
c
CO
2 
-3o 
.Q 
+3
§
K
"CO) Tf
m
(/5
CQ
%
"o>►0
1
ain
CJC
ga
fict
rq
K
So
I
'O
âi
a
Bou A
m a) S
^  S f 'S  
c
K  fi
f ,  g
(A ^
•2i T3
e  § , I
ICQ L,0>-C „y  Æ
2 - §
!i
i  §w) S
gCQ
C/5
C/5 » S
oua
0/o>u
-w
0>
E  3 -C
91
Results
Chromatin immunoprécipitation analyses on h-prune, nm23-H2 and nm23-Hl 
promoter sequences
Since over-expression of H-PRUNE is correlated to an increase in NM23-H1 
and NM23-H2 protein levels, the primary sequence o f H-PRUNE reveals the 
presence of a leucine zipper domain and H-PRUNE has a predominant nuclear 
localization in NB cell lines, we hypothesized that H-PRUNE could be able to 
influence directly NM23-H1 and NM23-H2 expression. Luciferase reporter assays 
performed in Dr. Zollo’s laboratory indicate that H-PRUNE is able to drive NM23- 
H2 expression but is not able to increase nm23-Hl transcription. These results shed 
light on the new role o f H-PRUNE protein in the nucleus compartment as a 
transcriptional activator of NM23-H2 protein.
Since H-PRUNE is not able to transactivate NM23-H1 expression and NM23- 
H2 has been described as a transcription factor able to increase CMYC expression, 
luciferase reporter assays (performed in Dr. Zollo’s laboratory) indicate that NM23- 
H2 is able to increase NM23-H1 expression.
To explain H-PRUNE increase of expression in stage 4 of NB, we analyzed 
h-prune promoter region, containing two putative E-boxes. We hypothesized that H- 
PRUNE overexpression in vivo could be directly influenced by MYCN, a gene 
frequently amplifled in NB tumours and encoding for a transcription factor binding 
the E-boxes.Luciferase reporter assays performed in Dr. Zollo’s laboratory indicate 
that MYCN increases slightly h-prune expression, suggesting that MYCN could be 
responsible o f H-PRUNE increased levels in NB cohorts. All the transactivation 
assays were performed in Dr. Zollo’s laboratory by Dr. A. Andre’ and Dr. N. Marino 
(unpublished results).
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To investigate the binding regions o f the transcription factors analyzed 
(MYCN, H-PRUNE and NM23-H2) on their respective promoters {H-PRUNE, 
NM23-H2 and NM23-H1), we performed the chromatin immunoprécipitation (ChIP) 
assay using SH-SY5Y neuroblastoma cell lines. To study the capability of MYCN to 
bind h-prune promoter in the regions containing the E-boxes we immunoprecipitated 
total chromatin with anti-human MYCN clone 2 (Santa Cruz, USA) and anti-nm23- 
H l, clone NM301 (Santa Cruz, USA) as negative control. Then, we performed PCR 
reactions using two pairs of oligonucleotides for promoter region containing the two 
E-boxes. The analysis revealed that MYCN is able to bind weakly the region 
containg the E-box 2 (Figure 22A).
In order to investigate the H-PRUNE capability to bind the N M 23-H 2  
promoter, we immunoprecipitated total chromatin with anti-human prune A59 and 
anti-nm23-Hl, clone NM301 (Santa Cruz, USA) as negative control. We performed 
PCR reactions using nine pairs o f oligonucleotides spanning the entire NM 23-H2  
minimal promoter region. The analysis revealed that H-PRUNE is able to bind a 
region of 331bp on NM23-H2 promoter, containing a GC box (Figure 22B).
To investigate the binding region o f NM23-H2 on NM23-H1 promoter, we 
immunoprecipitated total chromatin with anti-nm23-H2, clone H2-206 (Seikagaku 
Corporations) and anti-human prune A59 as negative control. We performed PCR 
reactions, using seven pairs o f oligonucleotides spanning the entire NM23-H1 
minimal promoter region. The ChIP analysis revealed that nm23-H2 is able to bind a 
region of 217bp on m n23-H l promoter, containing TATA boxes and an Oet-2 
binding site (Figure 22C).
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Eigure 22. Chromatin immunoprécipitation experiment using SH-SY5Y 
cells.
A) PCR reactions were performed on total chromatin immunoprecipitated with anti- 
Nmyc (left lane), only with Protein-A Sepharose resin (center lane) or not 
immunoprecipitated chromatin. PCR reactions were performed also on total 
chromatin immunoprecipitated with the unrelated antibody, anti-nm23-Hl (right 
lane). B) PCR reactions were performed on total chromatin immunoprecipitated 
with anti-h-prune (left lane), only with Protein-A Sepharose resin (center lane) or 
not immunoprecipitated chromatin. PCR reactions were performed also on total 
chromatin immunoprecipitated with the unrelated antibody, anti-nm23-Hl (right 
lane). C) PCR reactions were performed on total chromatin immunoprecipitated 
with anti-nm23-H2 (left lane), only with Protein-A Sepharose resin (center lane) or 
not immunoprecipitated chromatin. PCR reactions were performed also on total 
chromatin immunoprecipitated with the unrelated antibody, anti-h-prune (right 
lane).
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Results
H-PRUNE and breast cancer
Stable breast MDA h-prune clones
To study the H-PRUNE function in regulating NM23-H1 anti-motility and 
suppressor metastasis activities well characterized in breast cancer, we have taken 
advantage o f the breast cancer cellular models MDA-ClOO and H I-177 (Mao et ah, 
2001; Tseng et ah, 2001).
We produced several stable clones overexpressing the h-prune cDNA (clone 
#3 and #4), the h-prune A cDNA (clone #10 and #11), the h-prune4DA cDNA (clone 
#19 and #20) and the PDE5A cDNA (clone #14 and #16) in MDA-ClOO cells. We 
stabilized the h-prune cDNA in MDA-Hl-177 overexpressing nm23-Hl (clone #7 
and #8), in MDA overexpressing nm23Hl-P96S (clone #4 and #5) and in MDA 
overexpressing nm23Hl-S120G (clone #2 and #3). Several o f these clones were 
characterized by western blot analyses to determine the expression level o f H- 
PRUNE (Figure 23A), nm23 and PDE5A (Figure 23B) proteins, using anti-h-prune 
(A59), anti-nm23-Hl (clone NM301) and anti-Penta-His antibodies respectively.
Stable breast MDA h-prune clones and correlation to cellular motility
The stable clones produced were assayed for cellular motility using the 
Trans-well cell culture chambers (Freije et ah, 1997a). Six independent clones 
(MDA-ClOO; MDA-prune clone #3 and #4; MDA-H1-177-prune clone #7 and #8; 
M DA-Hl-177) were assayed. Overall, the MDA-prune clones have a 2-folds 
increase in motility when compared to the control cell line MDA-ClOO (Figure 24).
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____________________________________________________________________Results
The values observed for the MDA-Hl-177-prune clones are increased of 2.2 
folds as compared to the cell line M DA-Hl-177, overexpressing nm23-Hl alone 
(Figure 24). The clone MDA-Hl-177 value observed is reduced by a mean of almost 
40% compared to the MDA-ClOO cell line (Figure 24), as it was described 
previously (Leone et al., 1993a), thus confirming the role o f NM23-H1 in inhibition 
of cellular motility.
In order to study the contribution of H-PRUNE PDE activity to cell motility 
we performed the motility assay on MDA-ClOO, MDA-Hl-177, MDA-prune (clone 
#3 and #4), MDA-prune A (clone #10 and #11) and MDA-prune4DA (clone #19 and 
#20). We choose these mutants because o f their different ability to influence H- 
PRUNE PDE activity. We observed a 40% decrease o f cell motility in MDA-pruneA 
clones and almost a complete decrease (90%) in MDA-prune4DA both compared to 
MDA-prune stable clones (Figure 25A). To verify if  H-PRUNE PDE activity 
contribute alone to cell motility in breast cancer cell lines, we tested the clones 
overexpressing a well characterized PDE (PDE5A) in MDA-ClOO (MDA-PDE5A 
clone #14 and #16). No increase in cell motility was observed in both PDE5A 
overexpressing clones (Figure 25A), thus indicating that the only H-PRUNE PDE 
activity is able to induce cell motility in this conventional cellular model.
In addition, it has been reported (Freije et al., 1997a; MacDonald et al., 1996) 
that the nm23Hl-S120G (a mutant showing an impaired interaction with H-PRUNE) 
(Reymond et ah, 1999) and nm23Hl-P96S (a mutant that retains its ability to bind H- 
PRUNE) proteins are able to induce cellular motility. We investigated the role of H- 
PRUNE in cellular motility overexpressing mutants alone and together with H- 
PRUNE and correlated this to cellular motility.
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____________________________________________________________________ Results
The MDA-nm23Hl-S120G-prune clones show an almost 60% increase in 
motility as compared to the MDA-ClOO control cell line, while the MDA-nm23Hl- 
P96S-prune clones show a 200% increase in motility when compared to MDA-ClOO 
cells (Figure 25B).
In conclusion, our findings indicate that overexpression o f H-PRUNE in 
MDA-ClOO cells increase their cellular motility. H-PRUNE is able to promote cell 
motility reducing NM23-H1 anti-metatstatic function. This effect is not observed 
when H-PRUNE is overexpressed in the presence o f the impaired interacting 
nm23Hl-S120G mutant, thus postulating a role o f NM23-HI-H-PRUNE complex on 
increasing cellular motility.
In vivo H-PRUNE PDE activity
In vitro studies of H-PRUNE PDE activity in the presence o f NM23-H1 have 
demonstrated a correlation between the direct physical interaction o f H-PRUNE and 
NM23-H1 and the increase of H-PRUNE PDE activity (Figure 13 A). To correlate H- 
PRUNE PDE activity and/or H-PRUNE NM23-H1 complex formation contribution 
to motility, each stable clone used in the motility assay was analysed for specific H- 
PRUNE cAMP-PDE activity on immuno-precipitated protein. Through these 
analyses, the MDA-prune clones have an increase o f 8-folds cAMP-PDE activity as 
compared to the MDA-ClOO clone (Figure 26). Instead, the MDA-pruneA clones 
have a decrease o f 0.5-folds cAMP-PDE activity as compared to the MDA-prune 
clones and this correlates to their cell motility properties (Figure 26). In addition, we 
found that H-PRUNE PDE activity in MDA-H-PRUNE compared to double stable 
clones MD A-H 1-177 -prune is increased of 1.4-folds (Figure 26). These results show 
a direct correlation of H-PRUNE PDE activity to cell motility.
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____________________________________________________________________ Results
Furthermore, the M DA-nm 23Hl-S120G-prune clones have a 3-folds 
decrease of H-PRUNE PDE activity as compared to the MDA-nm23Hl-P96S-prune 
clones (Figure 26), thus implying a direct correlation between H-PRUNE cAMP- 
PDE activity, cellular motility and protein-protein interactions. In conclusion, we 
noted a direct correlation between H-PRUNE PDE function and protein-protein 
interactions, resulting in a significant influence on cellular motility.
H-PRUNE inhibitor influence on breast cancer stable clones
Since the ability o f H-PRUNE to hydrolyze cAMP was inhibited selectively 
in vitro by dipyridamole (Figure 13B), we decided to elucidate H-PRUNE 
physiological role in MDA-MB-435 breast cancer cell line. We choose to use H- 
PRUNE overexpressing MDA clones and, as additional controls MDA-pruneA 
clones, because of a partial reduction (40%) of H-PRUNE PDE activity as discussed 
above (Figure 6B and lOB), to verify at which extent dipyridamole was able to 
inhibits their activities and correlate them to cellular motility. Both the MDA-prune 
and pruneA clones were incubated with dipyridamole (8 pM, a 10-fold higher 
concentration with respect to its IC50) for 24 h to obtain the complete enzyme 
inactivation and then the motility assay was repeated as described above. After 
treatment with dipyridamole, the MDA-prune and MDA-pruneA clones showed a 
reduction in average o f 40% and 20% in motility, respectively, showing that the 
inhibitor acts against H-PRUNE PDE activity thus inferring on a substantial decrease 
in cellular motility (Figure 27). These results are o f pharmacological impact, because 
of partial success in the use of dipyridamole in combination with other drugs in 
clinical trials in breast (Budd et al., 1990, Budd et al., 1994) and gastric and intestinal 
carcinoma (Hejna et ah, 1999).
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Results
Breast carcinoma study on métastasés affected patients
To verify in vivo the oncogenic role of H-PRUNE we have randomly selected 
fifty-nine cases for which metastasis have been reported (TxNxMl according to 
TNM classification which describes the anatomical extent of disease). Analysis was 
performed on a multiple tissue array (MTA) containing primary tumour tissues cases 
that showed metastasis at the time o f diagnosis or during follow-up (at least five 
years of follow-up; date of diagnosis: 1992-97). Immunohistochemical analyses of 
normal as well as no metastatic cancer tissues were performed (Figure 28A and B). 
Immunohistochemical analysis on MTA was performed using two antibodies that 
recognize specifically H-PRUNE and NM23-H1/-H2, respectively (Figure 28C and 
D).
According to immuno-histopathology grading, twenty-two cases (37%) with 
cytogenetic amplification o f H-PRUNE  chromosomal region, presented high H- 
PRUNE protein expression in contrast to the low or moderate expression level of 
NM23-H1, thus suggesting that about one third of breast metastasis formation may 
be due to both h-prune amplification and overexpression with concurrent diminished 
level of the NM23-H1 suppressor metastasis function. In addition, seven cases (12%) 
do not present h-prune amplification but possess high H-PRUNE protein level while 
NM23-H1 level is low. This suggests the presence of an alternative mechanism of H- 
PRUNE overexpression independent from gene amplification.
For the remaining 37 out o f 59 (63%) cases with TxNxMl tumors, we can 
hypothesize the involvement o f an alternative pathogenetic pathway responsible for 
metastasis formation. These data indicate a metastasis-promoting role of H-PRUNE 
protein in breast carcinoma.
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Results
cAMP content in MDA stable clones
In order to identify the molecular mechanism responsible o f the increased 
motility effect, we have investigated to which extent the increase in cell motility was 
depending on the cAMP content o f the MDA-MB-435 clones overexpressing H- 
PRUNE protein. For this reason we have analysed MDA-prune #3 and # 4 clones 
using a cAMP detecting immunoassay. The two MDA clones overexpressing h- 
prune show a reduction o f -25%  in cAMP content (Figure 29), indicating that a 
correlation between H-PRUNE PDE activity and increase o f cellular motility o f the 
MDA-prune clones is observed together with a reduction o f free cAMP nucleotides 
levels in these cells.
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Results
Bioinformatic analysis of differentially expressed genes in breast cancer stable 
clones
In order to verify the gene expression profile o f the stable clones 
overexpressing nm23-Hl alone and/or in combination with h-prune, gene expression 
profiling was performed in Dr. Zollo’s laboratory (D’Angelo et al., 2004). 
Expression levels o f several genes involved in metastasis processes were found 
differentially regulated (P value < 0.05) in the clone MDA-Hl-177-prune (clone #8) 
compared to MDA-Hl-177.
We found up-regulated, in the above described cellular model, genes known 
to be involved in cytoscheleton re-organization (phosphatidylinositol 4-kinase type 
II), protease activation (proteasome 26S subunit, Nedd4 binding protein  2), 
oncogenesis {L-plastin, RablB, BRCAl-interacting protein -BRAP2), protein 
phosphorylation and nuclear transport {Casein Kinase 2 interacting protein 1- 
CKIPl). Furthermore, we found other two genes, correlated to motility, up-regulated 
in the clone overexpressing h-prune and nm23-Hl with respect to nm 23-H l 
overexpressing alone: the dynein, light intermediate polypeptide 1 (DNALIl) and o f 
the pleiotrophin. Moreover, four genes, involved in extracellular matrix contacts and 
cellular adhesion (plakophilin, LIM), cytoscheleton re-organization (plakin) and in 
the oncosuppressor activity (EXTl), were found down regulated in the M DA-Hl- 
177-prune #8 clone.
In summary, genes involved in processes linked to oncogenesis were 
discovered significantly altered in their level o f expression, thus indicating a 
contribution of H-PRUNE to the higher oncogenic potential o f the breast cancer cell 
line analysed (MDA-MB-435).
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Discussion
H-PRUNE biochemical characterization
The human PRUNE  gene was identified on the basis o f homology with the 
Drosophila prune gene, first identified on the basis of a mutant phenotype (Reymond 
et ah, 1999). The study of the new gene included different steps and approaches in 
order to perform a functional characterization of the protein product. The Drosophila 
model represented an important starting point to direct the studies of the human gene. 
In fact, in Drosophila mutations in the prune gene affected only eye colour (brownish 
purple in contrast to the wild-type red eye) but have no effect on viability and 
fertility. The association of prune mutation with a mutation in the abnormal wing 
disc gene (awd/K-pn; also named Killer-of-Prune) result in a lethal phenotype 
characterized by development o f pseudo-melanotic tumours, thus, suggesting a 
synergism between the prune  and aw d  genes. The human orthologue o f A w d  is 
NM 23-H I, the first metastasis suppressor gene identified, which encodes for a 
nucleoside diphosphate kinase (NDPK) (Steeg, 1988).
A clustering analysis of the human and Drosophila PRUNE proteins shows 
that the proteins belong to the DHH fam ily, which includes several 
phosphoesterases, such as the RecJ nuclease from bacteria and the pyrophosphatases 
from yeast and bacteria (Aravind and Koonin, 1998b). These enzymes hydrolyse 
phosphoester bonds in a broad spectrum of substrates at different affinities including 
single non-adenine-containing triphosphates (CTP, GTP, TTP), polynucleotides, 
DNA and RNA, producing single mono- and diphosphate nucleotides. The DHH 
proteins possess four conserved motifs, five invariant Aspartates and two conserved 
positively charged residues.
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Structural analyses based on the two proteins belonging to the DHH 
superfamily, namely the RecJ nuclease and the inorganic pyrophosphatase (Ahn et 
ah, 2001; Yamagata et ah, 2002), suggested that H-PRUNE is likely to possess a 
metal-ion-dependent phosphoesterase activity. Moreover, the PRUNE proteins 
contain the DHR form (typical of some known PDEs) as substitution of the canonical 
DHH (Motif-3) that is observed in all other members of the DHH family. The cyclic 
nucleotide phosphodiesterases catalyses the hydrolysis of 3’:5’-cyclic nucleotides to 
their corresponding nucleoside 5’-monophosphates.
Furthermore, a leucine zipper domain (positions from 157 to 185) was found 
in H-PRUNE primary sequence, thus suggesting a possible involvement o f H- 
PRUNE in DNA binding capability and/or transcriptional activation.
The sequence alignments and structural analysis indicate that H-PRUNE 
could possess exonuclease, pyrophosphatase, polyphosphatase, phosphodiesterase 
and/or transcriptional activation activities. Among all the putative H-PRUNE 
activities, we decided to investigate first the phosphodiesterase activity, which act on 
cyclic nucleotides well known as second messengers and eorrelated to signal 
transduction. Additionally, the interaction between H-PRUNE and the NM23-H1 
isoform that has NDPK activity, which is known to function on nucleotides, 
suggested us to focus our attention on the characterization o f the cyclic nucleotides 
phosphodiesterase activity and its role in cellular signalling.
We demonstrated that mammalian H-PRUNE possesses a cyclic nucleotide 
phosphodiesterase activity (Figure 6B) and produced a mutant (H-PRUNEA) that 
contains substitutions in the conserved motif 3 of the DHH family. The H-PRUNEA 
shows a reduction o f the PDE activity (Figure 6B), indicating that m otif 3 is 
important for the PDE activity.
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In order to define the putative catalytic site, a mutation analysis at single and 
multiple site in histidine (127), argine (128), and proline (129) of motif 3 and in the 
aspartic acids D28, D106, D126, D179 present respectively in motif 1, 2, 3 and 4 was 
performed. We determined PDE activity o f all the mutants produced (Figure lOB). 
The analysis revealed that all the aminoacids mutated (except the aminoacid D106) 
are involved in PDE activity with different influence, indicating that motifs 1, 3 and 
4 are most likely part o f the catalytic site.
The characterization o f the catalytic properties of recombinant H-PRUNE, 
expressed in Sf-9 cells, revealed that the affinity of H-PRUNE PDE for cAMP is 2.5- 
fold higher than that for cGMP. Vmax with cGMP is 1.25-fold faster than that with 
cAMP (Figure 11A and B). The conserved motif 3 region is potentially responsible 
for the binding of Mg^^ ions as predicted by protein modelling (Figure 2A). In fact, 
H-PRUNE PDE activity is stimulated by MgCb and is reduced by MnCb but the H- 
P RUNE A, mutated in DHR (motif 3) shows a reduced PDE activity influenced at 
lower extent by the presence of the ions (Figure 12B). Nevertheless, we observed 
that H-PRUNE is also able to function in the absence or at low metal ion 
concentrations (Figure 12A).
Since H-PRUNE is able to interact with NM23-H1 and NM23H1-P96S but 
this interaction is impaired with NM23H1-S120G, a mutation occurring in advanced 
stages of neuroblastoma, we tested if H-PRUNE PDE activity could be influenced by 
physical interaction with NM23-H1 in vitro. We observed an increase in H-PRUNE 
PDE activity as a result o f the protein-protein interaction, indicating a mechanism of 
regulation between the two proteins (Figure 13 A).
In order to identify the physiological role o f H-PRUNE we tested a panel o f 
eight PDE inhibitors, which have an important pharmacological application as anti-
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inflammatory agents, anti-depressants, anti-proliferative agents, antihypertensive and 
cardiovascular agents. We found that dipyridamole is able to inhibit H-PRUNE PDE 
activity with a significant IC50 value (IC50 0.78^M) (Figure 13B). H-PRUNE is 
sensitive, like most other PDEs, to the non selective inhibitor IBMX with an IC50 of 
40.2|iM; also, vinpocetine, a specific inhibitor for PDE 1C inhibits H-PRUNE PDE 
activity (IC50 22.3 jxM). Dipyridamole, a selective inihibitor of H-PRUNE, is able to 
inhibit various PDEs as PDE5, 6, 9, 10 and 11. It will be of interest to examine other 
inhibitors to determine a more specific or selective inhibitor for H-PRUNE.
To date, we cannot exclude that H-PRUNE possess other activities as 
exonuclease, phosphoesterase or polyphosphatases, thus potentially defining for H- 
PRUNE, belonging to the DHH superfamily, a new family of phosphodiesterases.
H-PRUNE and sarcoma tumours
H -PRU NE  maps to lq21 chromosomal region, frequently amplified in a 
variety o f human cancers. In some tumour types, this aberration is more frequent in 
metastatic than in primary lesions, associated with short overall survival (Tarkkanen 
et ah, 1999), and/or chemotherapy resistance (Kudoh et ah, 1999). These findings 
suggest that possible target genes could be involved in metastasis-related processes, 
for instance by inhibiting possible metastasis suppressor proteins, or in mechanisms 
of drug resistance. In sarcomas the amplification o f lq21 has been reported (Forus et 
ah, 1995a,b; Szymanska et ah, 1996), and the NM23-H1 expression is generally 
highly associated to high metastatic stages (Royds et ah, 1997).
On the basis of the amplification of lq21 chromosomal region and o f the 
NM23-H1 expression level (generally high) in sarcomas, we decided to study the 
expression levels o f H-PRUNE in these mesenchymal tumours.
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Amplification of H-PRUNE at various levels in 18 out of 19 sarcoma samples 
has been observed (Forus et ah, 2001), suggesting that amplification and increased 
expression o f H-PRUNE could be a mechanism for inhibition of NM23-H1 activity. 
In the more aggressive sarcoma types, LMS, MFH and MS, H-PRUNE amplification 
was generally accompanied by moderate to high protein levels (Figure 14). All these 
samples expressed NM23-H1 protein, mostly at low or moderate levels. Thirteen of 
the patients in this group showed amplification of H-PRUNE, and among those, nine 
developed métastasés, and seven of those died o f cancer. For the patients with an 
unknown copy number of H-PRUNE  (16 LS and MFH cases) there was no clear 
correlation between H-PRUNE and/or NM23-H1 protein expression and prognosis. 
Nevertheless, the four patients that developed métastasés and died all showed 
moderate to high expression levels of H-PRUNE, and low to moderate levels of 
NM23-H1.
The number of patients analysed is too low to draw any conclusion on the 
association o f H-PRUNE amplification and overexpression with metastasis events in 
sarcoma or disease outcome, but it is remarkable that the expression levels of the 
gene is generally higher in aggressive tumours than in the relatively benign well- 
differentiated liposarcomas (WDLPS).
Indeed, the study o f H-PRUNE and NM23-H1 in sarcoma suggested that 
amplification and overexpression o f H-PRUNE could abrogate the possible 
regulatory function of NM23-H1. Such a mechanism could be comparable to the 
effect of amplification o f MDM2 and CDK4/CCND1 on p53 and pRbl, respectively. 
Increased expression of these oncoproteins, caused by increased copy numbers of the 
respective genes, has been shown to inhibit the function o f the two tumour 
suppressors (Khatib et ah, 1993; Momand et ah, 1992; Oliner et ah, 1992).
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The finding that H-PRUNE is amplified and overexpressed both in aggressive 
tumours and tumours of borderline malignancy is similar to what has been reported 
for MDM2 in sarcomas (Forus et ah, 1993). The increased expression of H-PRUNE 
in tumours of borderline malignancy indicates that H-PRUNE could partecipate to 
the neoplastic transformation at different levels. In fact, tumorigenesis is a multistep 
process characterized by increase in cell proliferation, escape from apoptosis 
program, and increase in motility and invasiveness as the final steps.
In fact, we focused our attention on H-PRUNE contribution to proliferation 
and we performed an in vitro proliferation assay showing that overexpression of H- 
PRUNE increases proliferation in both transiently transfected and infected NIH3T3 
cells (Figure 15 and 16).
Furthermore, the literature data correlating low expression o f NM23-H1 to 
tumour aggressiveness are rather conflicting, and the exact role of NM23-H1 as a 
metastasis suppressor is not clear to date. There are several reports that link NM23- 
H1 to cell growth and proliferation. In some cases, decreasing levels of NM23-H1 is 
associated with increased proliferation (Caligo et al., 1997), whereas in other studies, 
the opposite has been shown (Cippolini et al., 1997).
Finally, the study o f H-PRUNE in sarcoma supports the hypothesis o f H- 
PRUNE, as the negative regulator o f NM23-H1. H-PRUNE is generally amplified 
and overexpressed in our sarcoma collection and even if the number o f case is too 
low to draw any conclusion, this first part o f the thesis work was very important to 
direct the studies on other two tumours of interest, neuroblastoma and breast cancer, 
described as follow.
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H-PRUNE and neuroblastoma tumours
In order to elucidate H-PRUNE role in oncogenesis, we decided to 
investigate H-PRUNE in neuroblastoma, a pediatric tumour and an intriguing model 
for NM23-H1 function and its protein partner. In fact, the interaction o f H-PRUNE 
with NM23-H1 results impaired with the gain o f function mutation, NM23H1- 
S120G, frequently encountered in neuroblastoma (Chang et al., 1994; Hailat et al., 
1991; Lascu et al., 1997) and interestingly, high levels o f NM23-H1, identified as a 
non metastatic gene, are generally associated to high metastatic potential in 
neuroblastoma cell-lines and in affected patients (Codified et al., 2002).
H-PRUNE was found predominantly into the cytoplasm o f transiently 
transfected COS-7 cells and of breast cancer cells (Reymond et al., 1999; D ’Angelo 
et al. 2004). However, we found in several NB cell lines and in vivo cohorts a 
preferential nuclear localization o f H-PRUNE using both immunofluorescence and 
immunohistochemical analyses of endogenous protein detection (Figures 17 and 21).
H-PRUNE interacts with NM23-H1 protein, a nucleoside diphosphate kinase 
(NDPK-A) (Reymond et al., 1999). The NM23-H2 isoform, with a predominant 
nuclear localization (Kraeft et al., 1996), has been implicated in transcription 
regulation o f CMYC “via” its specific binding to a single strand DNA, a nuclease- 
hypersensitive polypurine/polypyrimidine element (NHE-PuF) (Berberich and 
Postel, 1995; Postel et al., 1993; Postel et al., 1996; Postel, 1996).
We investigated the capability of H-PRUNE to bind to the nuclear NM23-H2 
protein (NDPK-B). By co-immunoprecipitation experiments we demonstrated that 
H-PRUNE binds to NM23-H2 wild-type protein (Figure 17B and C; Figure 18B) and 
to NM23-H2-N69H (Figure 19A), a mutant form impaired into the DNA binding. In 
addition H-PRUNE is not able to bind to the most occurring mutation, associated to
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metastatic potential in melanoma cancer, NM23H2-S122P (Figure 19C and E). The 
interaction o f H-PRUNE is also impaired with NM23H2-H118F, a catalytically 
inactive form of NM23-H2 (Figure 19B and D). Evidences indicate that H-PRUNE- 
NM23-H2 interaction is serine phosphorylation dependent (region containing S I20, 
S I22, S I25) and based on Casein Kinase I phosphorylation (Garzia et ah, submitted). 
How this function and nuclear binding regulation between these two proteins 
mechanistically is carried out is, to date, under investigation.
To elucidate H-PRUNE role in neuroblastoma, we used the SH-SY5Y cell 
line, an in vitro model, to observe if  H-PRUNE overexpression could influence the 
expression of the other genes of interest. For this reason, we investigated NM23-H1 
and NM23-H2 expression in SH-SY5Y neuroblastoma cell line overexpressing h- 
prune and we observed an increase at protein levels of both NM23-H1 and NM23- 
H2 (Figure20A), suggesting a potential role o f H-PRUNE in neuroblastoma, directly 
or indirectly, correlated to the H-PRUNE protein partners (NM23-H1 and -H2 
isoforms).
Moreover, an in vivo immunohistochemical analysis o f H-PRUNE, nm23-Hl 
and nm23-H2 on several NB cohorts was performed and revealed over 47 NB 
cohorts (classified between stages 1, 2, 3 4), a significant increase o f nm 23-H l, 
nm23-H2 and H-PRUNE protein expression. In particular, comparing stage 1-2 (NB 
early onset tumour) and stage 4 (highly aggressive and pro-metastatic tumours) an 
increase of nm 23-Hl, nm23-H2 and H-PRUNE protein levels was encountered 
(Figure 21). The in vitro and the in vivo analyses tightly correlate H-PRUNE 
overexpression associated to nm23-Hl and nm23-H2 overexpression in both cases. 
To explain the correlation, we hypothesized a mechanism of regulation between 
these three genes (H-PRUNE, NM23-H1 andNM23-H2).
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Sequence alignments indicated the presence of a leucine zipper domain in H- 
PRUNE suggesting that it could act as a DNA binding protein and/or a transcription 
factor in the nucleus of NB cells. Thus, we investigated the capability o f H-PRUNE 
to increase directly nm 23-H l and nm 23-H 2  mRNA expression levels and by 
transactivation assays, we found that H-PRUNE does transactivate nm23-H2 mRNA 
expression but has no effect on nm23-Hl promoter. These results shed light on the 
new role of H-PRUNE protein in the nucleus compartment as a transcriptional 
activator o f NM23-H2 protein.
Because o f the over-expression observed of NM23-H1 and NM23-H2 genes 
in neuroblastoma SH-SY5Y cell line upon H-PRUNE over-expression and the trans­
activation capability of nm23-H2 on CMYC promoter region, we further investigated 
the potential role of NM23-H2 directly on nm23-Hl mRNA expression. We found 
that NM23-H2 is able to increase NM23-HI expression. The in vitro transactivation 
assays were supported by in vivo ChIP analyses. Indeed, we identified the binding 
region o f H-PRUNE on nm23-H2 promoter (Figure 22B) and the binding region o f 
NM23-H2 on nm23-Hl promoter (Figure 22C). Thus, we identified a new function 
of H-PRUNE correlated to its nuclear localization; in fact, H-PRUNE is able to bind 
to nm23-H2 promoter and regulate the transcription of NM23-H2.
To explain H-PRUNE increased expression in stage 4 of NB, we analyzed h- 
prune  promoter region and we found two putative E-boxes, by sequence analysis 
comparison. We hypothesized that H-PRUNE overexpression in vivo could be 
directly influenced by MYCN, a gene frequently amplified in NB tumours and 
encoding for a transcription factor binding the E-boxes. By luciferase reporter assays 
(performed in Dr. Zollo’s laboratory) we demonstrated that MYCN  increases slightly 
H-PRUNE expression, and by ChIP analysis we showed that MYCN is able to
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weakly bind the region containing one of the two E-boxes found (E-box 2) (Figure 
22A), suggesting that MYCN  could be responsible of H-PRUNE increased levels in 
NB cohorts. Thus, we propose a new mechanism involving MYCN, H-PRUNE, 
NM23-H1 and NM23-H2 to explain NM23-H1 and -H2 increase in advanced stages 
of neuroblastomas.
The mRNA increase o f both NM23-HI and NM23-H2 genes, included in 
17q21.3 chromosomal region, was previously reported (Godrfried et al., 2002) for 
advanced stages of neuroblastoma, either in affected patients or in neuroblastoma 
cell lines. In Neuroblastoma 17q gain and M Y C N  amplification are important 
negative prognostic factors (Bown et al., 1999; Seeger et al., 1985). Then, the 
NM23-H1 and H2 up-regulation in Neuroblastoma can be due to gene dosage (17q 
gain) and/or to direct or indirect transcriptional regulation (MYCN  overexpression), 
as reported into the discussion section by Godfried et al. (2002).
In our analysis, the mRNA increase of NM23-H1 and -H2 could be explained 
by a mechanism of transcriptional regulation between H-PRUNE, NM23-H1 and 
NM23-H2, where the first key actor might be MYCN  increased copy number.
In fact, to explain H-PRUNE overexpression associated to the progression of 
NB as observed in in vivo analyses, we demonstrated here the direct role o f MYCN 
on h-prune promoter (Figure 22A).
Altogether, these results indicate a nuclear pathway o f action in NB 
development involving M YC N  amplification. MYCN transactivates H -PRU N E  
expression through its binding to the E-box, and H-PRUNE in turn induces NM23- 
H2 expression. Then, we found that NM23-H2 is able to transactivate NM23-H1  
mRNA expression levels. We postulate here H-PRUNE oncogenic action in NB 
malignancy by a transcriptional loop between different genes, including activation o f
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NM23-H1 and NM23-H2, as presented in a model (Figure 30). Although the 
molecular findings presented here need a more comprehensive analysis in a larger 
NB affected patient group, our results indicate a new nuclear function of H-PRUNE 
in combination with M YC N  increase copy number (already known as marker of 
m alignancy and poor prognosis in advanced neuroblastom a), and a new 
transcriptional activation mechanism involving H-PRUNE and, NM23-H1, NM23- 
H2 which can be new potential target for clinical intervention to prevent NB 
progression and cancer development.
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H-PRUNE and breast cancer
The anti-motility effect of NM23-H1 is widely demonstrated in breast cancer 
by several reports (Freije et ah, 1997a; Freije et ah, 1997b; Leone et ah, 1993a).
A part o f this thesis work demonstrated that H-PRUNE and the NM23s 
protein levels are unbalanced in sarcoma, suggesting that H-PRUNE may negatively 
regulate NM23-H1 anti-metastatic function. An increase in H-PRUNE expression is 
directly correlated with aggressiveness o f those tumours and cancer progression 
(Forus et ah, 2001). Since the literature has postulated that the anti-metastatic 
activity of NM23-H1 is independent of the NDPK activity (Wagner et ah, 1997), we 
investigated at which extent the H-PRUNE influences cellular motility, which 
represents one o f the first cellular acquired functions by the cancer cell to migrate 
away from the primary tumor site.
In order to study the influence of H-PRUNE PDE activity on cell motility, we 
overexpressed H-PRUNE, H-PRUNEA and H-PRUNE4DA in breast cancer model, 
and observed that overexpression of the wild type protein induces cell motility, while 
a decrease o f its PDE function (H-PRUNEA, H-PRUNE4DA) corresponds to a 
decrease of cell motility (Figure 24 and 25A). Indeed, we observed for the mutant H- 
PRUNE4DA an 80% reduction of PDE activity and overexpression in MDA clone do 
not show significant increase in cell motility, thus excluding that other potential H- 
PRUNE activities are responsible o f increasing motility. To correlate specifically H- 
PRUNE PDE activity to cell motility, we overexpressed PDE5A, in the same cellular 
model and tested for cell motility (Figure 25A). PDE5A, chosen for its sensitivity to 
dipyridamole (IC50 0.9fxM), did not affect MDA breast cell motility, thus indicating
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that only H-PRUNE PDE function is responsible of increasing cell motility in breast 
cancer cells.
In addition, we observed that overexpression of H-PRUNE in a high NM23- 
H1 expression background displays a decreased motility phenotype and a lower H- 
PRUNE PDE activity compared to the cells overexpressing H-PRUNE alone (Figure 
24). Although, H-PRUNE PDE activity is increased in vitro upon interaction with 
NM23-H1 (Figure 13A), this effect is not observed in vivo. These phenomena can be 
explained by different processes, influencing the H-PRUNE-NM23H1 complex 
formation: in fact, the protein-protein complex formation might depend on the 
presence o f different oligomeric and/or post-translationally modified NM23-H1 
forms (for example: serine phosphorylation) (Steeg, 2003).
In order to test the hypothesis that the negative regulation o f H-PRUNE on 
the NM23 anti-metastatic function is due to an increase in PDE activity as a result o f 
the protein-protein interaction, we investigated what effect two NM23-H1 mutants 
hold on H-PRUNE PDE activity. These protein mutants are NM23H1-P96S, able to 
physically interact with H-PRUNE, and NM23H1-S120G, that does not interact with 
H-PRUNE (Reymond et ah, 1999); both mutants transfected in breast cancer cells 
(MDA-435) are able to suppress the endogenous anti-motility effect o f the NM23-H1 
wild-type protein (Freije et al., 1997a, MacDonald et al., 1996). Additionally, we 
show that breast cancer cells overexpressing H-PRUNE in a high NM23-H1-S120G 
expression background have lower cellular motility in comparison to cells 
overexpressing H-PRUNE in a high NM23-H1-P96S background (Figure 25B), thus 
further indicating that the physical interaction between these two proteins may be 
responsible for the motility promoting role. Furthermore, the H-PRUNE-NM23-H1- 
S120G clone has almost 66% lower PDE activity compared to the PDE value
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observed in the clone overexpressing both H-PRUNE and NM23-H1-P96S (Figure 
26), thus definitively indicating a correlation between protein-protein interaction, H- 
PRUNE cAMP-PDE activity and cellular motility effects.
In addition, the use o f dipyridamole severely reduced the motility of the 
stable H-PRUNE breast clones and at less extent the H-PRUNEA overexpressing 
clones (Figure 27). Although dipyridamole might not be the most effective H- 
PRUNE cAMP PDE inhibitor and further experiments have to be performed to 
identify a new highly specific compound, these findings are o f pharmacological 
interest. It is common opinion, that anti-coagulants such as dipyridamole and similar 
drugs exert their function on interfering the blood-clotting pathway activation 
through inhibition of adhesion of metastatic cells to capillary walls. These results are 
an added value to those presented in vivo (Haaz et al., 1996) describing the positive 
effect o f dipyridamole and fluorouracil (FU) combination in chemotherapy and in 
several clinical trials; examples are in breast (Budd et al., 1994) and gastric and 
intestinal carcinoma (Hejna et al., 1999). Dipyridamole in combination with protease 
inhibitors, interferon, and 5-fluoroUracil inhibits metastasis formation. In view of the 
results reported here, we believe that the use of dipyridamole might hold promise for 
prevention and treatment o f breast métastasés spread and a large controlled 
investigation study might provide further evidences.
Moreover, we confirmed in vivo the data observed on cellular motility 
activation in vitro, using a significant number of breast cancer tissues from TxNxMl 
patients. In fifty-nine tumours from cases presenting distal metastasis, H-PR UNE 
was found amplified in copy number and overexpressed in twenty-two cases (37%), 
whereas NM23-H1 was found expressed at lower levels in all analysed cases (Figure 
28). The data presented are indicating that H-PRUNE up-regulates genes involved in
124
Discussion
metastasis and its activity in vivo increases the risk of more aggressive tumour 
behaviour, contributing negatively to the clinical outcome in breast cancer patients. 
The results reported here have important pharmacological consequences, as drugs 
able to selectively inhibit H-PRUNE PDE activity can be used in treatment of breast 
carcinoma, in order to block H-PRUNE pro-metastasis malignancy function.
Overall, these experiments shed light on the role of H-PRUNE on promotion 
of cellular motility and métastasés influencing negatively the NM23-H1 anti­
metastatic function. Our model o f the role o f H-PRUNE in cancer progression 
invokes in general its amplification in tumour cells. The amplification leads to an 
increased H-PRUNE PDE activity in the cytoplasmic compartment, thus influencing 
negatively the suppressor of metastasis function o f the NM23s. The activation o f the 
H-PRUNE PDE activity is due to a physical interaction with the NM23-H1 protein; 
the complex formation results in a substantial decrease of the level of free NM23-H1 
forms, thus influencing cell proliferation, cellular motility and metastatic processes 
(Figure 31).
How H-PRUNE-NM23 protein complex influences NM23-H1 metastasis 
suppressor function by promoting motility, it is not yet known. These questions and 
their following experimental plans will be aims of future research efforts.
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Further specific investigations to address the biological functions of H- 
PRUNE and NM23 in other model organisms should help in uncovering the potential 
significance of this pathway in metastasis as well as in cellular motility and 
development.
H-PRUNE PDE overexpression and molecular changes
The study of H-PRUNE in breast cancer, previously described, revealed that 
H-PRUNE overexpression in the MD-MB-435 breast carcinoma cell line causes the 
increase o f cell motility associated either to H-PRUNE PDE activity or to the 
complex formation with NM23-H1 (D’Angelo et al., 2004).
In order to identify the m olecular mechanism responsible o f this 
phenomenon, we have investigated to which extent the increase in cell motility was 
depending on the cAMP content o f the MDA-MB-435 clones overexpressing H- 
PRUNE protein. For this reason we have analysed MDA-prune #3 and # 4 clones 
using a cAMP detecting immunoassay. The two MDA clones overexpressing H- 
PRUNE show a reduction of ~25% in cAMP content (Figure 29), indicating that a 
correlation between H-PRUNE PDE activity and increase o f cellular motility o f the 
MDA-prune clones is observed together with a reduction o f free cAMP nucleotides 
levels in these cells.
In Dictyostelium, Wessels et al. (2000) reported a direct link between cAMP 
cellular gradient (increase and decrease in a spatially and temporary manner) and 
cellular motility during chemotaxis processes. A model in which frontal waves of 
spatial gradient of cAMP, frequency of lateral pseudopodal formation and turning, 
direct the motility o f the cell shows how cAMP regulates and drives pseudopodal
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extention. How these findings and other working hypothesis are linked to H-PRUNE 
protein function in mammalian cellular motility are topics of further studies.
The features of metastatic cells are acquisition of invasive ability, changes in 
adhesion, initiation of motility and extra-cellular matrix proteolysis. We focused our 
attention on motility o f metastatic cells and demonstrated that H-PRUNE is 
responsible of an increase of cell motility.
In order to verify the molecular changes occurring in tumour cells as a 
consequence of H-PRUNE and NM23-H1 protein overexpression, a gene expression 
profiling analysis of breast MDA clones, overexpressing nm23-Hl alone (M DA-Hl- 
177) and together with H-PRUNE (MDA-H1-177-prune #8), was performed in Dr. 
Zollo’s laboratory (D’Angelo et al., 2004).
The thesis work focused the attention on the study, by PubMed literature 
analyses, o f the genes found differentially expressed in breast cellular models and 
discuss their potential function as being key actors on changing the biology o f the 
cell and influencing the motility processes. A graphic cell representation is shown in 
Figure 32.
In the clone overexpressing both H-PRUNE and NM23-H1 (MDA-Hl-177- 
prune #8), we found up-regulated the phosphatidylinositol 4-kinase type II (PI 4-K) 
(Heilmeyer et al., 2003), a key enzyme involved in the modelling o f the actin 
cytoskeleton and into the activation of protein kinase C (Subrahmanyam et al., 2003) 
(Figure 32). One of the major pathways of signaling in mammalian cells involves the 
turnover of phosphatidylinositol (PI) and the generation of diacylglycerol (DAG) for 
protein Kinase C (PKC) activation and inositol-1,4,5-triphospate (IP3) for 
intracellular Ca2+ mobilization.
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PI 4-kinases convert PI into PI-4-phosphate (PI-4-P), a highly relevant 
intermediate in multiple phosphatidylinositide signaling pathways. The enzyme 
activities have been classified into type II and type III, based on their sensitivity to 
adenosine and wortmannin. Type II PI 4- kinases are implicated in early signaling 
cascades during T cell activation. In addition to their putative role in mitogenic 
signal transduction, PI 4-kinases are also implicated in integrin-mediated signaling 
mechanisms, cytoskeletal reorganization and secretion. PI-4-P and PI-4,5-P2 
themselves can interact with actin-binding proteins to regulate actin polymerization. 
The demonstration o f physical association between a S p i  integrin and PI 4-K 
suggests a link between integrin activation and metabolism of phosphoinositides 
(Berditchevski et al., 1997). Indeed, cell attachment is mediated by transmembrane 
receptors in the integrin family triggers signal transduction cascades that regulate cell 
proliferation, apoptosis, morphology, and cellular motility (Hynes et al., 2002; 
Blaess et al., 2004).
We additionally observed the up-regulation of 26S proteasome (Figure 32). 
Recent studies of the Smad family proteins, which are the signal transducers o f the 
TGF-beta family ligands, have revealed the ability of Smads to interact with various 
components of the 26S proteasome system allowing to connect with those induced 
by many other extracellular regulators, thereby regulating a wide range of biological 
activities, including motility (Wang, 2003).
The overexpression o f H-PRUNE in the MDA breast carcinoma clones up- 
regulates also the expression of Nedd4 binding protein 2 (N4BP2) (Figure 32). Yeast 
two-hybrid screening identified the N4BP2 protein and its full-length protein was 
referred to as BCL-3-binding protein (Watanabe et al., 2003). Several additional 
studies showed a correlation of bcl-3 induction in epithelial Na^ transport processes.
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Furthermore, plastins, members of a family of actin-binding protein, which 
exhibit a tissue-specific expression pattern were found up-regulated (Figure 32). L- 
plastin, which is specifically expressed in hematopoietic cell lineage, involved in the 
control o f cell adhesion and motility was found up-regulated in the clones with high 
motility properties (M DA-Hl-177-prune #8). This protein is also frequently 
expressed in cell lines derived from mammary solid tumors and therefore might be 
involved in cancer invasion and metastasis. One example is the experiment 
performed by Zheng et al. (1999), where they demonstrated the suppression o f 
prostate carcinoma cell invasion by expression of antisense L-plastin gene.
In addition, the small GTPase R ablb results up-regulated as the consequence 
o f the overexpression o f both H-PRUNE and NM23-H1 (Figure 32). R ab lb  is 
essential for the transport from endoplasmic reticulum (ER) to Golgi. The secretory 
pathway in mammalian cells consists of a linear assembly of dynamic compartments. 
Transport and recycling between these compartments occur through generation of 
intermediates from the donor compartment and the delivery o f such intermediates to 
the appropriate acceptor compartment. In the early secretory pathway, two isoforms 
of R abl, R abla and Rablb, have been shown to be required for protein transport 
from the endoplasmic reticulum (ER) to the cis-Golgi (Find et al., 1994). Rabs have 
been proposed to act in a variety aspects of vesicular transport, including vesicle 
formation, motility, docking, and fusion. However, despite considerable advances in 
the discovery of some of its molecular mechanisms, the exact role o f Rab function 
remains to be completely deciphered. Rabs proteins interact with Ras, a small 
guanosine triphosphate binding protein, which plays an important role in signal 
transduction pathways that influence cellular proliferation, apoptosis, cytoskeletal 
organization, and other important biological processes (Li and Sparano, 2003;
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Kennedy and Davis, 2003; James et al., 2003). Ras mutations that result in 
constitutive activation of the Ras pathway are common in certain human cancers, and 
transfection o f cell lines with mutant Ras induces tumorigenesis.
In the MDA clone, with an increased level of motility (MDA-Hl-177-prune 
#8), up-regulation o f Impedes Mitogenic signal Propagation (IMP), previously 
reported as a BRCAl-interacting protein 2 (Brap2), has also been observed (Figure 
32). The IMP is a Ras effector that negatively regulates MAP kinase activation by 
limiting the formation of Raf-MEK complexes (Matheny et al., 2004). The protein 
was identified by its ability to bind to the nuclear localization signal o f BRCAl. This 
latest protein, located into the cytoplasm, regulates negatively nuclear targeting 
transport by retaining proteins with a nuclear localization signal into the cytoplasm.
Among the genes up-regulated in the MDA-Hl-177-prune #8 we additionally 
have found a novel Casein Kinase 2 Interacting Protein, designated CKIP-1 (Bose et 
al., 2000) (Figure 32). CKIP-1 is a new component of PI3-K signaling in muscle 
differentiation. This protein additionally might regulate Casein Kinase (CK2) 
function, an essential, highly conserved, serine/threonine protein kinase present in all 
eukaryotic cells. Indirectly, CKIP-1 overexpression by binding to CK2 regulate a 
broad range o f cellular proteins located in a variety of cellular compartments overall 
influencing transcription, translation, morphogenesis, and cell cycle progression.
Moreover, four genes, involved in extracellular matrix contacts and cellular 
adhesion (plakophilin, LIM), cytoscheleton re-organization (plakin) and in the 
oncosuppressor activity (EXTl), were found down regulated in the M DA-Hl-177- 
prune #8 clone (Figure 32).
Desmosomes (DMs) are specialized cadherin-mediated adhesion complexes 
showing stability and rigidity to tissues under mechanical stress. These structures are
132
Discussion
dynamic and continual renewal of stratifying epidermis layers involves both rapid 
synthesis and degradation o f cellular junctions. Desmosomal adhesion may be 
compromised in invading and transitional métastasés cell carcinomas, leading to a 
possible tumor suppressor function of desmosomal attachment (Tselepis et al., 1998; 
South et al., 2003) demonstrated that lack of plakophilin 1 increases keratinocyte 
migration and reduces desmosome stability, thus indicating a undoubted role o f 
plakophilin in cell adhesion mechanisms.
One of the major signaling pathways involved in tumor metastasis is the 
Rho/ROCK/LIM kinase pathway, involved in the regulation of the actin cytoskeleton 
(Yoshioka et al., 2003). The skeletal muscle LIM protein 1 (SLIM l) localizes in an 
integrin-dependent manner to the nucleus and focal adhesions where it functions 
downstream of integrin activation to promote cell spreading and migration. LIM 
expression is down-regulated in the clones analyzed (M DA-Hl-177-prune #8), 
indicating an alteration in a pathway correlated to cell migration.
Among the molecular mechanisms changes in gene expression in the MDA 
clones due to H-PRUNE and NM23-H1 overexpression, we observed down- 
regulation o f plakin, appertaining to the family of adhesion junction plaque proteins, 
involved in the extracellular matrix contacts (Leung et al., 2001).
Supporting the hypothesis of the contribution of H-PRUNE to the higher 
oncogenic potential of the MDA breast carcinoma cell line analyzed (MDA-Hl-177- 
prune #8) we observed the down-regulation of Exostose 1 gene, a putative tumour 
suppressor (Figure 32). Hereditary multiple exostoses, a dominantly inherited genetic 
disorder, characterized by multiple cartilaginous tumors, is caused by mutations in 
members of the EXT gene family, EXTl or EXT2 (Senay et al., 2000). The proteins 
encoded by these genes, EXTl and EXT2, are endoplasmic reticulum-localized type
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II transmembrane glycoproteins that possess or are tightly associated with 
glycosyltransferase activities involved in the polymerization of heparan sulfate.
Interestingly, we found other two genes, correlated to motility, up-regulated 
in the clone overexpressing H-PRUNE and NM23-H1 with respect to NM23-H1 
overexpressing alone.
The first gene encodes the dynein, light intermediate polypeptide 1 
(DNALIl) (Figure 32). The motor protein cytoplasmic dynein is responsible for most 
of the minus-end-directed microtubule traffic within cells, obtaining from ATP 
hydrolysis to generate force and move in a step-like manner on microtubules. Dynein 
contains four evolutionarily conserved AAA (ATPase associated with various 
cellular activities) domains that are thought to bind nucleotide. Cytoplasmatic dynein 
is associated in vivo with vimentin intermediate filament and directly interacts with 
kinesin 1, coordinating motor activity (Ligon et al., 2004).
Furthermore, in the MDA clone overexpressing H-PRUNE we have found 
up-regulated the pleiotrophin (HB-GAM) (Figure 32), a protein involved in tumor 
growth, in the regulation o f cell motility (Rauvala et al., 2000) and in the activation 
of tumor angiogenesis (Souttou et al., 2001). The pleiotrophin (PTN) and the namely 
heparin-binding growth factors belong to the midkine (MK) family. Pleiotrophin is 
expressed in embryonic and early post-natal fiber pathways o f the nervous system, 
and it enhances axonal growth/guidance by binding to N-syndecan (syndecan-3) at 
the neuron surface. Widespread deregulation o f pleiotrophin and midkine is found in 
many known human cancers and derived tumor cell lines, and it is known that 
pleiotrophin blocks tumor cell signaling, thus limited cell proliferation and tumor 
growth and metastasis in animal models (Zhang et al., 1999).
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Understanding the molecular mechanism o f the cellular motility and 
deciphering which other partners are acting together with H-PRUNE-NM23-H1 
protein complex is now our major research direction. Certainly the above described 
breast carcinoma cellular model is our starting point to unravel new pathways 
correlated to cellular motility process and cancerogenesis. The cellular models 
presented here, will be a useful source to interpret the comprehensive protein 
networks responsible o f cell migration, the first occurring event responsible o f the 
e n h a n c e m e n t  o f  m e t a s t a s t i c  c e l l u l a r  p r o c e s s e s .
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Conclusions
This thesis has reviewed the biochemical activity o f H-PRUNE and its 
functional role in correlation to NM23-H1, an anti-metastatic protein, in three 
different tumour types: sarcoma, neuroblastoma, and breast cancer. First, we have 
identified its phosphodiesterase activity and characterized its kinetic properties. H- 
PRUNE PDE activity is enhanced by the physical interaction with NM23-H1, and is 
suppressed by dipyridamole, a selective inhibitor of H-PRUNE.
We propose here two different models of action of H-PRUNE with respect to 
NM23-H1 anti-metastatic function, in correlation to H-PRUNE different cellular 
compartmentalization.
In sarcoma and in breast cancer, H-PRUNE localizes to the cytoplasm and 
high levels of H-PRUNE expression are associated with low levels o f NM23-H1, 
suggesting a role o f negative regulation o f NM23-H1. In particular, we have 
demonstrated that both H-PRUNE PDE activity and H-PRUNE-NM23-H1 complex 
increase cell motility in MDA-MB-435 breast cancer cell line. In addition, H- 
PRUNE overexpression in the MDA-MB-435 cell line influences pathways and the 
expression of other genes, indicating its role in oncogenesis and metastatic processes. 
Moreover, we have found that dipyridamole, H-PRUNE selective inhibitor is able to 
reduce H-PRUNE pro-motility effect in vitro, suggesting that the selective H- 
PRUNE inhibitor could be a potential therapeutic drug for metastic diseases.
Furthermore, since H-PRUNE shows a nuclear localization in neuroblastoma
cell lines and high levels of H-PRUNE, NM23-H1, and NM23-H2 have been found
in advanced stages of the tumour, neuroblastoma resulted an intriguing model of
study. In fact, we have demonstrated a new function o f H-PRUNE associated to its
nuclear localization, as being able to bind to the N M 2 3 -H 2  prom oter and
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transactivate its expression. In our model H-PRUNE contributes, both directly and 
indirectly, to NM23-H1 and NM23-H2 increased expression levels, suggesting that 
H-PRUNE positively regulates NM23s, which are associated to high metastatic 
potential in neuroblastoma.
Because o f the H-PRUNE PDE function characterized and its role in cancer 
by increasing the metastatic potential in breast carcinoma and neuroblastoma, and 
because o f its specific expression in brain development (Reymond et al., 1999), a 
conditional KO animal model will be an useful source to study its additional function 
by tissue specific functional ablation during mouse development. The recombinant 
vector containing both arms required for recombination has been additionally 
produced in my PhD laboratory bench work thesis. The construct will be injected 
into ES murine cells in order to generate chimerae and then, conditional KO mice, 
which will be an useful tool to elucidate H-PRUNE function in mouse development.
Finally, H-PRUNE is a novel phosphodiesterase and it is involved in tumour 
progression, regulating by different mechanisms the NM23-H1 anti-metastatic 
function. The overexpression o f H-PRUNE has been associated to advanced stages 
of various types o f tumours and the protein could be a potential target for clinical 
intervention.
The mouse model will be useful to clarify H-PRUNE role in development 
and further investigations will be addressed in order to elucidate the role o f H- 
PRUNE-NM23-H1 complex in metastatic pathways.
137
References
References
Ahn S, Milner AJ, Futterer K, Konopka M, Ilias M, Young TW and White SA. 
(2001) The "open" and "closed" structures o f the type-C inorganic 
pyrophosphatases from Bacillus subtilis and Streptococcus gordonii. J  Mol 
R /o /313, 797-811.
Aravind L. (1999) An evolutionary classification of the metallo-beta-lactamase fold 
proteins. In Silico Biol 1, 69-91.
Aravind L and Koonin EV. (1998a) The HD domain defines a new superfamily of 
metal-dependent phosphohydrolases. Trends Biochem Sci 23, 469-472.
Aravind L and Koonin EV. (1998b) A novel family of predicted phosphoesterases 
includes Drosophila prune protein and bacterial RecJ exonuclease. Trends 
Biochem Sci 23, 17-19.
Backer JM, Mendola CE, Kovesdi I, Fairhurst JL, O'Hara B, Eddy RL Jr, Shows TB, 
Mathew S, Murty VV, Chaganti RS. (1993) Chromosomal localization and 
nucleoside diphosphate kinase activity of human metastasis-suppressor genes 
NM23-1 and NM23-2. Oncogene 8, (2):497-502.
Barlund M, Monni O, Kononen J, Comelison R, Torhorst J, Sauter G, Kallioniemi 
OLLI-P, Kallioniemi A. (2000) M ultiple genes at 17q23 undergo 
am plification and overexpression in breast cancer. Cancer Res 1, 
60(19):5340-5344.
Beavo JA and Brunton LL. (2002) Cyclic nucleotide research -  still expanding after 
half a century. Nat Rev Mol Cell Biol 3, 710-718.
Berberich SJ and Postel EH. (1995) PuF/NM23-H2/NDPK-B transactivates a human 
cmyc promoter-CAT gene via a functional nuclease hypersensitive element. 
Oncogene 10, 2343-2347.
138
_________________________________________________________________References
Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME. (1997) A novel 
link between integrins, transmembrane-4 superfamily proteins (CD63 and 
CD81), and phosphatidylinositol 4-kinase. JB io l Chem 272, 2595-2598.
Biggs J, Tripoulas N, Hersperger E, Dearolf C, Shearn A. (1988) Analysis o f the 
lethal interaction between the prune and Killer o f prune mutations o f 
Drosophila. Genes D e v i,  1333-1343.
Blaess S, Graus-Porta D, Belvindrah R, Radakovits R, Pons S, Littlewood-Evans A, 
Senften M, Guo H, Li Y, Miner JH, Reichardt LF, Muller U. (2004) Betal- 
integrins are critical for cerebellar granule cell precursor proliferation. J  
Neurosci 24, 3402-3412.
Bose DG, Graham KC, Saulnier RB, Zhang C, Prober D, Gietz RD, Litchfield DW. 
(2000) Identification and characterization o f CKIP-1, a novel pleckstrin 
homology domain-containing protein that interacts with protein kinase CK2. 
JB io l Chem 275, 14295-14306.
Bown N. (2001) Neuroblastoma tumour genetics: clinical and biological aspects. J  
Clin Pathol 54, 897-910.
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, 
Danglot G, Brinkschmidt C, Christiansen H et al. (1999) Gain o f  
chromosome arm 17q and adverse outcome in patients with neuroblastoma. N  
EnglJM ed34Q , 1954-1956.
Bradford MM. (1976) A rapid and sensitive method for the quantitation o f 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem 72, 248-254.
Brodeur GM. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat 
Rev Cancer 3, (3):203-216. Review.
139
________________________________________________________________ References
Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. (1997) Biology and 
genetics of human neuroblastomas. Rev. J  Pediatr Hematol Oncol 19, (2):93- 
101.
Budd GT, Herzog P and Bukowski RM. (1994) Phase I/II trial o f dipyridamole, 5- 
fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. Invest 
New Drugs 12, 283-287.
Budd GT, Jayaraj A, Grabowski D, Adelstein D, Bauer L, Boyett J, Bukowski R, 
Murthy, S. and Weick, J. (1990) Phase I trial o f dipyridamole with 5- 
fluorouracil and folinic acid. Cancer Res 50, 7206-7211.
Caligo MA, Cipollini G, Berti A, Viacava P, Collecchi P, Bevilacqua G. (1997) 
NM23 gene expression in human breast carcinomas: loss of correlation with 
cell proliferation in the advanced phase o f tumor progression. Int J  Cancer 
20, 74(1):102-111.
Chang CL, Zhu XX, Thoraval DH, Ungar D, Rawwas J, Hora N, Strahler JR, Hanash 
SM and Radany E. (1994) Nm23-Hl mutation in neuroblastoma [letter]. 
Nature 370, 335-336.
Chou MM and Blenis J. (1995) The 70 kDa S6 kinase: regulation of a kinase with 
multiple roles in mitogenic signalling. Curr Opin Cell Biol 7, (6):806-814.
Cimpean A, Stefan C, Gijsbers R, Stalmans W, Bollen M. (2004) Substrate- 
s p e c i f y i n g  d e t e r m i n a n t s  o f  t h e  n u c l e o t i d e  
pyrophosphatases/phosphodiesterases NPPl and NPP2. Biochem J. 1, 381(Pt 
l):71-77.
Cipollini G, Berti A, Fiore L, Rainaldi G, Basolo F, Merlo G, Bevilacqua G, Caligo 
MA. (1997) Down-regulation of the nm23.hl gene inhibits cell proliferation. 
W  JCaMcgr 9, 73(2):297-302.
140
_________________________________________________________________References
Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M. (1994) MYCN is retained 
in single copy at chromosome 2 band p23-24 during amplification in human 
neuroblastoma cells. Proc Natl Acad Sci U S A . l ,  91(12):5523-5527.
Cuny M, Kramar A, Courjal F, Johannsdottir V, lacopetta B, Fontaine H, Grenier J, 
Culine S, Theillet C. (2000) Relating genotype and phenotype in breast 
cancer: an analysis o f the prognostic significance of amplification at eight 
different genes or loci and of p53 mutations. Cancer Res 15, 60(4): 1077- 
1083.
D'Angelo A, Garzia L, André A, Carotenuto P, Aglio V, Guardiola O, Arrigoni G, 
Cossu A, Palm ieri G, Aravind L, Zollo M. (2004) Prune cAMP 
phosphodiesterase binds nm23-Hl and promotes cancer metastasis. Cancer 
Cells,  137-149.
Du J and Hannon GJ. (2002) The centrosomal kinase Aurora-A/STKl 5 interacts with 
a putative tumor suppressor NM23-H1. Nucleic Acids Res 15, 30(24):5465- 
5475.
Ejeskar K, Aburatani H, Abrahamsson J, Kogner P and Martinsson T. (1998) Loss of 
heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour- 
suppressor locus distal to the FHIT gene. B r J  Cancer 77, 1787-1791.
Engel M, Veron M, Theisinger B, Lacombe ML, Seib T, Dooley S, Welter C. (1995) 
A novel serine/threonine-specific protein phosphotransferase activity o f 
Nm23/nucleoside-diphosphate kinase. Eur J  Biochem 15, 234(l):200-207.
Enzinger FM and Weiss SW. (1995). Soft tissue tumors, 3"^  ^edn. Mosby-Year Book 
Inc., St. Louis.
141
_________________________________________________________________References
Fan Z, Beresford PJ, Oh DY, Zhang D and Lieberman J. (2003) Tumor suppressor 
NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, 
and the nucleosome assembly protein SET is its inhibitor. Cell 112, 659-672.
Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, 
Beavo JA, Phillips SC. (2000) Molecular cloning and characterization of a 
distinct human phosphodiesterase gene family: PDEl lA . Proc Natl Acad Sci 
USA.  28, 97(7):3702-3707.
Fix A, Peter M, Pierron G, Aurias A, Delattre O, Janoueix-Lerosey I. (2004) High- 
resolution mapping o f amplicons of the short arm of chromosome 1 in two 
neuroblastom a tum ors by m icroarray-based com parative genom ic 
hybridization. Genes Chromosomes Cancer 40, (3):266-270.
Fletcher CD. (2002) Distinctive soft tissue tumors of the head and neck. M od Pathol. 
15, (3):324-330. Review
Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS and Fodstad 
O. (1992) Levels o f nm23 messenger RNA in metastatic malignant 
melanomas: inverse correlation to disease progression. Cancer Res 52, 6088- 
6091.
Fong CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, Vogelstein B, 
Cantor AB, Look AT and Brodeur GM. (1992) Loss o f heterozygosity for 
chromosomes 1 or 14 defines subsets o f advanced neuroblastomas. Cancer 
Res 52, 1780-1785.
Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Florenes VA, 
Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Muller 
C, Sanvito F, Kononen J, Nesland JM, Fodstad O, Reymond A, Kallioniemi 
OP, Arrigoni G, Ballabio A, Myklebost O and Zollo M. (2001) Amplification
142
_________________________________________________________________References
and overexpression o f PRUNE in human sarcomas and breast carcinomas-a 
possible mechanism for altering the nm23-Hl activity. Oncogene 20, 6881- 
6890.
Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. 
(1993) Mapping of amplification units in the ql3-14 region of chromosome 
12 in human sarcomas: some amplica do not include MDM2. Cell Growth 
4,(12):1065-1070.
Forus A., Weghuis DO, Smeets D, Fodstad O, Myklebost O, Guerts van Kessel A. 
(1995a) Comparative genomic hybridization analysis of human sarcomas: I. 
Occurrence o f genomic imbalances and identification o f a novel major 
amplicon at Iq21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer 
14, (1): 8-14.
Forus A., Weghuis DO, Smeets D, Fodstad O, Myklebost O, Guerts van Kessel A. 
(1995b) Comparative genomic hybridization analysis of human sarcomas: II. 
Identification o f novel amplicons at 6p and 17p in osteosarcomas. Genes 
Chromosomes Cancer 14, (1): 15-21.
Freije JM, Blay P, MacDonald NJ, Manrow RE and Steeg PS. (1997a) Site-directed 
mutation o f Nm23-Hl. Mutations lacking motility suppressive capacity upon 
transfection are deficient in histidine- dependent protein phosphotransferase 
pathways in vitro. J  Biol Chem 272, 5525-5532.
Freije JM, Lawrence JA, Hollingshead MG, De la Rosa A, Narayanan V, Grever M, 
Sausville EA, Pauli K and Steeg PS. (1997b) Identification o f compounds 
with preferential inhibitory activity against low-Nm23-expressing human 
breast carcinoma and melanoma cell lines. Nat Med 3, 395-401.
143
________________________________________________________________ References
Galperin MY, Natale DA, Aravind L. and Koonin EV (1999) A specialized version 
o f the HD hydrolase domain implicated in signal transduction. J  Mol 
Microbiol Biotechnol 1, 303-305.
Garzia L, Andre A, Amoresano A, DAngelo A, Martusciello R, Cirulli C, Tsurumi 
T, Marino G and Zollo M. (2003) Method to express and purify nm23-H2 
protein from Baculovirus infected cells. Biotechniques 35, 384-391.
Garzia L, D A ngelo A, Volinia S, André A, Cirulli C, Amoresano A, Marino G, 
Campanella C, Zollo M. (2004) Phosphorylation of nm23-Hl and nm23-H2 
by CKIôinduces complex formation with h-prune and cellular motility. 
Submitted.
Gervasi F, DAgnano I, Vossio S, Zupi G, Sacchi A, Lombardi D. (1996) Nm23 
influences proliferation and differentiation of PC 12 cells in response to nerve 
growth factor. Cell Growth Differ 7, (12): 1689-1695.
Godfried MB, Veenstra M, v Sluis P, Boon K, v Asperen R, Hermus MC, v Schaik 
BD, Voute TP, Schwab M, Versteeg R. (2002) The N-myc and c-myc 
downstream pathways include the chromosome 17q genes nm23-Hl and 
nm23-H2. Oncogene 21,2097-2101.
Grand CL, Powell TJ, Nagle RB, Bearss DJ, Tye D, Gleason-Guzman M, Hurley 
LH. (2004) Mutations in the G-quadruplex silencer element and their 
relationship to c-MYC overexpression, NM23 repression, and therapeutic 
rescue. Proc Natl Acad Sci U S A .  20, 101(16):6140-6145. Epub 2004 Apr 
12.
Guin GH, Gilbert EF and Jones B. (1969) Incidental neuroblastoma in infants. Am J  
Clin Pathol 126-136.
144
_________________________________________________________________References
Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, 
Matthay KK, Seeger RC, Brodeur GM et a l  (1999) Allelic deletion at 1 lq23 
is common in MYCN single copy neuroblastomas. Oncogene 18, 4948-4957.
Haaz MC, Fischel JL, Formento P, Renee N, Etienne MC and Milano G. (1996) 
Impact o f different fluorouracil biochemical modulators on cellular 
dihydropyrimidine dehydrogenase. Cancer Chemother Pharmacol 3H, 52-58.
Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskom C, Brodeur GM, Reynolds 
CP, Seeger RC, Lottspeich F, Strahler JR. (1991) High levels of pl9/nm23 
protein in neuroblastoma are associated with advanced stage disease and with 
N-myc gene amplification. J  C/m Invest 88, 341-345.
Hamby CV, Abbi R, Prasad N, Stauffer C, Thomson J, Mendola CE, Sidorov V and 
Backer JM. (2000) Expression of a catalytically inactive H118Y mutant o f 
nm23-H2 suppresses the metastatic potential o f line IV Cl 1 human 
melanoma cells. Int J  Cancer 88, 547-553.
Hamby CV, Mendola CE, Potla L, Stafford G and Backer JM. (1995) Differential 
expression and mutation o f NME genes in autologous cultured human 
melanoma cells with different metastatic potentials. Biochem Biophys Res 
Commun 211, 579-585.
Hanahan D, Weinberg RA. (2000) The hallmarks o f cancer. C e ll l ,  100(l):57-70. 
Review.
Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, Clark G 
and Steeg PS. (2001) Elevation of breast carcinoma Nm23-Hl metastasis 
suppressor gene expression and reduced motility by DNA méthylation 
inhibition. Cancer Res 61, 2320-2327.
145
_________________________________________________________________References
Hartsough MT, Morrison DK, Salerno M, Palmieri D, Ouatas T, Mair M, Patrick J, 
Steeg PS. (2002) Nm23-Hl metastasis suppressor phosphorylation of kinase 
suppressor of Ras via a histidine protein kinase pathway. J  Biol Chem 30, 
277(35):32389-32399. Epub 2002 Jun 24.
Hartsough MT and Steeg PS. (1998) Nm23-Hl: genetic alterations and expression 
patterns in tumor metastasis. Am J  Hum Genet 63, 6-10.
Hartsough MT and Steeg PS. (2000) Nm23/nucleoside diphosphate kinase in human 
cancers. JBioenerg Biomembr 32, 301-308.
Heilmeyer LM Jr, Vereb Jr, Vereb G, Kakuk A, Szivak I. (2003) Mammalian 
phosphatidylinositol 4-kinases. lUBMB Life 55, 59-65.
Hejna M, Raderer M and Zielinski CC. (1999) Inhibition o f métastasés by 
anticoagulants. JN a tl Cancer Inst 91, 22-36.
Hennessy C, Henry JA, May FE, Westley BR, Angus B, Lennard TW. (1991) 
Expression of the antimetastatic gene nm23 in human breast cancer: an 
association with good prognosis. JN a tl Cancer Inst 20, 83(4):281-285.
Howlett AR, Petersen OW, Steeg PS and Bissell MJ. (1994) A novel function for the 
nm23-Hl gene: overexpression in human breast carcinoma cells leads to the 
formation of basement membrane and growth arrest. J  Natl Cancer Inst 86, 
1838-1844.
Hynes RO, Lively JC, McCarty JH, Tavema D, Francis SE, Hodivala-Dilke K, Xiao 
Q. (2002) The diverse roles o f integrins and their ligands in angiogenesis. 
Cold Spring Harb Symp Quant Biol 67, 143-153.
James RM, Arends MJ, Plowman SJ, Brooks DG, Miles CG, West JD, Patek CE. 
(2003) K-ras proto-oncogene exhibits tumor suppressor activity as its absence 
promotes tumorigenesis in murine teratomas. Mol Cancer Res 1, 820-825.
146
_________________________________________________________________References
Janoueix-Lerosey I, Penther D, Thioux M, de Cremoux P, Derre J, Ambros P, Vielh 
P, Benard J, Aurias A and Delattre O. (2000) M olecular analysis o f 
chromosome arm 17q gain in neuroblastoma. Genes Chromosomes Cancer 
28, 276-284.
Kallioniemi A, Kallioniemi 0-P , Sudar D, Rutovitz D, Gray JW, Waldman F and 
Pinkel D. (1992) Comparative genomic hybridization for m olecular 
cytogenetic analysis of solid tumors. Science 258, 818-821.
Kaneko Y and Knudson AG. (2000) Mechanism and relevance o f ploidy in 
neuroblastoma. Genes Chromosomes Cancer 29, 89-95.
Kantor JD, McCormick B, Steeg PS and Zetter BR. (1993) Inhibition of cell motility 
after nm23 transfection of human and murine tumor cells. Cancer Res 53, 
1971-1973.
Kennedy NJ, Davis RJ. (2003) Role o f JNK in tumor development. Cell Cycle 2, 
199-201.
Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ and Look AT. 
(1993) Coamplification o f the CDK4 gene with MDM2 and GLI in human 
sarcomas. Cancer Res 15, 53(22):5535-5541.
Kikkawa S, Takahashi K, Takahashi K, Shimada N, Ui M, Kimura N, Katada T. 
(1990) Conversion of GDP into GTP by nucleoside diphosphate kinase on the 
GTP-binding proteins. J  Biol Chem 15, 265(35):21536-21540. Erratum in: J 
Biol Chem 1991 Jul 5, 266(19):12795.
Kimura N, Shimada N, Ishijima Y, Fukuda M, Takagi Y, Ishikawa N. (2003) 
Nucleoside diphosphate kinases in mammalian signal transduction systems: 
recent development and perspective. J  Bioenerg Biomembr 35, (l):41-47. 
Review.
147
________________________________________________________________ References
Kraeft SK, Traincart F, Mesnildrey S, Bourdais J, Veron M and Chen LB. (1996) 
Nuclear localization of nucleoside diphosphate kinase type B (nm23-H2) in 
cultured cells. Exp Cell Res 221, 63-69.
Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K, 
Ishii K, Kita T, Kikuchi Y, Nagata I, Miwa M, Uchida K. (1999) Gains of 
Iq21-q22 and 13ql2-ql4 are potential indicators for resistance to cisplatin- 
based chemotherapy in ovarian cancer patients. Clin Cancer Res 5, (9):2526- 
2531.
Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. (2000) The human 
Nm23/nucleoside diphosphate kinases. J  Bioenerg Biomembr 32 , (3):247- 
258. Review.
Lascu I, Chaffotte A, Limbourg-Bouchon B, Veron M. (1992) A Pro/Ser substitution 
in nucleoside diphosphate kinase of Drosophila melanogaster (mutation killer 
o f prune) affects stability but not catalytic efficiency of the enzyme. J  Biol 
Chem 25,267(18):12775-81.
Lascu I, Schaertl S, Wang C, Sarger C, Giartosio A, Briand G, Lacombe ML and 
Konrad M. (1997) A point mutation o f human nucleoside diphosphate kinase 
A found in aggressive neuroblastoma affects protein folding. J  Biol Chem 
212, 15599-15602.
Leone A, Flatow U, VanHoutte K and Steeg PS. (1993a) Transfection o f human 
nm23-Hl into the human MDA-MB-435 breast carcinoma cell line: effects 
on tumor metastatic potential, colonization and enzymatic activity. Oncogene 
8,2325-2333.
Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, 
Slamon DJ and Steeg PS. (1993b) Evidence for nm23 RNA overexpression,
148
_________________________________________________________________References
DNA amplification and mutation in aggressive childhood neuroblastomas. 
Oncogene 8, 855-865.
Leung CL, Liem RK, Parry DA, Green KJ. (2001) The plakin family. J  Cell Sci 114, 
3409-3410.
Li T and Sparano JA. (2003) Inhibiting Ras signaling in the therapy of breast cancer.
Clin Breast Cancer 3, 405-416; discussion 17-20.
Ligon LA, Tokito M, Finkelstein JM, Grossman FE, Holzbaur EL. (2004) A direct 
interaction between cytoplasmic dynein and kinesin I may coordinate motor 
activity. JB io l Chem 30, 279(18):19201-19208. Epub 2004 Feb 24.
Liotta LA and Kohn EC. (2001) The microenvironment o f the tumour-host interface.
Nature 1 7 ,411(6835):375-379. Review.
Lombardi D, Lacombe ML and Paggi MG. (2000) Nm23: unraveling its biological 
function in cell differentiation. J  Ce// Physiol 182, 144-149.
Lombardi D, Sacchi A, D'Agostino G, Tibursi G. (1995) The association o f the 
Nm23-Ml protein and beta-tubulin correlates with cell differentiation. Exp 
Cell Res 111, (2):267-271.
Ma D, McCorkle JR, Kaetzel DM. (2004) The metastasis suppressor NM23-H1 
possesses 3'-5' exonuclease activity. J  Biol Chem 23, 279(17): 18073-18084. 
Epub 2004 Feb 11.
MacDonald NJ, De la Rosa A, Benedict MA, Freije JM, Krutsch H, Steeg PS. (1993) 
A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase 
activity, correlates with suppression of tumor metastatic potential. J  Biol 
C/zg/M 5 ,268(34):25780-25789.
MacDonald NJ, Freije JM, Stracke ML, Manrow RE and Steeg PS. (1996) Site- 
directed mutagenesis of nm 23-Hl. Mutation o f proline 96 or serine 120
149
_________________________________________________________________References
abrogates its motility inhibitory activity upon transfection into human breast 
carcinoma cells. J  Biol Chem 271, 25107-25116.
Mao H, Liu H, Fu X, Fang Z, Abrams J and Worsham MJ. (2001) Loss o f nm23 
expression predicts distal métastasés and poorer survival for breast cancer. Int 
J  Oncol 18, 587-591.
Maris JM and Matthay KK. (1999) Molecular biology o f neuroblastoma. J  Clin 
Oncol 17, 2264-2279.
Maris JM, Weiss MJ, Mosse Y, Hii G, Guo C, White PS, Hogarty MD, Mirensky T, 
Brodeur GM, Rebbeck TR. et al. (2002) Evidence for a hereditary 
neuroblastoma predisposition locus at chromosome 16pl2-13. Cancer Res 
62, 6651-6658.
Marshall B, Isidro G, Martins AG and Boavida MG. (1997) Loss of heterozygosity at 
chromosome 9p21 in primary neuroblastomas: evidence for two deleted 
regions. Cancer Genet Cytogenet 96, 134-139.
Matheny SA, Chen C, Kortum RL, Razidlo GL, Lewis RE, White MA. (2004) Ras 
regulates assembly of mitogenic signalling complexes through the effector 
protein IMP. Nature 427, 256-260.
Meltzer SJ, O'Doherty SP, Frantz CN, Smolinski K, Yin J, Cantor AB, Liu J, 
Valentine, M, Brodeur GM and Berg PE. (1996) Allelic imbalance on 
chromosome 5q predicts long-term survival in neuroblastoma. Br J  Cancer 
74, 1855-1861.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. (1992) The mdm-2 
oncogene product forms a complex with the p53 protein and inhibits p53- 
mediated transactivation. Cell 26, 69(7): 1237-1245.
150
_________________________________________________________________References
Mora J, Cheung NK, Oplanich S, Chen L and Gerald WL. (2002) Novel regions of 
allelic imbalance identified by genome-wide analysis o f neuroblastoma. 
Cancer Res 62, 1761-1767.
Muleris M, Almeida A, Gerbault-Seureau M, Malfoy B, Dutrillaux B. (1994) 
Detection o f DNA amplification in 17 primary breast carcinomas with 
homogeneously staining regions by a modified comparative genomic 
hybridization technique. Genes Chromosomes Cancer 10, (3): 160-70.
Muller W, Schneiders A, Hommel G, Gabbert HE. (1998) Expression o f nm23 in 
gastric carcinoma: association with tumor progression and poor prognosis. 
Cancer 15, 83(12):2481-2487.
Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M and 
Honma Y. (2001) Serum nm 23-Hl protein as a prognostic factor in 
aggressive non-Hodgkin lymphoma. Blood 97,1202-1210.
Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N. (2004) 
Amplification of chromosome 1 sequences in lipomatous tumors and other 
sarcomas. Int J  Cancer 10, 109(3):363-369.
Oliner JD, Kinzler KW, M eltzer PS, George DL and Vogelstein B. (1992) 
Amplification o f a gene encoding a p5 3-associated protein in human 
sarcomas. Nature 2, 358(6381):80-83.
Orevi N, Falk R (1975) Temperature-sensitive prune (pn) mutations o f Drosophila 
melanogaster. Mutat Res 33, 193-200.
Otsuki Y, Tanaka M, Yoshii S, Kawazoe N, Nakaya K, Sugimura H. (2001) Tumor 
metastasis suppressor nm23Hl regulates Racl GTPase by interaction with 
T iam l. Proc Natl Acad Sci US A.  10, 98(8):4385-4390. Epub 2001 Mar 27.
151
________________________________________________________________ References
Ouatas T, Salerno M, Palmieri D, Steeg PS. (2003) Basic and translational advances 
in cancer metastasis: Nm23. J Bioenerg Biomembr. 35, (l):73-9. Review.
Pear WS, Nolan GP, Scott ML, and Baltimore D (1993) Production o f High-Titer 
Helper-Free Retroviruses by Transient Transfection Proc Natl Acad Sci U S  
.4 90, 8392-8396.
Find SN, Nuoffer C, McCaffery JM, Plutner H, Davidson HW, Farquhar MG, Balch 
WE. (1994) Rabl and Ca2+ are required for the fusion o f carrier vesicles 
mediating endoplasmic reticulum to Golgi transport. J  Cell Biol 125, 239- 
252.
Postel EH. (1996) NM23/Nucleoside diphosphate kinase as a transcriptional 
activator o f c-myc. Curr Top Microbiol Immunol 213 (Ft 2), 233-252.
Postel EH. (1999) Cleavage of DNA by human NM23-H2/nucleoside diphosphate 
kinase involves formation of a covalent protein-DNA complex. J  Biol Chem. 
6 ,274(32):22821-22829.
Postel EH, Berberich SJ, Flint SJ and Ferrone CA. (1993) Human c-myc 
transcription factor PuF identified as nm23-H2 nucleoside diphosphate 
kinase, a candidate suppressor of tumor metastasis. Science 261,478-480.
Postel EH, Weiss VH, Beneken J and Kirtane A. (1996) Mutational analysis o f 
NM23-H2/NDP kinase identifies the structural domains critical to recognition 
o f a c-myc regulatory element. Proc Natl Acad Sci U S A  93, 6892-6897.
Randazzo PA, Northup JK, Kahn RA. (1991) Activation o f a small GTP-binding 
protein by nucleoside diphosphate kinase. Science 8, 254(5033):850-853.
Rauvala H, Huttunen HJ, Pages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, 
Kilpelainen I. (2000) Heparin-binding proteins HB-GAM (pleiotrophin) and 
amphoterin in the regulation o f cell motility. Matrix Biol 19, (5):377-387
152
_________________________________________________________________References
Reymond A, Volorio S, Merla G, Al-Maghtheh M, Zuffardi O, Bulfone A, Ballabio 
A and Zollo M. (1999) Evidence for interaction between human PRUNE and 
nm23-Hl NDPKinase. Oncogene 18, 7244-7252.
Rosengard AM, Krutzsch HC, Sheam A, Biggs JR, Barker E, Margulies IM, King 
CR, Liotta LA, Steeg PS. (1989) Reduced Nm23/Awd protein in tumour 
metastasis and aberrant Drosophila development. Nature 9, 342(6246): 177- 
180.
Ross JS and Fletcher JA. (1999) HER-2/neu (c-erb-B2) gene and protein in breast 
cancer. Am J  Clin Pathol 112, 53-67. Review.
Royds JA, Robinson MH, Stephenson TJ, Rees RC, Fisher C (1997) The association 
between nm23 gene expression and survival in patients with sarcomas. Br J  
Cancer 75, 1195-1200.
Salerno M, Ouatas T, Palmieri D, Steeg PS. (2003) Inhibition of signal transduction 
by the nm23 metastasis suppressor: possible mechanisms. Clin Exp 
Metastasis. 20, (1):3-10. Review.
Sambrook J, Fritsch EF, and Maniatis T. (1989) Molecular cloning. A laboratory 
manual. 2a ed. USA, Cold Spring Harbor Laboratory Press.
Savelyeva L, Schwab M. (2001) Amplification o f oncogenes revisited: from 
expression profiling to clinical application. Cancer Lett 26, 167(2): 115-123. 
Review.
Schaertl S, Geeves MA and Konrad M. (1999) Human nucleoside diphosphate 
kinase B (Nm23-H2) from melanoma cells shows altered phosphoryl transfer 
activity due to the S122P mutation. J  Biol Chem 274, 20159-20164.
Schneider J, Pollan M, Jimenez E, Marenbach K, Martinez N, Volm M, Marx D, 
Meden H. (2000) nm23-Hl expression defines a high-risk subpopulation o f
153
________________________________________________________________ References
patients with early-stage epithelial ovarian carcinoma. Br J  Cancer 82, 
(10):1662-1670.
Schwab M. (1991) Enhanced expression o f the cellular oncogene MYCN and 
progression of human neuroblastoma. Adv Enzyme Regul 31, 329-338.
Schwab M. (1997) MYCN Amplification in Neuroblastoma: a Paradigm for the 
Clinical Use of an Oncogene. Pathol Oncol Res 3, (l):3-7.
Schwab M. (1998) Amplification o f oncogenes in human cancer cells. Bioessays 20, 
(6):473-479.
Schwab M, Westermann F, Hero B, Berthold F. (2003) Neuroblastoma: biology and 
molecular and chromosomal pathology. Lancet Oncol 4, (8):472-480. 
Review.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY and Hammond 
D. (1985) Association o f multiple copies o f the N-myc oncogene with rapid 
progression o f neuroblastomas. N  Engl J  Med  313, 1111-1116.
Senay C, Lind T, Muguruma K, Tone Y, Kitagawa H, Sugahara K, Lidholt K, 
Lindahl U, Kusche-Gullberg M. (2000) The EXT1/EXT2 tumor suppressors: 
catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep 1, 
282-286.
Sleeman JP. (2000) The lymph node as a bridgehead in the metastatic dissemination 
of tumors. Recent Results Cancer Res 157, 55-81.
Smith SH, Weiss SW, Jankowski SA, Coccia MA, M eltzer PS. (1992) SAS 
amplification in soft tissue sarcomas Cancer Res 1, 52(13):3746-3749.
Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition 
(1997). Union Internationale Contre le Cancer and the American Joint 
Committee on Cancer. Cancer 1, 80(9): 1803-1804.
154
References
South AP, Wan H, Stone MG, Dopping-Hepenstal PJ, Purkis PE, Marshall JF, Leigh 
IM, Eady RA, Hart IR, McGrath JA. (2003) Lack of plakophilin 1 increases 
keratinocyte migration and reduces desmosome stability. J  Cell Sci 116, 
3303-3314.
Souttou B, Raulais D, Vigny M. (2001) Pleiotrophin induces angiogenesis: 
involvement o f the phosphoinositide-3 kinase but not the nitric oxide 
synthase pathways. J  Cg// Physiol 187, 59-64.
Srivatsa PJ, Cliby WA, Keeney GL, Dodson MK, Suman VJ, Roche PC, Podratz 
KC. (1996) Elevated nm23 protein expression is correlated with diminished 
progression-free survival in patients with epithelial ovarian carcinoma. 
Gynecol Oncol 60, (3):363-372.
Steeg PS. (2003) Metastasis suppressors alter the signal transduction of cancer cells. 
Nat Rev Cancer 3, 55-63.
Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel 
ME. (1988) Evidence for a novel gene associated with low tumor metastatic 
potential. JN a tl Cancer Inst 6, 80(3):200-204.
Subrahmanyam G, Rudd CE, Schneider H. (2003) Association of T cell antigen CD7 
with type II phosphatidylinositol-4 kinase, a key component in pathways of 
inositol phosphate turnover. Eur J  Immunol 33,46-52.
Subramanian C, Cotter MA 2nd, Robertson ES. (2001) Epstein-Barr virus nuclear 
protein EBNA-3C interacts with the human metastatic suppressor Nm23-Hl: 
a molecular link to cancer metastasis. Nat Med 7, (3): 350-355.
Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomquist C, Asko- 
Seljavaara S, Tukiainen E, Elomaa I and Knuutila S. (1996). Gains and losses
155
________________________________________________________________ References
of DNA sequences in liposarcomas evaluated by comparative genomic 
hybridization. Genes Chromosomes Cancer 15, (2):89-94.
Takita J, Hayashi Y, Takei K, Yamaguchi N, Hanada R, Yamamoto K and Yokota J. 
(2000) Allelic imbalance on chromosome 18 in neuroblastoma. Eur J  Cancer 
36, 508-513.
Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto 
K, Hayashi Y, Aburatani H. (2004) Gene expression profiling and 
identification o f novel prognostic marker genes in neuroblastoma. Genes 
Chromosomes Cancer 40, (2): 120-132.
Tanaka T, Sugimoto T, Sawada T. (1998) Prognostic discrimination among 
neuroblastomas according to Ha-ras/trk A gene expression: a comparison of 
the profiles of neuroblastomas detected clinically and those detected through 
mass screening. Cancer 15, 83(8).T626-1633.
Tanaka S, Tajiri T, Noguchi S, Shono K, Ihara K, Hara T, Suita S. (2004) Clinical 
significance o f a highly sensitive analysis for gene dosage and the expression 
level of MYCN in neuroblastoma. J  Pediatr Surg 39, (1): 63-68.
Tarkkanen M, Elomaa I, Blomqvist C, Kivioja AH, Kellokumpu-Lehtinen P, 
Bohling T, Valle J, Knuutila S. (1999) DNA sequence copy number increase 
at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J  
Cancer 20, 84(2):114-121
Timmons L and Sheam A. (1996) Germline transformation using a prune cDNA 
rescues pmne/killer of pmne lethality and the pmne eye color phenotype in 
Drosophila. Genetics 144,1589-1600.
156
_________________________________________________________________References
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. (1998) 
M olecular cytogenetics o f prim ary breast cancer by CGH. Genes 
Chromosomes Cancer 21,(3): n i - \ M .
Tonini GP, Longo L, Coco S and Perri P. (2003) Familial neuroblastoma: a complex 
heritable disease. Cancer Lett 197, 41-45.
Tselepis C, Chidgey M, North A, Garrod D. (1998) Desmosomal adhesion inhibits 
invasive behavior. Proc Natl Acad Sci U S  A 95, 8064-8069.
Tseng YH, Vicent D, Zhu J, Niu Y, Adeyinka A, Moyers JS, Watson PH and Kahn 
CR. (2001) Regulation of growth and tumorigenicity of breast cancer cells by 
the low molecular weight GTPase Rad and nm23. Cancer Res 61, 2071-2079.
Venkitaraman AR. (2002) Cancer susceptibility and the functions o f BRCAl and 
BRCA2. Cell25, 108(2):171-182. Review.
Wagner PD, Vu ND. (2000) Histidine to aspartate phosphotransferase activity of 
nm23 proteins: phosphorylation of aldolase C on Asp-319. Biochem J  IS, 346 
Pt 3:623-630.
Wagner PD, Steeg PS, Vu ND. (1997) Two-component kinase-like activity of nm23 
correlates with its motility- suppressing activity. Proc Natl Acad Sci U S A  
94, 9000-9005.
Wang T. (2003) The 26S proteasome system in the signaling pathways of TGF-beta 
superfamily. Front Biosci 8, d l 109-1127.
Watanabe N, Wachi S, Fujita T. (2003) Identification and characterization of BCL-3- 
binding protein: implications for transcription and DNA repair or 
recombination. JB io l Chem 278, 26102-26110.
Wessels DJ, Zhang H, Reynolds J, Daniels K, Held P, Lu S, Kuspa A, Shaulsky G, 
Loomis WF, Soli DR. (2000) The internal phosphodiesterase RegA is
157
References
essential for the suppression o f lateral pseudopods during Dictyostelium 
chemotaxis. Mol Biol Cell 11, 2803-2820.
Yamagata A, Kakuta Y, Masui R and Fukuyama K. (2002) The crystal structure of 
exonuclease Reel bound to Mn2+ ion suggests how its characteristic motifs 
are involved in exonuclease activity. Proc Natl Acad Sci U S  A 99, 5908-12.
Yoshioka K, Foletta V, Bernard O, Itoh K. (2003) A role for LIM kinase in cancer 
invasion. Proc Natl Acad Sci U S A  100, 7247-7252.
Zhang N, Yeh HJ, Zhong R, Li YS, Deuel TF. (1999) A dominant-negative 
pleiotrophin mutant introduced by homologous recombination leads to germ­
cell apoptosis in male mice. Proc Natl Acad Sci U S A  96, 6734-6738.
Zheng P, Eastman J, Van de Pol S, Pimplikar SW. (1998) P A T l, a microtubule- 
interacting protein, recognizes the basolateral sorting signal o f amyloid 
precursor protein. Proc. Natl. Acad. Sci. USA 95, 14745-14750.
Zheng J, Rudra-Ganguly N, Powell WC, Roy-Burman P. (1999) Suppression of 
prostate carcinoma cell invasion by expression o f antisense L-plastin gene. 
Am J  Pathol 155, 115-122.
158
A cknowîedgements
Acknowledgements
I would like to thank my director of studies Dr. Massimo Zollo for giving me 
the opportunity to work in his laboratory. I’m very thankful to him for his assistance, 
support, encouragement and ideas in project development. These thanks extend to 
Prof. Ashok Venkitaraman, my supervisor, for his interest in my work and for his 
help throughout my PhD course and in the preparation of this thesis.
I’m grateful to the Telethon Institute of Genetics and Medicine (TIGEM), and 
I appreciatively acknowledge the Director Prof. Andrea Ballabio for giving me the 
opportunity to work into the institute. A distinctive acknowledgement goes to Dr. 
Elena Rugarli, who has coordinated the first Open University program at TIGEM 
with patience and determination.
I thankfully acknowledge all the “Zollo’s group” members, Veruska, 
Alessandra A., Livia, Pietro, Ombretta, Natascia, and Annamaria for their support 
and for sharing the additional data inserted in this PhD thesis to make a more 
comprehensive thesis work.
An exclusive thanks is for my special friend Adriano who always listened to 
me and gave me strength, encouragment, and esteem. I’m thankful for sharing the 
“Lab 94” laboratory with Alessandro, Mariella, Giovanna, Manuela, Valeria N., 
Giusy, Dario, Claudia, Barbara R. and Sabrina, who made my “laboratory lifetime” 
enjoyable. I ’m very grateful to Alessia and Stefano C. for sharing helpful 
discussions.
My PhD laboratory bench work thesis has also been pleasurable for
discussing and working with Antonio T., Carmine Sp., Carmine S., Ciro, Enzo,
159
Acknowledgements
Federico, Silvana, Barbara Z., Bianca, Ester, MT, Stefano P., Manlio, Francesco, 
Valeria C., Alessandra N., Salvatore B., Fabio, MariaTeresa D., Filoména and 
AnnaMonica.
My thanks extend to Mario T. and Peo for their informatic support, and to all 
the TIGEM researchers who gave me trust and esteem.
I’m very thankful to my friends Patrizia and Gabriella and to all my “Castel 
Morrone’s” friends who have always supported me.
Finally, my gratefulness goes to my mother Franca and my grandparents 
Alessandro and Maria, who let my dream become true.
160
Publications from  this thesis
Publications from this thesis
Forus A, D’Angelo A, Henriksen J, Merla G, Maelandsmo GM, Florenes VA, 
Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Muller 
C, Sanvito F, Kononen J, Nesland JM, Fodstad O, Reymond A, Kallioniemi 
OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M. Amplification and 
overexpression o f PRUNE in human sarcomas and breast carcinomas-a 
possible mechanism for altering the nm23-Hl activity. Oncogene. 2001 Oct 
18;20(47):6881-90.
Garzia L, Andre A, Amoresano A, D’Angelo A, Martusciello R, Cirulli C, Tsurumi 
T, Marino G, Zollo M. Method to express and purify nm23-H2 protein from 
baculovirus-infected cells. Biotechniques. 2003 Aug;35(2):384-8, 390-1.
D Angelo A, Garzia L, Andre A, Carotenuto P, Aglio V, Guardiola O, Arrigoni G, 
Cossu A, Palmieri G, Aravind L, Zollo M Prune cAMP phosphodiesterase 
binds nm 23-Hl and promotes cancer metastasis. Cancer Cell. 2004 
Feb;5(2): 137-49.
DAngelo A. and Zollo M. Unraveling genes and pathways influenced by h-prune 
PDE overexpression: a model to study cellular motility. Cell cycle. June 
2004, Volume 3, Issue 6.
Zollo M., André A., Cossu A., Sini MC., D’Angelo A., Marino N., Budroni M., 
Tanda F., Arrigoni G., and Palmieri G. Overexpression of h-prune in breast 
cancer is correlated with advanced disease status. (2004) Submitted.
Garzia L., DAngelo A., Volinia S., André A., Cirulli C., Amoresano A., Marino G., 
Campanella C., Zollo M. (2004) Phosphorylation of nm23-Hl and nm23-H2 
by CKIôinduces complex formation with h-prune and cellular motility. 
Submitted.
161
Reproduced with permission of copyright owner. Further reproduction prohibited without permission.
